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Background: With a prevalence of up to 16.5%, depression is one of the commonest mental disorders
in people with advanced cancer. Depression reduces the quality of life (QoL) of patients and those close
to them. The National Institute for Health and Care Excellence (NICE) guidelines recommend treating
depression using antidepressants and/or psychological treatments, such as cognitive–behavioural therapy
(CBT). Although CBT has been shown to be effective for people with cancer, it is unclear whether or not
this is the case for people with advanced cancer and depression.
Objectives: To assess the clinical effectiveness and cost-effectiveness of treatment as usual (TAU) plus
manualised CBT, delivered by high-level Improving Access to Psychological Therapy (IAPT) practitioners,
versus TAU for people with advanced cancer and depression, measured at baseline, 6, 12, 18 and
24 weeks.
Design: Parallel-group, single-blind, randomised trial, stratified by whether or not an antidepressant was
prescribed, comparing TAU with CBT plus TAU.
Setting: Recruitment took place in oncology, hospice and primary care settings. CBT was delivered in IAPT
centres or/and over the telephone.
Participants: Patients (N = 230; n = 115 in each arm) with advanced cancer and depression. Inclusion
criteria were a diagnosis of cancer not amenable to cure, a DSM-IV (Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition) diagnosis of depressive disorder using the Mini-International
Neuropsychiatric Interview, a sufficient understanding of English and eligibility for treatment in an IAPT
centre. Exclusion criteria were an estimated survival of < 4 months, being at high risk of suicide and
receiving, or having received in the last 2 months, a psychological intervention recommended by NICE for
treating depression.
Interventions: (1) Up to 12 sessions of manualised individual CBT plus TAU delivered within 16 weeks
and (2) TAU.
DOI: 10.3310/hta23190 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 19
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Serfaty et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
v
Outcome measures: The primary outcome was the Beck Depression Inventory, version 2 (BDI-II) score at
6, 12, 18 and 24 weeks. Secondary outcomes included scores on the Patient Health Questionnaire-9, the
Eastern Cooperative Oncology Group Performance Status, satisfaction with care, EuroQol-5 Dimensions
and the Client Services Receipt Inventory, at 12 and 24 weeks.
Results: A total of 80% of treatments (185/230) were analysed: CBT (plus TAU) (n = 93) and TAU (n = 92)
for the BDI-II score at all time points using multilevel modelling. CBT was not clinically effective [treatment
effect –0.84, 95% confidence interval (CI) –2.76 to 1.08; p = 0.39], nor was there any benefit for other
measures. A subgroup analysis of those widowed, divorced or separated showed a significant effect of CBT
on the BDI-II (treatment effect –7.21, 95% CI –11.15 to –3.28; p < 0.001). Economic analysis revealed that
CBT has higher costs but produces more quality-adjusted life-years (QALYs) than TAU. The mean service costs
for participants (not including the costs of the interventions) were similar across the two groups. There were
no differences in EQ-5D median scores at baseline, nor was there any advantage of CBT over TAU at 12 weeks
or 24 weeks. There was no statistically significant improvement in QALYs at 24 weeks.
Limitations: Although all participants satisfied a diagnosis of depression, for some, this was of less than
moderate severity at baseline, which could have attenuated treatment effects. Only 64% (74/115) took up
CBT, comparable to the general uptake through IAPT.
Conclusions: Cognitive–behavioural therapy (delivered through IAPT) does not achieve any clinical
benefit in advanced cancer patients with depression. The benefit of CBT for people widowed, divorced or
separated is consistent with other studies. Alternative treatment options for people with advanced cancer
warrant evaluation. Screening and referring those widowed, divorced or separated to IAPT for CBT may
be beneficial. Whether or not improvements in this subgroup are due to non-specific therapeutic effects
needs investigation.
Trial registration: Current Controlled Trials ISRCTN07622709.
Funding: This project was funded by the National Institute for Health Research Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 19.
See the NIHR Journals Library website for further project information.
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Plain English summary
There are high rates of depression in people with advanced (cannot-be-cured) cancer. Depressionworsens a person’s quality of life (QoL), may become a burden for carers and may prolong a patient’s
hospital stay. Cognitive–behavioural therapy (CBT) challenges unhelpful thinking and ways of doing things
to help improve mood. CBT is effective for treating depression, but it is unclear if it works for depression in
advanced cancer patients.
Advanced cancer patients with depression were entered into a research trial to see if the addition of CBT
to usual care was better at improving depressive symptoms than usual care alone. We also wished to
evaluate whether or not CBT helped to save costs.
We enrolled 230 participants from hospital clinics, general practitioner (GP) surgeries and the Marie Curie
Hospice, Hampstead. A computer program randomly allocated people to one of two groups: (1) CBT plus
usual care or (2) usual care alone. Everyone received usual care from their GPs and oncology teams. Patients
who were offered the addition of CBT received up to 12 1-hour sessions delivered through a community
service called Improving Access to Psychological Therapies. We measured depression using a questionnaire
called the Beck Depression Inventory, version 2 collected at the start of, and at 6, 12, 18 and 24 weeks into,
the trial. We also collected other measures, including those relating to health, QoL and resource costs at
various times.
Overall, there was no improvement in symptoms of low mood or cost savings with the addition of CBT to
usual care compared with usual care alone. This means that CBT does not benefit people with depression
and advanced cancer, and should not be routinely offered. However, those widowed, divorced or
separated appeared to benefit from CBT over and above their usual care. CBT targeted to these people
may be helpful and may ensure that resources are allocated in the best way.
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Scientific summary
Background
The CanTalk trial was a randomised controlled trial (RCT) testing the clinical effectiveness and cost-effectiveness
of cognitive–behavioural therapy (CBT) for depression in ‘advanced cancer’, defined as cancer that is not
amenable to cure or cancer in people with metastatic disease for whom standard curative therapies have
failed and/or in those with a poor prognosis.
A meta-analysis of depression in advanced cancer suggested the prevalence of clinical depression to be
16.5%. There is a considerable economic cost associated with depression, and individuals with cancer and
depression face several negative health outcomes.
An updated Cochrane review has considered which psychosocial therapies are effective in advanced cancer
and depression (Akechi T, Okuyama T, Onishi J, Morita T, Furukawa TA. Psychotherapy for depression among
incurable cancer patients. Cochrane Database Syst Rev 2008;2:CD005537). A recent review suggested that
CBT appeared to be the most promising. CBT challenges negative ways of thinking and unhelpful ways of
behaving by teaching the individual to challenge and modify negative thoughts and unhelpful behaviours
to help improve mood.
Currently, the UK agenda for treating depression aims to widen access to psychological treatment
delivered in primary care by trained mental health practitioners attached to the Improving Access to
Psychological Therapies (IAPT) programme.
As RCTs are the gold standard in research, we chose a parallel RCT design comparing treatment as usual
(TAU) with TAU plus the addition of individual manualised CBT for treating depression in advanced cancer.
Stirling Moorey, Kathryn Mannix and Marc Serfaty (co-applicants) developed a treatment manual and
a training package for IAPT therapists and supervisors on how to apply their CBT skills to people with
advanced cancer.
The revised Consolidated Standards of Reporting Trials guidelines for reporting non-pharmacological trials
recommend that a description of different components of the intervention is provided when evaluating
non-pharmacological interventions. It is recommended that three measures are recorded to evaluate
treatment implementation: (1) delivery, (2) receipt and (3) enactment. We used mixed methods to record
all measures except enactment.
Objectives
To conduct a RCT to test the clinical effectiveness and cost-effectiveness of TAU compared with TAU plus
individual CBT (delivered through IAPT) for treating depressive symptoms in people with advanced cancer.
Methods
Design
Parallel-group RCT.
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Participants
Patients (n = 230) with advanced cancer and depression.
Inclusion criteria
l Diagnosis of cancer not amenable to cure.
l A Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of depressive disorder
using the Mini-International Neuropsychiatric Interview (MINI).
l Sufficient understanding of English.
l Eligibility for treatment in an IAPT centre.
Exclusion criteria
l Clinician-estimated survival of < 4 months.
l High suicide risk established using the MINI.
l Currently receiving, or having received in the last 2 months, a psychological intervention recommended
by the National Institute for Health and Care Excellence (NICE) for treating depression.
Setting
Participants were recruited from oncology centres, general practitioner practices, a local hospice and
through self-referral.
Randomisation
Participants were randomised 1 : 1 to TAU or TAU plus CBT using Sealed Envelope™ (Sealed Envelope Ltd,
London, UK), a web-based system. Randomisation was conducted using permuted blocks with sizes of four
or six, stratified for antidepressant usage (yes/no).
Masking
Researchers and Primary Care Research Network assessors were blinded to group allocation.
Interventions
Treatment as usual
All participants received TAU from clinicians involved in their care.
Cognitive–behavioural therapy (in addition to treatment as usual)
Cognitive–behavioural therapy was delivered by high-level British Association for Behavioural and Cognitive
Psychotherapies-accredited IAPT therapists. The intervention comprised up to 12 sessions of individual,
manualised CBT delivered either face to face or over the telephone over 3 months. These sessions are
outlined below:
l session 1 – assessing and introducing the cognitive–behavioural model
l session 2 – developing an understanding of problems within a cognitive framework
l session 3 – reviewing the formulation, identifying new insights/changes through guided discovery.
Identifying helpful versus ‘unhelpful’ thinking
l sessions 4–5 – reformulating success experiences, identifying triggers and developing new coping
strategies through guided discovery
l session 6–7 – challenging thoughts and generating alternative ‘helpful’ ways of thinking
l session 8 – problem solving, checking that concepts are understood and realistic concerns addressed
along with introducing ‘worry time’
l session 9 – consolidating CBT strategies, prioritising problems and using worry management strategies
l session 10 – reviewing progress
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l session 11 – conducting relapse prevention through reviewing difficulties, identifying achievements and
promoting personal resilience
l session 12 – future planning by creating relapse prevention checklists and planning for action if distress
or unhelpful behaviours/thinking recurs.
Training
Improving Access to Psychological Therapies therapists were given a day’s training by the CanTalk team
(SM, MS and KM) to help apply existing CBT skills to people with advanced cancer.
Location of therapy
Therapy was offered at the local IAPT centre or by telephone CBT for those who had seen the therapist at
least three times.
Assessment of delivery of cognitive–behavioural therapy
Delivery of CBT was assessed using the Cognitive Therapy Scale – Revised (CTS-R) and through
qualitative interviews.
Qualitative methods
Three embedded qualitative studies were included:
1. clinicians’ experiences of referring into the CanTalk trial
2. therapists’ experiences of delivering CBT
3. patients’ experiences of CBT.
Primary outcome
l Beck Depression Inventory, version 2 (BDI-II): a 21-item self-report measure with a maximum score of
63 points.
Secondary outcomes
l Patient Health Questionnaire-9 (PHQ-9): a nine-item measure validated as a measure of depression in
primary care.
l EuroQol-5 Dimensions (EQ-5D): a generic utility measure of quality of life.
l Satisfaction with care: a five-item scale.
l Eastern Cooperative Oncology Group Performance Status (ECOG-PS): a measure of physical functioning.
l Client Service Receipt Inventory (CSRI): a short, modified CSRI that collects data on service use.
Timing of measures
The BDI-II, PHQ-9, EQ-5D, ECOG-PS and CSRI were collected at baseline, 12 and 24 weeks. The BDI-II was
also collected at 6 and 18 weeks.
Sample size
Our primary outcome was an overall effect of treatment over the 24 weeks. The power was to enable a
detection of a difference in BDI-II of 6 points [standard deviation (SD) 12 points] between the TAU and
CBT groups measured at 12 weeks, assuming a treatment effect of 3 points after 6 weeks and a sustained
6-point difference after 18 and 24 weeks. We assumed a 70% follow-up at 6 weeks, decreasing to 65%
at 12 weeks and 60% at 24 weeks.
The correlation between BDI-II values from sessions 1 week apart is reported as 0.93. We estimated the
correlation between measures taken 6 weeks apart to be 0.935 = 0.65.
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Sample size calculations estimated that, at 90% power and 5% significance, 109 participants were
required per trial arm. This was inflated by a factor of 1.10 to allow for therapist clustering, giving
120 participants per trial arm.
Analysis
Clinical outcomes
The primary analysis was a comparison on an intention-to-treat basis between the CBT and control arms
for the BDI-II score measured at 6, 12, 18 and 24 weeks using multilevel modelling, allowing for repeated
measurements with equal weighting for each time point, adjusting for therapist clustering. The model
comprised three levels: (1) repeated measures, (2) individuals and (3) therapists. Baseline BDI-II score and
antidepressant use were included as fixed effects. The model was fitted using a linear mixed-effects model
assuming a Gaussian error distribution.
Supportive analysis included the primary analysis, which was repeated (1) using clustering by IAPT service,
(2) ignoring clustering, (3) including additional covariates and (4) with separate analyses carried out for
each follow-up point. Exploratory and subgroup analysis included the primary analysis in addition to (1) a
treatment by time interaction, (2) a treatment by marital status interaction and (3) a treatment by education
status interaction. We also conducted a contamination-adjusted intention-to-treat (CAITT) analysis using the
18- and/or 24-week total BDI-II score.
For the secondary outcomes of PHQ-9 and satisfaction with care, we used a similar approach to the
primary analysis.
Cost-effectiveness
Quality-adjusted life-years (QALYs) were calculated from EQ-5D scores at baseline, 12 and 24 weeks’
follow-up. Service use costs were calculated from resource data to calculate the total cost of resources
used by each study participant.
Costs were compared for the groups using a bootstrap regression model to account for non-normality
in the distribution of cost data. A cost–utility analysis was undertaken using QALYs calculated from the
EQ-5D measure. Cost-effectiveness was assessed by estimating an incremental cost-effectiveness ratio
(ICER) to show the extra cost incurred by CBT to generate one extra QALY. To deal with uncertainty
around the ICER, a cost-effectiveness plane (CEP) and cost-effectiveness acceptability curves (CEACs)
were created.
Qualitative data
Semistructured interviews were conducted and transcribed. Data were analysed using thematic
content analysis.
Results
Recruitment and follow-up
We screened 2224 patients with advanced cancer. Of those, 819 did not meet the inclusion criteria, 1021
declined to participate, 144 were excluded for reasons not recorded and 240 participants were referred for
baseline. Of the 240 patients referred for baseline, 230 consented to participate and were randomised.
Participants were predominantly female (66%) and of white ethnicity (73%) with a mean age of 59.5 years.
Two-thirds of patients had tumours in one of the five main groups: (1) breast, (2) colorectal, (3) lung,
(4) prostate and (5) haematological. A total of 60% of participants had a previous history of depression.
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Over the follow-up period, 37 participants in the CBT group and 25 participants in the TAU group died or
withdrew from the study. The number of participants with at least one follow-up point was 93 in the CBT
group and 92 in the TAU group.
Clinical outcomes
The primary analysis of the BDI-II score did not find a significant benefit of CBT plus TAU versus TAU alone
[treatment effect –0.84, 95% confidence interval (CI) –2.755 to 1.083; p = 0.39]. Subsidiary analysis also
showed no benefit of CBT over TAU. Out of the exploratory analysis, in our predetermined analysis plan,
marital status demonstrated a benefit for CBT plus TAU over TAU alone for participants who were
widowed, divorced or separated (treatment effect –7.21, 95% CI –11.15 to –3.28; p < 0.001).
For the CAITT analysis, 153 participants were included. The estimated ‘per-session’ effect on the BDI-II was
–0.30 points (95% CI –0.76 to 0.17 points; p = 0.21).
Similar to the BDI-II, PHQ-9 scores and satisfaction with care scores showed a lack of significant benefit for
CBT plus TAU compared with TAU alone.
Eastern Cooperative Oncology Group Performance Status scores were similar throughout the study,
with around one-fifth of participants being fully active and two-fifths being of restricted mobility. Overall
satisfaction with care was around 80%.
Cost-effectiveness
At baseline, 12 and 24 weeks, there were no significant differences in service use (excluding CBT) between
TAU and TAU plus CBT. The mean service costs for participants (not including the costs of the interventions)
were similar across the two groups.
There were no differences in EQ-5D median scores at baseline, nor was there any advantage of CBT over
TAU at 12 weeks or 24 weeks. There was no statistically significant improvement in QALYs at 24 weeks.
The CEP indicates a 15.5% chance that CBT is cheaper and produces more QALYs, and a 74% chance
that CBT is more expensive and produces more QALYs. The CEAC indicates that, at the NICE threshold,
the probability of CBT being effective is 52%.
Intervention
A total of 543 (39.3%) sessions out of a potential total of 1380 were taken up, of which 32 (5.9%)
were by telephone. The mean time from being referred to being seen by an IAPT therapist was 29.4 days
(SD 26.7 days). For participants randomised to CBT, the mean number of sessions received was 4.7
(SD 4.9) and 41 participants (35.6%) did not take up any sessions.
Of the 543 therapy sessions delivered, 55 tapes (1 in 10) were rated. The mean CTS-R score by phase of
therapy was 47.9 points (SD 10.6 points) for 21 early sessions, 48.1 points (SD 18.8 points) for 19 middle
sessions and 46.7 points (SD 10.9 points) for 15 late sessions, indicating strong adherence to the
therapeutic model in CBT.
Guided discovery, activity scheduling, discussion about specific cancer topics, covering the impact of the
physical illness and beliefs and expectations about the illness were most the most common interventions.
Qualitative findings
Health-care workers’ views about the CanTalk trial
This substudy asked 14 health-care workers about their views of psychological (non-pharmaceutical)
research. Themes included recruitment issues – finding time and money, competing interests, catchment
area limits; the role of the clinician – their influence on the team, patient participation and trying to protect
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patients; the sensitive nature of the research – clashes with existing services and concerns regarding people
not eligible for the trial; and concerns about the trial team mis-selling research to units but wanting the
trial team to be involved in recruiting.
Therapists’ views of treating patients with advanced cancer
Sixteen therapists were interviewed using semistructured interviews. Themes included knowledge of
cancer – would have liked more knowledge, but gained this from talking to the patient; experience of
training – would have liked more information about type of cancer; concerns about treating advanced
cancer patients – anxiety about treating cancer patients, but surprise at how receptive patients were;
supervision – would have liked more specialist support; experience of working with patients – generally
easy to co-ordinate meetings and experience more positive than expected; and therapy materials –
therapists generally liked the materials, but it was not always easy to adhere to the manual.
Patients’ views about cognitive–behavioural therapy
Interviews were conducted with 10 patients who had received CBT. Themes included expectations and
knowledge of CBT – some knowledge, but little experience of CBT; structure and delivery of CBT – service
location was convenient, but transport could be a barrier; experience of CBT – CBT was helpful, facilitated
their ability to talk about cancer and to deal with unhelpful thinking; and other therapeutic options for
advanced cancer patients – it was felt that CBT would not be for everyone and that therapy should be
tailored to the needs of the patient. Suggested improvements included offering therapy in hospital, a
manual/workbook for patients, therapy for carers and reducing the frequency of sessions.
Discussion
In this sufficiently powered trial, CBT delivered through IAPT was not clinically effective or cost-effective for
treating depression in those with advanced cancer, despite the quality of therapy delivered being high and
the uptake consistent with the number of sessions taken up through IAPT. However, CBT was clinically
effective for those widowed, divorced or separated and this is consistent with data on the use of CBT to
treat depression in the community.
Conclusions
Cognitive–behavioural therapy delivered through IAPT is not recommended for treating depression in
people with advanced cancer, although a subgroup of those who are widowed, divorced or separated may
benefit from screening and referral to IAPT for CBT. Alternative research evaluating integrative care models
for treating depression in people with a range of cancers is worth testing. It remains to be established
whether or not mechanisms of change in our widowed, divorced or separated population was associated
with specific or non-specific treatment effect.
Trial registration
The trial is registered as ISRCTN07622709.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
The CanTalk trial was devised in response to a specific call from the National Institute for Health Research
(NIHR)’s Health Technology Assessment (HTA) programme to provide evidence on the clinical effectiveness
and cost-effectiveness of cognitive–behavioural therapy (CBT) for the treatment of depression in patients
with advanced cancer. Those who took part had an estimated minimum clinically assessed prognosis of
4 months so as to maximise the potential to retain participants in the trial, deliver the intervention and
collect outcome data.
Definition of advanced cancer
For this study, we defined ‘advanced cancer’ as cancer that is considered by oncology experts not to be
amenable to cure. People vary in terms of prognosis and the impact of the disease on their physical
functioning. Advanced cancer may include metastatic disease for which standard curative therapies have
failed, disease that is already widespread at the time the patient presents and that is unlikely to be cured,
and cancers with a poor prognosis, such as lung or pancreatic cancers.
Depression and advanced cancer
In this study, we defined ‘depression’ using the Mini-International Neuropsychiatric Interview (MINI). It is
distinct from adjustment disorders that might be expected in those with a terminal illness, for whom
appropriate sadness is a common response.
Depression is one of the most common mental disorders in people with cancer.1 Among those with
advanced cancer, the prevalence of depression measured using structured clinical interviews ranges from
5% to 45%2–4 and may vary with type of cancer.5,6 A meta-analysis3 of depression in advanced cancer
found the pooled prevalence of clinical depression to be 16.5%. There is a considerable burden on public
finances presented by depression; the overall economic cost of depression generally in England was
estimated to be £9B in 2000.7
Depression in people with cancer is associated with several negative health outcomes. It undermines quality
of life (QoL) for both patients and their carers,8–10 can reduce adherence to medications and treatment,10
and may prolong episodes of hospitalisation and increase health-care costs.11 Psychological distress,12 and a
diagnosis of depression in particular, predicts elevated mortality among cancer patients,13 as do higher levels
of depressive symptoms. Among those with advanced cancer, untreated depression is an independent
predictor of early death.14
Therapy for depression in advanced cancer
There is a scarcity of evidence to guide the management of depressive symptoms in advanced cancer.15–17
Among cancer patients with mixed prognoses (not limited to advanced cancer), evidence suggests that a
nurse-led intervention including education about depression, problem-solving and behavioural activation is
effective in treating depression in people with cancer (not advanced).18,19 However, this intervention was
also found to be effective among patients with poor-prognosis (lung) cancer.20 Guidelines developed for
the European Palliative Care Research Collaborative suggest that patients whose cancer is unlikely to be
cured and who present with depression should be referred to specialist palliative care.21 Treatment will
include psychosocial support and the use of antidepressants and/or psychosocial therapy.22
Three Cochrane reviews23–25 have looked at which psychosocial therapies are effective in advanced cancer.
One of these, a meta-analysis23 of psychosocial therapies for depression in advanced cancer, cited six
studies: four26–29 used supportive psychotherapy, one30 used group CBT and one31 used problem solving.
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The results of this meta-analysis23 were heterogeneous, and the authors concluded that further, well-designed
trials were needed to evaluate if CBT is effective at treating depression in patients with advanced cancer.
The other two Cochrane reviews24,25 looked at psychological interventions in women with metastatic breast
cancer. One24 identified five well-designed studies.26,30–33 The first two of these studies30,32 suggested that CBT
resulted in a short-term improvement in the Profile Of Mood States (POMS) score; however, the effects were
lost at the 6-month follow-up, possibly because group therapy did not sufficiently address the needs of
specific individuals. An updated review of psychological interventions in women with metastatic breast cancer
and depression25 identified 10 well-designed studies.26,30–38 Three of these studies26,31,33 showed evidence of a
small improvement in the POMS score among patients receiving group CBT, although this finding did not
reach statistical significance.
Cognitive–behavioural therapy
Cognitive–behavioural therapy is an empirically effective treatment for major depression. The rationale
behind CBT is that depression is associated with negative ways of thinking and unhelpful ways of behaving,
and teaching the individual to challenge and modify negative thoughts and unhelpful behaviours helps to
improve mood. CBT for treating depression compares favourably with antidepressant treatments and has
been shown to be associated with significant therapeutic gains over time. Trials of CBT have demonstrated
some evidence of efficacy in treating depression in cancer patients. A recent Cochrane review39 of trials of
psychosocial interventions for women with non-metastatic breast cancer indicated that patients receiving
CBT were less depressed than patients in control groups. CBT is an approach that may be pertinent to
treating a population who may experience significant symptom burden from advanced cancer and palliative
treatments, such as nausea and pain. A review40 of treatments for depression in patients with advanced
cancer has suggested that CBT approaches are the best evaluated and show the most encouraging results;
the studies are summarised here.
Screening and recruitment of advanced cancer patients
The European Association for Palliative Care calls for the screening and treatment of depression in patients
with advanced cancer.41 A number of different methods have been used and recommended to screen for
depression in cancer patients.42 The simplest method asks two simple questions43 that have been shown to
exclude depression in non-depressed individuals in cancer and palliative care with a 97% negative predictive
value.44,45 The first two questions of the Patient Health Questionnaire-9 (PHQ-9), known as the Patient Health
Questionnaire-2 (PHQ-2), are routinely used to screen for depression in primary care. Such brief screening
is acceptable if followed by a clinical interview to confirm the clinical diagnosis of depression.46 The MINI47
provides a brief and reliable method for diagnosing depression according to Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV) and International Classification of Diseases,
Tenth Edition (ICD-10) criteria in cancer patients.47–55 It has been validated against the Structured Clinical
Interview for DSM,56 Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised57 and
the Composite International Diagnostic Interview58 and has been widely used in cancer patients.
Recruitment into, and retention of participants in, palliative care studies can be difficult for several
reasons.59,60 First, associated mental and physical exhaustion present major hurdles to recruitment and
retention.61 Second, there may be high rates of attrition due to early death.61 Third, well-meaning health
professionals may be protective towards patients by discouraging them from making the extra effort
required to participate in a study. For example, in previous trials of CBT for depression in advanced cancer,
9–19% of patients approached agreed to participate in the research.30,62,63 Follow-up rates as low as 44%
at 10 weeks have been reported in severely ill palliative care patients,62 although higher follow-up rates are
possible and some studies have reported 75% follow-up at 3 months.30,63 Previous research conducted by
our research team within the London cancer networks have achieved follow-up rates of at least 65%.64,65
A number of strategies and recommendations have since been made to increase recruitment of people
with cancer in clinical trials.59,60
In trials conducted in our research group to evaluate CBT in older people with depression,66 CBT in cancer
patients67 and advance care planning discussions in cancer,68 follow-up rates of > 85% were recorded.
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In each of these studies we offered both treatment at home and telephone interview follow-ups,
significantly minimising attrition. Telephone CBT has been shown to be both feasible and clinically effective
and cost-effective.69,70 Individualised, rather than group, CBT is likely to facilitate recruitment and minimise
attrition. Individual CBT has been found to be preferred by patients with head and neck cancer.15,71
Benefits of individualised CBT have also been reported in a study of CBT for depression in women with
metastatic breast cancer.63
Rationale for providing therapy for depression in advanced cancer through the NHS
The research outlined suggests that CBT is an effective treatment for depression and may be a promising
treatment for depression among advanced cancer patients. However, advanced cancer patients are not
routinely screened and treated for depression within the NHS, despite National Institute for Health and
Care Excellence (NICE)’s recommendations that this be done.72 There is currently no manual-based therapy
aimed at treating depression in this patient group and there is not currently a sufficient evidence base to
determine that CBT is clinically effective and cost-effective in advanced cancer patients.
Our therapy, consistent with the evidence given, consisted of individual as opposed to group CBT. The UK
agenda for treating depression is to widen access to psychological treatment through Improving Access to
Psychological Therapies (IAPT) centres that operate in primary care and provide a stepped care approach
provided by trained mental health practitioners. In order to provide a pragmatic trial of the effectiveness of
CBT in treating patients with advanced cancer, we utilised this existing IAPT infrastructure to provide CBT
to advanced cancer patients who screen positive for clinical depression.
Evaluation of cognitive–behavioural therapy provided, fidelity to the intervention and
its principles
Moncher and Prinz73 proposed guidelines to enhance treatment fidelity, which have been further developed
by Lichstein et al.74 and Bellg et al.75 They recommend assessing whether or not a psychological treatment is
delivered by the therapist and is understood and carried out by the client; these stages have been respectively
described as delivery, receipt and enactment. The primary purpose of the CanTalk trial was to evaluate the
addition of CBT to treatment as usual (TAU) compared with TAU alone. We adopted a pragmatic approach
within the constraints of the resources available by focusing on evaluation of the treatment delivery, and
assessing whether or not the patient seemed to have understood the principles of CBT.
The first question, of treatment delivery, was assessed using quantitative methods. The second question,
about whether or not the treatment was received, was explored using qualitative semistructured interviews
with 10 participants who had received CBT. The background to this is reported in Background to qualitative
work and the methodology in Chapter 3, with a summary of the findings in Chapter 5. A fuller report on
qualitative experience of therapy will be prepared for publication elsewhere. The third question, relating
to enactment and determining whether or not the CBT model prompted behaviour change in the patient,
was beyond the aims of the study and, therefore, was not evaluated.
Concerning treatment delivery, two areas are worthy of consideration. The first important consideration is
whether or not the CBT is being delivered competently, including whether or not the therapist is sufficiently
flexible and able to use a range of techniques to engage the patient. Competent delivery of CBT, evaluated
using the Cognitive Therapy Scale (CTS), has been shown to be related to outcome,76 although the relationship
between therapist adherence and competence in determining symptom change is less clear cut than
originally thought.77 The second important consideration is whether or not the therapist adheres to the
treatment manual described by Moorey, Mannix and Serfaty. The CanTalk treatment manual was intended
to be made available for download on the NIHR webpage for this project. However, the manual was based
on work published in Moorey78 and it was not possible to obtain permission from the publisher to make this
document available. Please contact the corresponding author for more information about the manual.
Indeed, we would like to point out that the revised Consolidated Standards of Reporting Trials (CONSORT)
guidelines for reporting non-pharmacological trials79 have suggested that a description of different components
of the intervention is to be provided when evaluating non-pharmacological interventions.
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With respect to the first question concerning treatment delivery, we decided that two issues were worthy
of consideration. First, an assessment of the therapist’s competence and, second, a measure to confirm
that adherence to the CanTalk manual had taken place. In effectiveness studies such as the current one, it
can be more difficult to ensure competence and adherence owing to the challenges inherent in delivering
the treatment in a routine clinical service. Therapists may be time pressured, there may be differences
between services in how CBT is delivered and, crucially in a study of patients with advanced cancer,
therapists may not have experience in treating people with physical conditions.
Training of therapist for CanTalk to deliver cognitive–behavioural therapy specific for
people with advanced cancer
To maximise competence and adherence to the protocol, mental health therapists with existing CBT skills
were selected and trained to apply these skills to people with advanced cancer. This seemed appropriate
given that the Five Year Forward View for Mental Health80 aims to expand the IAPT services for people
with long-term conditions (LTCs). However, we chose to stipulate that, within IAPT services, therapists
would need to be accredited by the professional organisation of the British Association for Behavioural
and Cognitive Psychotherapies (BABCP). Accreditation is not in itself sufficient assurance that high-quality
treatment is delivered; however, it does improve the likelihood. When adherence is concerned, it needs to
be acknowledged that accreditation cannot ensure that therapists deliver the therapy in accordance with
a specific protocol for the treatment of depression associated with cancer. However, selecting high-level
therapists minimises any distraction caused by needing to learn CBT techniques and allows them to apply
their skills to cancer patients. This was done by training all therapists and some of the supervisors on how
to assess and deliver the Moorey, Mannix and Serfaty model to advanced cancer patients; more details are
provided in Chapter 3, Training Improving Access to Psychological Therapies therapists.
Background to qualitative work
In the CanTalk trial, we explored both patients’ experience of receiving CBT and and therapists’ experience
of delivering it, as well as clinicians’ views of referring into CanTalk. As this work was not commissioned
or funded by the HTA programme, we have included only a summary in this report. Nevertheless, we
would suggest that findings from this qualitative work are likely to guide practice. The full background,
methodology, results and discussion are to be reported elsewhere.
Clinicians’ experience of the CanTalk trial
During the course of the study, we became aware that cancer clinicians involved in identifying patients
who did not come from a mental health background had a wide range of views about psychological
research in people with advanced cancer. We informally detected a range of views about the relevance of
psychological research in advanced cancer patients. Some clinicians were strongly supportive and others
suggested that CanTalk was outside their remit or that they felt uncomfortable with the psychological
nature of the trial. Further examination of the literature suggested that there was a dearth of research
in the area. As cancer clinicians play an essential role in facilitating recruitment, we decided to conduct
qualitative work to determine the views of clinicians about psychological research in advanced cancer,
their experience of referring into the CanTalk trial, any obstacles they may have experienced and how to
improve recruitment into similar trials.
Therapists’ views of treating people with advanced cancer
Both the client and therapist play a role in the outcome of CBT,81 with the therapeutic alliance having an
impact on the outcome of therapy.82 When randomised controlled trials (RCTs) have failed to demonstrate
an impact on cancer populations,83,84 interpretations of the findings are purely theoretical. Empirical
literature suggests that a number of therapist-specific factors play a major role in the outcome of CBT.85,86
Despite the importance of the therapists’ role in this type of therapy, there is a dearth of qualitative
INTRODUCTION
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research conducted from a therapist perspective that addresses their personal experiences of delivering
therapy. Indeed, most of published research into experiences of CBT has used quantitative methods,
and concerns about such methods have been raised,87 with the focus being purely on client perspectives
of CBT with no attempts to explain things qualitatively and directly from a therapist perspective.
In order to determine whether or not the costs outweigh the benefits of this particular treatment in this
population, we took a holistic approach so that, as well as quantitatively addressing the effectiveness
of treatment, we undertook a qualitative assessment (not required in the brief) of treatment from the
therapists’ perspectives on (1) their overall views and experiences of delivering CBT, (2) how services and
therapy may be improved, (3) specific training requirements and (4) issues in delivering therapy sessions.
This was to help inform the optimum use of resources.
Experience of cognitive–behavioural therapy in people with advanced cancer
There is evidence to suggest that CBT is an effective treatment for people with depression and advanced
cancer63 but little is known about how patients in this group perceive CBT or about their thoughts and
experiences of it.
For cancer patients attending group CBT, their experiences have been positive; patients enjoy the
interpersonal and social environment of the group88 and learn skills to challenge and solve problems.89
Feedback from patients receiving individual CBT has also been encouraging. Omylinska-Thurston and
Cooper90 interviewed eight patients with primary cancers who had received a course of psychological
therapy within a NHS service for cancer patients and found that participants found talking about their
feelings to someone outside their family and problem solving helpful. In a study in Australia,91 cancer
patients with metastatic disease commented that CBT allowed them to share their thoughts and feelings
with an understanding, caring therapist. Finally, Anderson et al.92 found that hospice patients reported
CBT to be acceptable and effective.
Although qualitative work has focused on cancer patients’ experience of individual CBT, there is little
information about the experience of advanced cancer patients. The remit of IAPT services in the UK is
to be expanded to cover patients with chronic health conditions,93 including cancer. Despite the London
Cancer Alliance94 having some reservations about the ability of IAPT therapists with brief training to treat
older people with complex needs, there are few data evaluating how patients should best be managed.
The qualitative work was designed to elucidate what aspects of CBT participants found helpful, their
thoughts about their therapist and the impact of CBT on their QoL, and patients’ views about the best
way to support them emotionally.
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Chapter 2 Objectives
The study aimed to test, within a RCT, the clinical effectiveness and cost-effectiveness of IAPT-deliveredmanualised individual CBT together with TAU for people with a depressive disorder and advanced
cancer compared with TAU alone on depressive symptoms over a 6-month period.
An economic evaluation was undertaken using a cost-effectiveness analysis comparing differences in
treatment costs for patients receiving the CBT intervention with quality-adjusted life-years (QALYs)
computed from the EuroQol-5 Dimensions (EQ-5D) and societal weights over a 6-month follow-up.
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Chapter 3 Methods
Acknowledgement
This chapter contains information previously published by Serfaty et al.95 © 2016 Serfaty et al. Open Access.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction
in any medium, provided you give appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made
available in this article, unless otherwise stated.
Trial design and governance
Trial registration
This trial is registered as ISRCTN07622709. The full protocol is available online and published in Trials.95
Trial design
This is a parallel-group RCT, stratified by antidepressant prescribed at baseline (yes/no), comparing TAU
with TAU plus up to 12 sessions of manualised CBT. Allocation ratio for the two trial arms was 1 : 1.
Patient and public involvement
The trial was designed in response to a HTA programme call. Janet St.John-Austen, a user of cancer
services, was an active contributor to the design of the project, the preparation of the materials (including
the layout and wording for clarity and sensitivity) and ethical considerations. She attended regular steering
group meetings and was invaluable in commenting on methods to boost recruitment. She also contributed
to the interpretation of the results and write-up.
Ethics approval
A favourable opinion for the conduct of the study was granted by the London–Camberwell St Giles
National Research Ethics Service committee, Central London (REC3 reference number 11/LO/0376). This
study formed part of the National Cancer Research Network (NCRN) clinical trials portfolio (registration
number 10255, ISRCTN07622709). The trial was conducted in compliance with the Declaration of
Helsinki.96 Informed written consent was obtained from all participants.
Changes to protocol
Several amendments were made to the study’s procedures during the course of the study, including
changes to streamline recruitment methods and the addition of three qualitative substudies. These
amendments are outlined in Table 1.
Eligibility criteria for participants
Inclusion criteria
1. People with a diagnosis of cancer not amenable to curative treatment as assessed by their clinician and
defined as those receiving palliative radiotherapy or chemotherapy, and those with metastatic disease or
subsequent incurable recurrence. The diagnosis was verified by oncologists or general practitioners (GPs).
2. A DSM-IV diagnosis of depressive disorder using the MINI.47
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3. Sufficient understanding of English judged by clinic staff to enable them to engage in CBT.
4. Eligible for treatment in an IAPT centre. Either the patient or their GP had to be located in an
appropriate IAPT catchment area.
Exclusion criteria
1. Clinician-estimated survival of < 4 months, verified by the patients’ oncologists or GPs.
2. People at high risk of suicide, established through module C of the MINI.
3. Currently receiving, or having received in the last 2 months, a psychological intervention recommended
by NICE aimed at treating depression (e.g. interpersonal psychotherapy, CBT).
4. Suspected alcohol dependence using the Alcohol Use Disorders Identification Test.97
We did not recruit in areas where the local palliative care service includes routine access to CBT, to avoid
contamination of TAU arm by non-study CBT.
TABLE 1 Changes made to the original study protocol and procedures
Amendment
number
Date of amendment
approval Summary of changes
1 4 December 2012 1. Consent procedure: removal of the step in which a nurse telephones the
participant 48 hours after screening to arrange a baseline appointment.
Instead, participants screening positive will be offered a baseline
appointment straight away, to take place not < 48 hours later
2. Self-referral: added an option of self-referral to the study via posters and
leaflets in approved oncology and GP sites. Patients can then either approach
the clinical team within the site or contact the study team directly
2 28 October 2014 1. Consent to audio record therapy: participants will be asked for consent to
audio recordings of therapy being made and used for research, for example
to assess the quality of therapy
2. Obtain consent for participants to be approached for future research related
to CanTalk. (Refusal to consent to this will not exclude someone from
the study)
3 22 January 2015 1. Addition of substudy: addition of qualitative substudy ‘CanTalk Study:
your experience of CBT’, exploring experience and opinions of the therapy in
participants who have received CBT from the CanTalk trial
4 1 July 2015 1. Addition of substudy: additional qualitative substudy ‘CanTalk Study: views
and experiences of therapists delivering CBT to advanced cancer patients’,
exploring, with therapists who have delivered CBT as part of the trial, how
they felt working with this group, any issues encountered, any training
requirements and their thoughts on how best to support these patientsa
5 14 September 2015 1. Addition of substudy: additional qualitative substudy ‘CanTalk Study:
clinicians experiences of referring to the CanTalk study’, exploring the
attitudes to psychological interventions and experience of recruiting patients
for psychological interventions among health-care staff involved with the
CanTalk study
6 21 September 2015 1. Changes to the qualitative substudy ‘CanTalk Study: your experience of CBT’.
Addition of a follow-up call to check that participants have received the letter
of invitation and whether or not they wish to take part in the substudy
a Although we already had consent from people and obtained permission to record therapy sessions as part of the trial
and for quality control, it was not specified that this was for research purposes; therefore, we notified the sponsor and
ethics committee of this breach of protocol and applied for an amendment to clarify this.
METHODS
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Recruitment methods and procedures
Timeline and setting
Recruitment of participants commenced on 1 September 2012. Recruitment finished on 14 December
2015 (the end of the study’s agreed recruitment period). The first participant was recruited into the study
on 27 November 2012. The first 6-week follow-up took place on 15 January 2013 and the final 24-week
follow-up took place on 19 May 2016.
Participants were identified in four ways: (1) from oncology centres, (2) through GP practices, (3) through
the Marie Curie Hospice, Hampstead and (4) through self-referral using leaflets left in GP surgeries and
oncology clinics.
Outpatient oncology clinics
National Cancer Research Network support staff working with University College London (UCL) researchers
facilitated recruitment from oncology outpatient clinics. Patients’ GP addresses were checked to determine
that they were eligible to be referred to an IAPT service before they were approached. UCL researchers
collected accurate data about the number of patients screened and the proportion of whom satisfied the
entry criteria. However, NCRN support staff or research nurses could not always commit to collecting data
on the number of people screened for eligibility. In addition, UCL researchers attempted to collect patients’
reasons for not wishing to take part in the study; however, this information was not always available as
the ethics application stipulated that patients did not need to give a reason.
We selected oncology services to represent a variety of patients from the main tumour groups: breast,
gastrointestinal (GI), lung, haematology, prostate and other. Patients attending radiotherapy and
chemotherapy clinics came from all tumour groups. Oncology centres were identified across England
and represented a variety of services, and we recruited from the following hospitals and clinics. Screening
data and numbers of participants recruited, when available, are presented in Chapter 5.
Unless otherwise specified, UCL research staff attended in the following clinics.
North London
l Royal Free Hospital: breast, radiotherapy, lung, urology, lymphoma, melanoma, head and neck,
and renal.
l Whittington Hospital: the clinic research nurses approached, screened and then sent screen-positive
details about patients from the following clinics – colorectal, upper GI, lung and breast.
l University College London Hospital: myeloma, lymphoma, melanoma, gynaecology and radiotherapy,
breast, lung, GI and sarcoma.
l North Middlesex University Hospital: lung, chemotherapy (all tumours), GI and breast. A cancer
researcher also screened from breast and lung clinics.
East London
l Homerton University Hospital: lung clinics.
l Barts and The London: prostate, GI, lung, breast (Barts) and melanoma (The Royal London Hospital).
South London
l University Hospital Lewisham: the clinic research nurses approached, screened and then sent
screen-positive details about patients from the following clinics – lung, colorectal and breast.
l Guy’s and St Thomas’ Hospital: myeloma, breast, upper GI, colorectal, hepatopancreatobiliary (HPB),
lung (Guy’s) and Neurology (St Thomas’).
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l Princess Royal University Hospital (PRUH): UCL research staff attended the lung clinic. Research nurses
at the PRUH approached, screened and sent screen-positive patients to contact from the breast and
haematology clinics.
l King’s College Hospital: breast, myeloma and neurology, and a research nurse screened in the
haematology, lung, breast and colorectal clinics.
l Queen Elizabeth Hospital: the clinic research nurses approached, screened and then sent screen-positive
details about patients from the following clinics – breast, lung, GI and colorectal, and urology.
Out-of-London sites
Patients in all of the out-of-London sites were identified, screened, recruited and followed up by research
nurses. The following clinics participated in the study:
l South-west England (Weston Super Mare) – participants were identified from the Weston General
Hospital haematology and prostate oncology clinics.
l Midlands (Coventry and Warwick) – oncology clinics (breast, colorectal, prostrate, GI, neurological, and
head and neck).
l The south of England (Brighton General Hospital) – identified patients for the study in the Midhurst
Macmillan multidisciplinary team meeting. Patients identified were then approached in their clinics
and screened.
l The north of England (South Tyneside) – patients were identified from oncology clinics (colorectal
and urology).
l The north-west of England – patients were identified in oncology clinics (gynaecology, HPB, breast,
palliative care and chemotherapy) at oncology centre 14.
General practitioner practices
Reeve et al.98 have used methods to identify those patients from registers of people with advanced metastatic
cancer who are receiving only palliative treatment. However, our preliminary examination of general practice
data prior to the study suggested that < 10% of all cancer patients are placed on palliative care registers
even though 60% of cancer patients may have advanced disease. Identifying patients from palliative care
registers approaches a restricted population; for example, only the sickest patients may be placed on such
registers and they may have been too ill to respond to the authors’ survey. Indeed, psychological and
psychiatric morbidity associated with cancer goes undetected and undertreated in > 80% of people.99,100
Given these varied data, for the purposes of our study, we assumed a more conservative prevalence rate for
major depression in advanced cancer patients with rates of depression of 15% in oncology outpatients and
10% in GP patients.
General practitioner practices were identified from areas where collaborating IAPT/well-being services were
located and were approached if they had previously expressed an interest in research and had ≥ 55 patients
on their cancer register. We used our established links with the Primary Care Research Network (PCRN) in
south London and the North Central London Research Consortium in north London to approach practices
that expressed an interest in research. Cancer registers were used rather than palliative care registers as the
latter include a significant number of people with non-cancer diagnoses.
Marie Curie Hospice, Hampstead
The Marie Curie Hospice, Hampstead, is purpose built and cares for around 450 registered patients.
Hospice clinic staff identified potential participants attending the hospice day-care, outpatients services and
the hospice gym and asked them if they could be approached by UCL researchers to see whether or not
they were eligible to take part in a research study.
Self-referral
With the permission of clinical leads in each service, posters and leaflets about the study were placed in
approved oncology clinics and GP practices.
METHODS
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Set-up procedures
The time taken for sites to become active was an important element of the research process as such
procedures may delay the start of recruitment and escalate the costs of research. In Chapter 5, we will
report when research and development (R&D) applications were made, when R&D approval was received
and when sites became active. In one centre, approval was required by the hospital board prior to
submitting an application for R&D approval.
Screening methods
Participants were screened for entry into the study between 1 September 2012 and 14 December 2015.
Oncology centres
Either support staff or UCL researchers screened suitable patients for depression using the PHQ-2,101,102
the first two questions of the PHQ-9,103 a valid screening measure for depression routinely used in general
practice.
Patients who scored ≥ 3 points were provided with a pre-screening information pack and asked if they
would be willing to be assessed for the study. If they scored ≥ 3 points but did not wish to participate, their
permission was sought for their GP or oncology team to be informed that they may be depressed. If they
agreed in principle to take part, a researcher undertook a further assessment, using the MINI to establish
a DSM-IV diagnosis of depressive disorder. If a DSM-IV diagnosis of depression was confirmed, the patient
was given an information pack. The patient was then given at least 48 hours to reflect on whether or not
they wished to participate in the study before giving written consent for participation. If a patient consented
to take part, the researcher then conducted baseline assessments and passed the participant’s details to an
independent trial administrator, who arranged randomisation through the PRImary care and MENTal health
(PRIMENT) Clinical Trials Unit (CTU). The study administrator informed the participant by telephone of their
group allocation. For those randomised to the treatment arm, the administrator liaised with IAPT to set up
the therapeutic sessions. Both administrator and PRIMENT were situated separately from the trial research
team to maximise masking of trial arm allocation from the researchers.
General practitioner practices
University College London researchers attended the practice and trained a practice research nurse in the
standard operating procedure on how to identify potential suitable participants. Practice administrators
identified people on the cancer register and consulted the GP on whether or not the patient had advanced
cancer as defined in the protocol. By mutual agreement according to availability at the practice, either the
practice nurse or PCRN staff contacted the patient by telephone or face to face in practices to explore
whether or not they were willing to answer the two PHQ-9 screening questions for depression. The
procedure was then the same as for the oncology centres but, in this case, the practice nurses/PCRN
nurses collected follow-up data at the relevant time points.
Marie Curie Hospice, Hampstead
University College London researchers consulted clinic records and checked the eligibility criteria for
those identified as suitable by hospice staff. They then approached potential participants for screening as
outlined above. Those suitable were then told about the trial and consented once they had had 48 hours
to consider participation.
Self-referral
The leaflet contained the PHQ-2 for patients to conduct a quick assessment of their mood themselves,
suggesting to people with a score of ≥ 3 points that they may have depression and that they should either
(1) approach the clinical team within the site or (2) contact the study team directly using the reply slip
attached to the leaflet. The process of recruitment was the same as that previously outlined.
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Screening data
In instances in which the UCL researchers undertook the screening, they were able to collect data about
the number of patients screened – the proportion of whom satisfied entry criteria – and, if patients
declined to take part, the reasons (if given). It is important to highlight that the ethical principle that
patients are free to decline to take part or withdraw from a study without giving a reason was included in
the project’s ethics approval submission. When Comprehensive Local Research Networks (CLRNs) were
undertaking identification, selecting and screening of patients, comprehensive data for numbers of people
screened and reasons for declining to take part in research were not always available as CLRNs indicated
that they did not have the resources to collect these data.
Randomisation
Participants were randomised to one of two conditions, (1) TAU or (2) TAU plus CBT, with an equal
allocation to each treatment arm. Randomisation occurred after patients had been assessed to meet the
eligibility criteria and had consented to participate and baseline measures had been collected. Once a
participant had been randomised, the trial administrator called the participant to inform them of their
group allocation. For participants randomised to the group receiving CBT, the trial administrator then
sent an e-mail to a contact in the relevant treatment centre providing details of the participant.
Randomisation was conducted by the trial administrator using Sealed Envelope (Sealed Envelope Ltd,
London, UK), an automated online randomisation system supplied by the PRIMENT CRU (a UK Clinical
Research Collaboration registered CTU). This system was pre-populated with a randomisation list using
a randomisation algorithm developed by the trial statisticians. The randomisation was tested using a test
version of the Sealed Envelope randomisation system. Randomisation was conducted using permuted
blocks with block sizes of four or six, stratified for antidepressant use (yes or no). Antidepressants are a
predictor of outcome.104 In cancer, tricyclic antidepressants (TCAs) may be preferentially prescribed over
selective serotonin reuptake inhibitors because they have fewer relevant side effects, such as nausea,
and may be used for both mood and, in lower doses, for pain. Indeed, even low doses of TCAs may be
effective.105 Therefore, we stratified our randomisation according to whether or not participants were
prescribed an antidepressant, irrespective of dose. We did not have the resources to measure compliance
with medication through pill counts or by taking blood levels, but we did ask participants what they were
taking, estimated their antidepressant doses and converted them to equivalent doses of fluoxetine using
methods previously described by Hayasaka et al.106 to assess whether or not the doses of prescribed
antidepressants were similar in both arms of the trial at randomisation (see Chapter 4, Analysis plan).
Masking
Once a participant had been randomised, the trial administrator unblinded that participant by clicking on
an ‘unblind’ link on the Sealed Envelope system that generated an e-mail to themselves with details of the
group allocation.
It is not possible for patients or therapists to remain blind to the treatment group. The trial manager was
unblinded only if needed, for example if there was a problem referring a patient to therapy. The trial team
worked at UCL and was based in a different location to the therapy teams that conducted the trial
intervention.
Assessment of blindness
The UCL researchers who were blinded were asked to guess group allocation (TAU alone, TAU plus CBT
or do not know) at 3 months (post intervention) and 6 months (follow-up). Although the PCRN assessors
were blinded, they requested that any additional data collection was kept to a minimum and, therefore,
they did not make an assessment of blindness.
Unmasking for those conducting the analysis did not occur until databases were closed.
METHODS
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Intervention
Treatment as usual
All participants received TAU from all clinicians involved in their care. This consisted of routine support,
such as appointments with GPs, clinical nurse specialists, oncologists and palliative care clinicians.
Participants’ physical health and medication were reviewed and treatment was modified according to
symptoms, such as pain. Psychotropic medication was allowed to be prescribed as necessary, by either the
GP or the oncologist. In line with NICE’s guidance,107 specific psychological support should have been
available for those who presented with psychological needs at any time, and study participants were not
exempt from receiving external psychological support. We discouraged specific psychological interventions
aimed at treating symptoms of depression (e.g. CBT or interpersonal psychotherapy), but, ultimately, we
could not interfere with usual care for ethical reasons. We recorded the numbers of participants receiving
any psychological therapy during the trial, although we predicted that the numbers were likely to be
small.66 We did not stipulate post randomisation that antidepressant medication could not be used or that
the dose should be fixed. Withholding a recognised treatment for depression would be unethical and
would not reflect TAU.
Cognitive–behavioural therapy (in addition to treatment as usual)
The CBT was delivered through IAPT93 and well-being centres. IAPT/well-being centres train, supervise and
supply therapists to treat people in primary care with mental health problems. For the purpose of the
study, only step 3 and 4 (high-intensity) therapists who had experience of CBT were used. They were given
1 day’s training by the CanTalk team (SM, MS and KM) so that their existing CBT skills could be adapted
to use a specially developed treatment manual for people with advanced cancer. The manual detailed
modifications in the structure of therapy and its content; in particular, it took into account physical health
problems, existential issues and communication with loved ones.
Structure of cognitive–behavioural therapy sessions
The National Institute for Health and Care Excellence recommends 16–20 sessions of CBT to treat severe
depression in secondary care. Experience shows that, in primary care, considerably fewer sessions are
taken up. People with advanced cancer may have difficulty coping with longer therapy as their health may
be deteriorating. Our intervention consisted of up to 12 sessions of individual CBT, which was delivered
either face to face or over the telephone over 3 months. Although telephone CBT was not delivered as
a substitute for face-to-face treatment, it was used to facilitate engagement and minimise dropout.
Twice-weekly sessions could be offered for the first 2 weeks, weekly sessions for weeks 3–9 and then
two sessions within weeks 10–12. The timing of sessions was flexible and pragmatic to fit in with the
existing commitments of the IAPT service and with patient availability, taking their other medical clinics
and treatments into account.
In order to facilitate engagement for those who may not be able to attend sessions face to face, telephone
CBT was offered if at least three sessions of face-to-face therapy had already been received. Telephone CBT
was already being used by IAPT therapists. Stirling Moorey, Marc Serfaty and Kathryn Mannix taught
CBT therapists how to adapt their CBT techniques for telephone-based therapy using similar methods
to Tutty et al.108
Content of cognitive–behavioural therapy sessions, guided by a written manual
Improving Access to Psychological Therapies guidelines recommend that patients with moderate to
severe depression and complex needs receive high-intensity (step 3) work. This is consistent with the level
4 psychological interventions recommended by NICE72 for people with cancer. The CBT intervention used
a flexible approach, adapted for use with people with advanced illness who face a poor prognosis. In the
manual, developed by Stirling Moorey, Kathryn Mannix and Marc Serfaty, therapists adapted their work to
patients with advanced cancer. The key shift was to identify whether thinking and behaviour are ‘helpful’
or ‘unhelpful’ rather than solely a reality-testing approach, thereby enabling patients to adopt adaptive
strategies to cope with adverse and often unpredictable health circumstances.
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The intervention broadly covered the following:
l Session 1 – an assessment of problems, psychoeducation about depressive disorder and an introduction
to the cognitive model was undertaken. A simple cross-sectional formulation of current emotional
distress was established, and the triggers to emotional distress and how to manage them were
identified, with steps towards one of the patient’s goals. A list of enjoyable activities was instigated,
and unhelpful thinking styles were identified, using specific examples from recent events.
l Session 2 – aimed to help patients develop an understanding of their problems within a cognitive
behavioural framework and began the process of therapy using cross-sectional formulation. This
included a discussion of past strengths and coping abilities. Behavioural activation techniques were
used within the constraints of the person’s physical illness.
l Session 3 – consisted of a review of the formulation, identifying any new insights/changes. Guided
discovery, through a deeper discussion of the patient’s thoughts/beliefs around their illness and their
resilience, was used to help them apply their resilience under current circumstances. A start was made
on identifying ‘helpful’ versus ‘unhelpful’ thinking and behaviours.
l Sessions 4 and 5 – helped the patient to apply new learning to current difficulties, recent successful
experiences were reformulated and helpful changes were identified. Guided discovery was used to help
the person notice successful experiences and build resilience. The triggers to emotional distress and
strategies for responding were explored. These included thought-testing and an in-session experiment
of allowing intrusive thoughts to pass.
l Sessions 6 and 7 – focused on thought-testing and finding ‘helpful’ alternative thoughts. This was
done within sessions, supplemented by homework completed by the patient between sessions, when
logs of patients’ mood, the associated thoughts and behaviours were reviewed. Thoughts and
behaviours could then be challenged and more helpful alternatives considered. Examples of recent
success experiences were added to successes lists and exploration of these for their associated
‘helpful’ thoughts.
l Session 8 – focused on problem solving and worry time. Confirmation was made that the thought-
testing/’helpful’ thoughts concept had been understood. Examples of realistic concerns were identified
to generate a ‘problems to address’ list. An example of one problem was taken to illustrate the
problem-solving approach. The concept of ‘worry time’ was introduced to reduce rumination.
l Session 9 – consolidated CBT strategies and reviewing and prioritising a problem list. Planning on
how to tackle harder problems was undertaken, identifying unhelpful thoughts and behaviours with
consideration of the pros and cons of potential solutions and the commitment to this process. The use
of worry management strategies was also reviewed.
l Session 10 – consisted of a review of the person’s perceived progress, including successes
and difficulties.
l Session 11 – consisted of relapse prevention. This included reviewing presenting difficulties, the
progress and personal achievement made, personal resilience and successes and the development of
a relapse prevention checklist.
l Session 12 – consisted of future planning, reviewing a relapse-prevention checklist, making concrete
plans for action if emotional distress recurred or unhelpful behaviours/thinking returned.
In addition, therapists were taught about materials contained in three sections in the manual, so that,
if relevant, these may be addressed with participants. These sections covered (1) existential issues in
addition to eliciting and discussing the patient’s fears about death, including their mode of dying, fears
about the effect of their death on others and fears about what happens after death; (2) applying CBT
when health is poor, which included running shorter sessions, and discussing how to deal with fatigue
and coping with loss of function; and (3) facilitating communication with a partner, families and carers.
This provided CBT therapists with confidence in adapting their skills to people with advanced cancer.
Please contact the corresponding author for more information about the CanTalk treatment manual.
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Improving Access to Psychological Therapies involvement
Identifying and contacting Improving Access to Psychological Therapies centres
The following methods were used to identify IAPT/well-being collaborating centres where the intervention
could take place. IAPT/well-being leads were approached for selected boroughs across London for the pilot
stage and further areas within, and outside, London for the definitive trial. Areas were selected for several
reasons: first, where study team personnel had existing links with oncology teams, hospices and GP centres
for recruitment to be feasible; second, where study personnel had existing links with IAPT/well-being services
and IAPT/well-being leads expressed an interest in research; third, IAPT/well-being services were approached
if they had a mature service running for ≥ 2 years and, therefore, would be more likely to be able to
participate in the delivery of specialist CBT; and fourth, we were also approached by a number of services
who identified the CanTalk trial through trust research co-ordinators.
Our approaches were initially made by telephone to IAPT/well-being leads, identified from websites and
by personal contact. These were followed by an e-mail summarising the project with the advantages to
IAPT/well-being services highlighted as follows:
1. free training for IAPT/well-being high-level CBT practitioners
2. improvement in IAPT/well-being therapists’ CBT skills
3. developing the delivery of IAPT to patients with long-term physical health conditions, which is consistent
with national aims
4. effective publicity for IAPT/well-being so that services are properly funded
5. demonstration that, if effective, CBT, delivered through IAPT, would represent a good model of care
for LTCs.
Training Improving Access to Psychological Therapies therapists
The IAPT/well-being services were asked to supply at least two high-intensity IAPT/well-being therapists for
manualised training. IAPT/well-being supervisors were also encouraged to attend.
Training was delivered by Stirling Moorey, Marc Serfaty and Kathryn Mannix. Therapists were supplied with
a therapists’ manual, presented with Microsoft PowerPoint® 2010 (Microsoft Corporation, Redmond, WA,
USA) slides giving an overview of sessions in the manual as well as videos and role plays and were asked to
participate in practising skills using a variety of scenarios. How they could access the resources online was
also explained. Finally, they were taken through processes required for, and associated with, the research.
Training took place at the following sites: UCL for London, the south of England, the Midlands and the
west of England (SM and MS); Chester for the North West (MS and KM); and Newcastle upon Tyne for the
North East (KM).
Training took place in 27 IAPT/well-being services. Of these, 25 participated in the study. Chester and
Newcastle upon Tyne did not participate as we could not set up recruitment centres in these areas. Details
of the 25 services engaged in the study, including the number of therapists (124 in total) represented from
each service and the IAPT/well-being leads, are presented below.
The number of people trained in applying CBT skills to patients with cancer came from the following services.
l London:
¢ North London – 13 people from five IAPT services from Barnet, Camden and Islington, Enfield
and Haringey.
¢ East London – 19 people from nine IAPT services from City and Hackney, St Bartholomew’s and
The London (Hospital), Tower Hamlets, Redbridge, Homerton, Newham, Waltham Forrest,
Havering, Barking and Dagenham.
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¢ South London – 30 people from seven IAPT services from Lambeth, Lewisham, Bromley, Bexley,
Croydon, Southwark and Greenwich.
l Outside London:
¢ the south of England – four people from two IAPT services (Sussex and Brighton and Hove).
¢ the west of England – two people from one IAPT service (Avon and Wiltshire).
¢ Midlands – four people from Coventry and Warwick IAPT services.
¢ North East – 11 people from one IAPT service (South Tyneside).
¢ North West – five people from one IAPT service (Stockport).
Evaluation of training
Training was evaluated using a feedback questionnaire with a Likert scale asking about specific aspects of
training; boxes enabled additional free-text comments. These findings are presented in Chapter 5.
Location of therapy
Patients were offered the opportunity for face-to-face therapy in their local IAPT/well-being centre. In some
cases, this was at a local GP practice, depending on the set-up of the service. We did consider delivering
therapy in the patients’ own homes but were constrained by limits on safe lone working and, thus, therapy
could not be delivered in this way through the IAPT/well-being service. When patients were too frail or
reluctant to continue to attend therapy in an IAPT/well-being centre, we allowed for the delivery of
telephone CBT, providing the patient had seen the therapist at least three times and it was deemed by the
therapist to be consistent with safe working practices. We asked therapists to record whether therapy was
delivered face to face or by telephone.
Supervision of Improving Access to Psychological Therapies therapists
Supervision structures are well set up within IAPT services. Routine supervision of therapy in IAPT takes
place at least monthly but is flexible within this period. However, in this trial, we recommended flexibility,
so that if any immediate issues needed attention, the therapists could consult their IAPT supervisors.
Stirling Moorey, Kathryn Mannix and Marc Serfaty were also available, by e-mail or by telephone, to
discuss any difficulties related to interventions in people with cancer. The CanTalk trial supervisors were
also accessible to the local IAPT supervisors by e-mail to answer any additional queries that arose between
supervision sessions. Flexibility in the ‘practice stage’ was used to learn about how clarification about the
CBT intervention might be required. Audio recordings of all therapy sessions are routinely made in IAPT
and these were also made available for the independent assessment of quality.
Delivery of cognitive–behavioural therapy
We decided that CanTalk should be a pragmatic approach, which aimed to determine whether or not our
target population would benefit from CBT delivered through IAPT. If the CanTalk approach were to be
rolled out across the UK, we decided that, for the findings to be generalisable, therapists should be
managed in the usual way.
We kept a record of which IAPT services and which therapist within the service delivered the intervention,
and of how many sessions were delivered to each patient.
Quantitative assessment of delivery of cognitive–behavioural therapy
The quality of therapy was assessed using mixed methods. Quantitatively, the Cognitive Therapy Scale –
Revised (CTS-R) was used to assess the delivery of CBT and adherence to the therapy manual was assessed
using an adherence checklist (described in Measure of adherence to cognitive–behavioural therapy in
cancer manual). Qualitatively, the patients’ experience of therapy and the therapists’ experience of
delivering CBT to people with advanced cancer with depression was explored through interview. Although
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this work was not commissioned by the HTA programme, we felt that this would provide a useful addition
to this report and the findings are summarised accordingly in Chapter 5.
Measure to assess competence of delivery of cognitive–behavioural therapy
A scale for measuring therapist competence in cognitive therapy, based on the original CTS,109 is the
12-item CTS-R.110
This revised version improves on the original CTS by eliminating the overlap between items, improves on
the scaling system and defines items more clearly. In this trial, we assessed competence by having an
independent rater listen to audio recordings of therapy sessions using the CTS-R.
Scoring
The CTS-R consists of 12 items: (1) agenda setting and adherence, (2) feedback, (3) collaboration, (4) pacing
and efficient use of time, (5) interpersonal effectiveness, (6) eliciting of appropriate emotional expression,
(7) eliciting key cognitions, (8) eliciting and planning behaviours, (9) guided discovery, (10) conceptual
integration, (11) application of change methods and (12) homework setting. Although the CTS-R is more
specific than the original CTS, in that therapist competence is defined very precisely, the CTS-R has poorer
inter-rater reliability. In the CTS-R, each item is rated from 0 to 6 on a visual analogue scale (VAS) encompassing
the following competencies: incompetent, novice, advanced beginner, competent, proficient and expert.
The total score ranges from 0 to 72 points, with a minimum score of 36 points taken as competency for
the delivery of therapy. We would expect therapists to achieve a minimum score of 36 points, which is the
standard criterion for competence within IAPT services.
How the quantitative measures of delivery of therapy were collected
Assessment of the quality of therapy to the manualised treatment was assessed as follows:
l Quality of delivery of CBT – a total of 194 therapy sessions were audio recorded. In accordance with
our plan to sample 1 in 10 of the therapy recordings, we selected 55 out of 543 audio recordings to
rate the therapy. As the sample was skewed, with the mode being one session, we purposefully
sampled recordings to obtain a balance of therapy sessions from the different phases of the
intervention (early, sessions 1–4; middle, sessions 5–8; or late, sessions 9–12). Tapes were allocated a
random identification number, but it enabled identification of the therapy session number (1–12) so
that a range of phases of therapy could be assessed.
l Therapists were asked to upload recordings of therapy, when possible, onto a secure database using
encryption software. Local health-care trust policy and therapists’ experience of information technology
(IT) systems may limit this process. Recordings of therapy were rated by an accredited member of the
BABCP using the updated version of the CTS109 (the CTS-R110), which is a reliable measure of the delivery
of CBT.76
Measure of adherence to cognitive–behavioural therapy in cancer manual
In this context, we defined therapist adherence as the extent to which the therapist adhered to the
essential ingredients described within the treatment manual developed for use in the trial by Marc Serfaty,
Stirling Moorey and Kathryn Mannix.
Detailed information about the content of the intervention was collected using a ‘Therapy Components
Checklist’ (TCC) (Table 2). The role of the TCC was threefold. First, it provided the therapist with a guide
to which elements were delivered (or not) from the manual. Second, it provided information about which
elements had been delivered by therapists during the course of the trial. Third, it enabled us to evaluate
whether a therapist’s self-report of what they said they did was consistent with what they actually did,
judged by an independent rater.
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TABLE 2 Therapy Components Checklist
Component
Session the component was covered
1 2 3 4 5 6 7 8 9 10 11 12
General procedures
Initial assessment
Describe Beck’s model and concept of CBT
Agree goals of therapy
Present a shared formulation
Goal-setting
Review of shared formulation
Review of success list
Relapse prevention/future planning
Behavioural techniques
Relaxation training
Breathing space
Activity schedule
Pleasure experiences sheet
Cognitive techniques
Refocusing techniques
Mindfulness
Four-step process for resilience and coping
Coping map
List of strengths and resources
Reattribution
Decatastrophising
Advantages/disadvantages
Success list
Thoughts diary
Personal rule (pros/cons)
Managing worry (worry tree handout)
Blueprint for coping
Cognitive–behavioural techniques
Guided discovery
Pleasure prediction sheet
Pleasure experiences sheet
Negative triad/negative automatic thoughts
Applying resilience
Thinking traps handout
Reality testing
Searching for alternatives
ABC form
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The general procedures and main interventions for successful treatment are as follows:
1. general procedures (eight elements)
2. behavioural techniques (four elements)
3. cognitive techniques (13 elements)
4. cognitive–behavioural techniques (nine elements)
5. specific cancer topics (12 elements).
We also collected information from the therapist about what they thought were the three most important
aspects of the therapy and why, whether or not they felt that there was anything missing from therapy
and whether or not they had any general comments.
How adherence was assessed
Adherence to the therapist manual was undertaken using two methods:
1. Self-report by therapists – therapists were asked to upload the TCC (see Table 2), which they completed at
the end of each therapy session. The therapy components were generated by the trial team (MS, SM, KM
and MK) to help identify the main elements thought to be important in this intervention. A checklist was
piloted in a previous study,66 and, in the present trial, was adapted for people with cancer.
2. Independent ratings of adherence – the assessor described in point 1 (above) was also asked to complete
the TCC so that it could be compared with the therapists’ reports of what their intervention comprised.
Analysis
Cognitive Therapy Scale – Revised
For normally distributed data, we have presented the means and standard deviations (SDs) of the CTS-R.
We chose a threshold of ≥ 36 points for competence on the 12-item CTS-R and also indicated the
proportion of therapists who fall under this score. A score of 36 points is also the accepted pass mark for
the postgraduate diploma in CBT that IAPT trainees take.
TABLE 2 Therapy Components Checklist (continued )
Component
Session the component was covered
1 2 3 4 5 6 7 8 9 10 11 12
Specific cancer topics
Impact of physical illness
Beliefs and expectations about illness
Plans and hopes for care as disease advances
Relationship between emotions and physical symptoms
Concerns about current and future ability to cope
Concerns about loss of control
Concerns about accepting help
Concerns about dying (mode/afterwards/life expectancy)
Impact of disease and mood on behaviour
Impact of disease/death on loved ones
Discussion of ‘the meaning’ of the illness
Acceptance of unfinished business
ABC form, antecedents, behaviours, consequences form.
DOI: 10.3310/hta23190 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 19
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Serfaty et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
21
We have also presented the means and SDs for CTS-R scores for different phases of therapy (early,
sessions 1–4; middle, sessions 5–8; and late, sessions 9–12).
Therapy Components Checklist
1. Elements of the adherence checklist that have been covered are presented as a proportion of the total
score for each of the five subsets: (1) general procedures, (2) behavioural techniques, (3) cognitive
techniques, (4) cognitive–behavioural techniques and (5) specific cancer topics.
We also provided a description of the various elements covered for all the TCCs submitted by therapists.
An independent assessor conducted an objective rating of 1 in 10 therapy sessions to see what elements
were delivered and we compared these with the therapists’ self-reports.
For each component of therapy, we calculated agreement between the independent assessor and the
therapist’s own assessment of whether or not the component was covered, providing the four possible
outcomes: (1) both rate that the component was delivered; (2) both rate that the component was not
delivered; (3) the therapist, but not observer, rated the component as being delivered; and (4) the
observer, but not therapist, rated the component as being delivered. Using these possible agreement
outcomes, we then calculated the prevalence-adjusted and bias-adjusted kappa111 (PABAK) for
each component.
Therapist supervision and workload
We recommended that two IAPT therapists would be required from each primary care trust to each treat
approximately 4.5 participants per year. We have experience in delivering a training programme for
palliative care nurses in CBT skills,112 which improves confidence in managing patients.113 Relevant sections
of this have been adapted to provide CBT therapists with confidence in adapting their skills to people with
advanced cancer.
Ensuring safety
This study was not a drug trial and our main concern was centred around risk of self-harm or suicide.
UCL researchers and the research nurses screening in oncology centres were given training by Marc Serfaty
covering the serious adverse events (SAEs) protocol (see Appendix 1), detailing what action should be taken
if patients assessed were considered to be high risk, even though they would be excluded from entry into
the study. These appropriate governance procedures and good clinical practice applied to all patients seen,
to ensure safety at all times. For those who were detected as being at high risk at follow-up, similar
procedures were actioned.
Examples of good practice and the difficulties associated with risk were discussed, including ensuring that
there was an opportunity for individual supervision on request with a senior member of the team who was
always available. This culture of transparency ensures that researchers are able to always raise concerns
about their participants. Time was also taken within supervision to highlight the importance of behaving
ethically and safely in all aspects of clinical work.
We considered the possibility that patients being seen by IAPT/well-being therapists may be detected as
being at increased risk. However, practitioners are bound by their own governance procedures in their
assessment of risk and are very familiar with managing suicidal patients. Because of the number of IAPT/
well-being centres collaborating in this study and minor variations in the procedures on how to manage
risk, we stipulated that IAPT/well-being therapists adopt their own governance procedures, as this is what
would happen if the intervention were to be rolled out across the country, but that they also complete and
return a SAE form. The chief investigator, Marc Serfaty, would then contact the IAPT/well-being team
within 2 working days to discuss the case and consider whether or not the participant should be
withdrawn from the study.
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Research staff support
It is recognised that working with patients with cancer and at the end of life could be distressing for field
researchers, particularly when it is likely that staff may have had direct personal experience of cancer.
Therefore, several systems were put in place to ensure the pastoral care of staff. First, scheduled weekly
meetings took place with the chief investigator and the team to discuss particularly distressing cases, and
research staff were also offered the opportunity to discuss any cases individually with the chief investigator.
Second, there was good cohesiveness among team members for peer support, enabling sharing of
difficult situations. Third, there was the opportunity for UCL researchers to meet monthly with Liz Cort,
an experienced palliative care nurse, at oncology centre 13. Liz Cort is not only independent from UCL but is
also very experienced in issues frequently faced with the often distressing day-to-day lives of people with
cancer. An important dimension of this support was to help researchers develop self-reflexivity, exploring
and making sense of their own responses to the people and situations that they were assessing. The
combination of group and individual supervision meant that researchers felt that their experiences were
validated by their shared experiences.
Cancer research nurses are very experienced in conducting research in this client group. Their support was
provided in the usual way, through group and individual supervision within different services.
Qualitative methods
Embedded qualitative study
In this report, we have included information about a qualitative substudy exploring clinicians’ views on
referring into the CanTalk trial, which we conducted independently. However, as qualitative research was
not commissioned by the HTA programme, only a brief summary of the methodology and results has been
provided (see relevant sections of this report):
l an evaluation of clinicians’ experience of referring into the CanTalk trial evaluated through qualitative
interviews (described in Clinicians’ views of the CanTalk trial)
l an evaluation of the patient experience of therapy was evaluated through qualitative interviews
(described in Patient interviews to determine experience of cognitive–behavioural therapy)
l an evaluation of the therapists’ experience of delivering CBT to advanced cancer patients using
semistructured interviews (described in Therapists’ views of delivering cognitive–behavioural therapy to
people with advanced cancer).
General interview procedures for qualitative data capture
Semistructured, one-to-one interviews using topic guides (presented in Appendices 2–4) ensured that all
participants within these three groups were asked the same questions to minimise researcher effects. The
topic guide initially consisted of a number of open-ended, non-leading questions. We aimed to cover the
six types of questions described by Patton114 for qualitative interviews. These include experience/behaviour
questions, opinion/belief questions, feeling questions, knowledge questions, sensory questions and
background/demographic questions.
The interview began with introductory questions in order to help establish a good relationship with
interviewees to encourage rapport. The topic guide followed a logical sequence with topics being grouped
together with corresponding categories. The questions were formulated to avoid influencing the participant.
We attached probes to each question to aid rapport building. The topic guide ended with a closing
question to encourage participants to discuss topics or issues that were not mentioned previously. Individual
interviews were audio recorded and transcribed verbatim. Flexibility allowed the interviewer or interviewee
to divert from questions to pursue other areas where necessary.115
The interviews took place where there were minimum distractions for the participant and for the
researcher to aid the dialogue. All interviews were audio recorded for transcription at a later date.
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We aimed to recruit up to 20 interviewees for each of the three areas of interest from the CanTalk trial to
allow a sufficient number to generate themes from the data until no new themes emerged from
the interviews.
Clinicians’ views of the CanTalk trial
Any clinician who had been involved in referring patients to the CanTalk trial was considered eligible for
inclusion. The study aimed to obtain a good cross-section of participants including consultants, registrars,
nurses and radiotherapists. The study also aimed to include the views of 15 clinicians from each of the
referring sites.
Clinicians were asked to describe their role in oncology clinics, their previous involvement in research, their
views on non-drug trials, the CanTalk trial, any patient feedback and their views about future psychological
studies. A detailed topic guide is provided in Appendix 2.
Therapists’ views of delivering cognitive–behavioural therapy to people with
advanced cancer
We used a purposive sampling frame and contacted all therapists who delivered CBT as part of the
CanTalk trial. We aimed to recruit up to 20 IAPT therapists for one-to-one, face-to-face, semistructured
interviews in a quiet setting agreed by both the researcher and therapist.
The therapists were asked to describe their role and how it applied to the CanTalk trial, what they knew
about the patient, their views on working with patients with advanced cancer and, with CanTalk patients
in particular, any components of CBT that were or were not useful, and any other important views.
A detailed topic guide is given in Appendix 3.
Patient interviews to determine experience of cognitive–behavioural therapy
All participants recruited from London sites who had reached the 24-week follow-up who had not died
or withdrawn from the study and who had received at least one session of CBT were approached by a
member of their clinical team via post and asked for permission to contact them. Those agreeable to being
contacted or who had already provided consent to contact were sent an invitation letter offering them the
chance to provide feedback about their experiences of CBT.
Interviews took place in the participants’ homes or within the department where the research was taking
place. The interview schedule was as follows: participants were asked to describe what therapy they had,
what knowledge they had of CBT, what they found helpful or not, their views of the therapist, how CBT
had an impact on their life and their views about CBT for low mood in cancer patients. The precise topic
guide is provided in Appendix 4.
Qualitative analysis
All interviews were audio recorded and transcribed. Thematic analysis was used to analyse data using
NVivo version 11 software (QSR International, Warrington, UK) by two researchers who were ‘immersed’ in
the data before proceeding with data analysis, as this can strengthen data analysis.116
Researchers used a matrix-based analytical method of framework analysis to analyse the data.117 The
method of ‘complete line-by-line coding’ was used to broadly identify any code or theme that emerged
without restricting analyses to detecting particular themes.116 Codes were then grouped into broader
themes. For the purposes of triangulation, researchers compared their findings with each other once they
had identified broader themes. Any discrepancies were discussed until agreement was reached.
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Chapter 4 Outcomes
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Assessments
Screening measures
Patient Health Questionnaire-2
The PHQ-2101 consists of the first two questions of the PHQ-9,103 a valid screening measure of depression
that has also been used in cancer services.
Mini-International Neuropsychiatric Interview
The MINI is a short structured diagnostic interview that takes 15 minutes to complete. It was developed
jointly by psychiatrists and clinicians in the USA and Europe for DSM-IV and ICD-10 psychiatric disorders47
and has been widely used in cancer patients.
The UCL researchers gave the assessors 1 day’s training on how to use the MINI. We did not have the
resources to make assessments of inter-rater reliability.
Demographic information
A baseline assessment form was used to ensure that entry criteria were satisfied and that the patient
had consented. It also included demographic information on sex, date of birth, marital status, ethnicity,
employment status, highest level of education, previous history of depression, cancer diagnosis and
whether the tumour was defined by clinicians as primary or secondary, along with date of diagnosis of
the primary or secondary tumour type. We also noted other treatments and prescribed medication, dose
and frequency.
Outcome measures
Quantitative
We collected a number of measures at the different time points summarised (see Table 3).
Primary outcome
Beck Depression Inventory, version 2
The Beck Depression Inventory, version 2 (BDI-II)118 is a 21-item self-report measure, with a maximum score
of 63 points indicating severe depressive symptoms. It contains few items measuring affective-somatic
symptoms, with 15 of the 21 items assessing negative cognitions, which are a target of cognitive
interventions. The psychometric properties of the BDI-II are similar to the Beck Depression Inventory119 (BDI),
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the most widely used self-report instrument for depressive symptoms, which has also been used in trials of
psychotherapy for people with advanced cancer.63,120,121 The BDI-II also has a number of cognitive elements
that are particularly useful for measuring change with CBT.
Secondary outcomes
Patient Health Questionnaire-9
The PHQ-9103 screens for depression. It is used in primary care settings including IAPT services. It has been
validated as a measure of depression in primary care,102,122 and can be administered over the telephone.123
EuroQol-5 Dimensions, five-level version
The EuroQol-5 Dimensions, five-level version (EQ-5D-5L),124,125 is a generic utility measure of QoL consisting
of five domains and a VAS intended for use in the cost-effectiveness analysis.
Satisfaction with care
Collected using a VAS (scored 0–10 towards higher satisfaction). This method has been used in previous
psychotherapy research.64
Eastern Cooperative Oncology Group-Performance Status
The Eastern Cooperative Oncology Group-Performance Status (ECOG-PS)126 is a scale measuring physical
functioning on five levels: 0 (asymptomatic normal activity), 1 (symptomatic but fully ambulatory),
2 (symptomatic and in bed < 50% of time), 3 (symptomatic and in bed > 50% of time), 4 (100%
restricted to bed) and 5 (dead).
Client Service Receipt Inventory
A short, modified version of the Client Service Receipt Inventory127 (CSRI), which collects data directly from
participants on use of hospital services, day centres, residential homes, rehabilitation centres, paramedic/
ambulance, community nurses, occupational/physiotherapists and local GP/practice nurses, as well as social
care/social housing use.
Measures to reduce bias at baseline
Antidepressant use
Participants were asked to provide information about all the medication they were taking. We were
particularly interested in collecting information about antidepressant use as this may influence the outcome
of depression.128,129 Antidepressants were identified from a list of prescribed antidepressants and daily doses
were recorded.130,131 Although compliance with medication, for example through pill counts, may be important,
this was beyond the resources of the study. We recorded the name and dose of any antidepressants prescribed
to participants during the course of the study, as well as any changes in prescribing patterns. Mean equivalent
doses of fluoxetine were calculated using data from the meta-analysis by Hayasaka et al.106 Mean (SD)
equivalent doses of fluoxetine at baseline were provided in the results section.
Other psychological therapies
We noted any psychological intervention reported by patients or recorded in their case notes during the
period of the trial.
Expectations at baseline
Prior to randomisation, participants were asked to predict the degree to which they thought that their
mood would improve or not on a 7-point Likert scale ranging from –3 to + 3.132
Treatment preference
Patients’ preferences for treatment were collected on a 4-point Likert scale (0–3), as in Serfaty et al.66
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Timing of measures
Timing of outcome measures
The BDI-II (main outcome measure), PHQ-9, EQ-5D-5L, ECOG-PS and CSRIs were collected at baseline and
at 12 and 24 weeks from baseline. In addition, we collected the PHQ-9 at 6 weeks (mid-intervention) and
18 weeks (mid-follow-up) (Table 3).
Timing of sources of bias
Post intervention (12 weeks post baseline)
Non-attendance for CBT Reason for not attending therapy sessions (e.g. did not like therapy, recorded death).
Patient satisfaction Participants were asked to rate on a five-point scale (ranging from not at all to very
much) whether or not they found CBT useful.
At follow-up (24 weeks post baseline)
Assessment of blindness Immediately prior to completing the BDI-II, the UCL researcher undertaking
assessments was asked to guess the patients’ trial arm (TAU alone, TAU plus CBT or do not know).
Attrition Reason for missing follow-up data (e.g. patient too ill, died). We did not pursue people who dropped
out with qualitative interviews to establish their reason for doing so. Although this may have generated useful
information, the ethics committee stipulated that no pressure should be placed on this vulnerable group.
Statistical methods
Sample size and power calculations
Published data for trials of CBT suggest that initial reductions in BDI-II with time may not be linear.
A separation in depression scores favouring therapy has been observed within 6 weeks of starting
treatment133,134 and continues after the treatment phase has finished.135,136
TABLE 3 Outcome measures each study time point
Measures
Time point
T3 T4 (6 weeks) T5 (12 weeks) T6 (18 weeks) T7 (24 weeks)
Baseline Mid-intervention Post intervention Follow-up Follow-up
PHQ-9 ✓ ✓ ✓
BDI-II ✓ ✓ ✓ ✓ ✓
EQ-5D-5L ✓ ✓ ✓
Satisfaction with care ✓
ECOG-PS ✓ ✓ ✓
CSRI ✓ ✓ ✓
Antidepressant use ✓ ✓ ✓
Expectation of therapy ✓
Blindness ✓ ✓
Attrition ✓ ✓
T, time.
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For ethical reasons, participants were entitled to withdraw from the study without giving a reason;
however, we recorded the reason for withdrawal from the trial if known. We recorded the timing of any
attrition. Differential dropout may occur early on because people are not satisfied with their trial arm
allocation. Dropout at later phases is more likely to be due to factors such as advancing disease or death,
which are less likely to be influenced by group allocation. Details of the assumptions made concerning
attrition and the effect of treatment are described below and summarised (see Table 4).
Power
Clinical effectiveness: our primary outcome was an overall effect of treatment over the 24-week period of
follow-up. We had powered the study to enable a detection of a difference in BDI-II of 6 points (SD 12 points)
between the TAU and CBT groups measured at 12 weeks, assuming a treatment effect of 3 points after
6 weeks and a sustained 6-point difference after 18 and 24 weeks. We were cautious in assuming a
sustained rather than an increasing treatment effect after 12 weeks. Follow-up at 12 weeks post baseline
in other trials range from 44%62 to > 75%.30,63 Although our client group may have been in the last year
of life, we did not plan to recruit people who were about to die. We assumed a 70% follow-up rate after
6 weeks, decreasing to 65% at 12 weeks and 60% after 24 weeks. Our 6-point difference was chosen
as a conservative estimate given that, for the BDI, which has similar psychometric properties, a 3-point
difference has been quoted as being clinically significant.137
The BDI-II manual reports that the correlation between BDI-II values from sessions 1 week apart is 0.93.118
To estimate the correlation between measurements 6 weeks apart, the simplest assumption possible
was that future values would depend only on the most recent past and not on any history prior to that
(in technical terms, this is called an ‘autoregressive process of order 1’). In this case, the correlation
between measurements would decay at a constant rate of 0.93 per week and our best estimate of the
correlation between BDI-II measures taken 6 weeks apart is 0.936 = 0.65.
Sample size calculations taking account of the longitudinal nature of the design, with correlation, attrition
and effect size, and pattern assumed to be as above, were undertaken following Equation 24 of Hedeker
et al.138 Assuming the given attrition rates and correlation, the sample size required to detect an overall
difference between the groups at 90% power and 5% significance was 109 participants per trial arm
(using a multilevel model adjusting for baseline BDI-II). To account for clustering by therapist, the sample
size needed to be inflated by a factor of 1.10:
½1 + (average cluster size− 1) × intraclass correlation coefficient. (1)
This was based on an intraclass correlation coefficient (ICC) of 0.02139,140 and an average of six participants
per therapist post intervention. Therefore, we intended to recruit 120 participants per trial arm, with
expected numbers available at each follow-up given in Table 4.
TABLE 4 Design assumptions for sample size calculation
Time (weeks)
CBT over TAU; difference
in BDI-II score
Per cent remaining
in the study
Randomisation group, n
TAU (N= 120) CBT (N= 120)
0 (baseline) 0 100 120 120
6 3 70 84 84
12 6 65 78 78
18 6 63 76 76
24 6 60 72 72
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An important secondary outcome was to assess how the treatment effect changes over time. The
proposed sample size of 120 would provide 90% power to detect a 6-point difference in BDI-II at
12 weeks and 80% power to detect a 6-point difference at 24 weeks if attrition rates were as assumed.
Analysis plan
Clinical data (overview)
Analyses of data were undertaken within the PRIMENT CTU and reported according to CONSORT guidelines.
A flow chart presents the follow-up rate for each group, with the reason for non-completion of the BDI-II
score (see Figure 2). Appropriate summary descriptive statistics (e.g. mean and SD for continuous data that are
approximately normally distributed) are given for baseline demographic data and pre-and post-treatment
outcome scores at each follow-up period by treatment group. Analyses are presented on an intention-to-
treat (ITT) basis using multilevel (hierarchical) models. The levels of hierarchy in the data are as follows: first
level – repeated measures; second level – participants; and third level – therapist.
The primary analysis tested for an overall treatment effect on BDI-II over the four follow-ups, controlling for
baseline BDI-II score and baseline antidepressant use (which was used for stratification in the randomisation).
Secondary analyses of BDI-II also looked at the effect of treatment separately at each time point and an
analysis adjusted for compliance (specifically, the number of sessions attended) was performed to take into
account the possible lack of adherence to CBT. Analyses were performed using the current version of Stata®
version 14 (StataCorp LP, College Station, TX, USA).
Antidepressants, including TCAs, which are often used in small doses for symptom control in end-of-life
care, were converted into a mean equivalent dose of fluoxetine following a method we used in another
trial66 of CBT for depressed older people.
Scoring questionnaires
Outcome scores for each scale were calculated from the scale’s individual items using the standard
recommended methods for the scale. For the BDI-II (primary outcome), PHQ-9 and the satisfaction with
care questionnaire, a scale score was calculated as the sum of the scale’s individual items. When any
individual items on these scales were missing, they were imputed using the mean of the completed items
on that scale, provided that ≥ 50% of the items for the scale had been completed. If < 50% of items had
been completed, the scale was treated as missing.
Analysis of the principal outcome variable: Beck Depression Inventory, version 2
Primary analysis
All analyses were pre-specified in the statistical analysis plan. The primary analysis was a comparison
between the CBT and control arms for the BDI-II score measured at all four follow-up points: 6, 12, 18 and
24 weeks. The BDI-II score was analysed using multilevel modelling, allowing for repeated measurements
with equal weighting for each time point. Clustering in the intervention group from the same therapist
treating multiple patients was included as a level within the model.
The model comprised three levels: (1) repeated measures, (2) individuals and (3) therapists. In the
intervention group, clusters were defined by therapist. For the control group, each individual was treated
as an individual cluster (n = 1).
Baseline BDI-II score and baseline antidepressant use (yes/no) were included in the model as fixed effects.
No other covariates were included. The model was fitted using a linear mixed effects model assuming
a Gaussian error distribution. Model assumptions of normality were checked visually using a normal
probability plot of standardised residuals, and assumptions of linearity and constant variance were checked
using a scatterplot of standardised residuals against predicted values.
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Supportive analysis
Supportive analysis included the primary analysis, which was repeated:
1. using clustering by IAPT service
2. ignoring the therapist clustering
3. including the following covariates (as fixed effects)
(a) baseline previous history of depression (yes/no)
(b) baseline EQ-5D total score
(c) baseline duration of current episode of depression (number of weeks)
(d) number of days between diagnosis of primary tumour and baseline visit
4. with separate analyses carried out for each post-baseline follow-up (6, 12, 18 and 24 weeks).
Exploratory and subgroup analyses
Exploratory and subgroup analyses included the following the primary analysis:
1. including a treatment by time interaction
2. repeated including a treatment by marital status (married/partner; divorced/separated/widowed;
single/never married) interaction
3. including a treatment by education status [Advanced level (A level) and above vs. below A level]
interaction.
Contamination-adjusted intention-to-treat analysis
The analysis adjusted for compliance that we undertook to account for possible lack of adherence to CBT
was a ‘CAITT’ rather than the better-known ‘complier average causal effects’ analysis. Here, a ‘per session’
effect of treatment is estimated rather than the effect for ‘compliers’ (which would require a binary
definition of ‘complier’ in terms of number of sessions attended). CAITT is the slightly more sophisticated
analysis141 and was carried out as follows.
The outcome used was the 18- and/or 24-week total BDI-II score. Only individuals with a post-CBT BDI-II
score available at either 18 and/or 24 weeks were included in this analysis. When an individual had both
18- and 24-week scores, the average of the two values was used. The measure of compliance was the
number of CBT sessions attended (when available) before the latest follow-up (18 or 24 weeks) for which
the individual had outcome data.
Instrumental variable regression using two-stage least squares was undertaken with the randomisation
group as an instrumental variable for the number of CBT sessions. The outcome was the total BDI-II score
(as described earlier). The model also included the baseline total BDI-II score as a covariate. In addition,
baseline antidepressant prescribed (yes/no) was included in the model as this was used as the stratification
variable for the randomisation while, for simplicity, clustering by therapist was ignored.
Analysis of secondary outcome variables
1. Patient Health Questionnaire-9: depression severity.
2. Satisfaction with care.
Both these variables were analysed in the same way, using multilevel modelling that allows for repeated
measures (at 12 and 24 weeks). As with the primary analysis, an additional level was included to allow
for therapist clustering within the intervention arm. Baseline score and antidepressant use (yes/no) were
included as fixed effects. The model was fitted using a linear mixed effects model assuming a Gaussian
error distribution, mirroring the principal analysis of the primary outcome variable (BDI-II). Additional
separate analyses were carried out for the 12- and 24-week time points.
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3. Eastern Cooperative Oncology Group Performance Status: physical functioning.
The ECOG-PS is an ordered categorical variable that cannot be regarded as approximately continuous.
The numbers and percentages (by group) falling into each category at baseline, 12 and 24 weeks were
tabulated and a simple (unstratified and unclustered) non-parametric comparison was made between
groups of the change in ECOG-PS score from baseline at each time point.
Analysis for bias
We compared participant data at baseline for those randomised to TAU with data for those randomised to
TAU plus CBT for the following factors: whether or not they were using any non-pharmacological treatment
for depression, their treatment preference (CBT group/TAU group/no preference) and expectations of
improvement if they were to receive CBT [rated from 1 (not at all) to 10 (completely)].
As previously indicated, even low doses of antidepressants may be effective. The therapeutic dose of an
antidepressant varies depending on which antidepressant is prescribed. In order to compare doses, the
medications were standardised by converting them into equivalent doses of fluoxetine, using dose
equivalents from data from Hayasaka et al.106
Health economics
A health and social care perspective was adopted, in line with NICE’s recommendations.142
Outcomes
Quality-adjusted life-years were calculated from EQ-5D scores at baseline, 12 and 24 weeks’ follow-up.
The EQ-5D is a non-disease-specific measure for describing and valuing health-related QoL.143 The measure
includes a rating of own health in five domains (1, mobility; 2, self-care; 3, usual activities; 4; pain/
discomfort; and 5, anxiety/depression) and a rating of own health by means of a VAS [a ‘thermometer’
(score of 0–100)]. The EQ-5D is widely used in economic evaluations for common mental health disorders.
The health states from the EQ-5D were given a utility score using responses from a representative sample
of adults in the UK.144 From these, QALYs were calculated using the area under the curve approach as
defined by the utility values at baseline and at each follow-up.
Costs
Study participants
Resource data cover community health and social services, although the use of hospital services has been
omitted in a modified version of the CSRI.145 The calculation of costs was separated into the identification,
measurement and valuation of relevant resources. A unit cost was applied to each resource use to
calculate the total cost of resources used by each study participant. For NHS primary care services, and
social care and voluntary services, we used costs from Curtis.146
Trial intervention
Recorded details of attendance and non-attendance at sessions for each study participant were used as the
basis for the calculation of the total cost of the intervention. Furthermore, costs associated with therapists
attending a CBT coaching session (including subsistence and travel) were incorporated. It was assumed that,
in those instances in which a session was offered but not attended, this still constituted IAPT’s therapist
opportunity cost. We assumed that trial therapists were on band 7 or 8 on the Agenda for Change salary
scale,147 and employer’s national insurance, superannuation contributions and overheads were added to the
average salary.148
Cost–utility and cost-effectiveness analyses
Costs were compared for the groups using a bootstrap regression model to account for non-normality in
the distribution of cost data.
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A cost–utility analysis was undertaken using QALYs calculated from the EQ-5D measure of QoL.
Cost-effectiveness was assessed by estimating an incremental cost-effectiveness ratio (ICER) to show the
extra cost incurred by CBT to generate one extra QALY.149 This is defined as the cost difference divided by
the outcome difference, after adjusting for costs and outcomes measured at baseline. However, there will
inevitably be uncertainty around the cost and outcome differences. In the ICER calculation, we adjusted for
baseline costs and utility in the correlation structure between costs and effects the variance – covariance
matrix is generated via Cholesky’s decomposition.
To deal with uncertainty around the ICER, a cost-effectiveness plane (CEP) and cost-effectiveness
acceptability curves (CEACs) were created.150 We used the standard net benefit regression to produce the
CEAC, using participant-level effect and incorporating associated cost data in the estimation. For the CEP,
1000 bootstrapped estimates of cost and outcome differences were produced, adjusted for baseline and
plotted against each other. This aimed to show the probability that CBT had (1) higher costs and better
outcomes, (2) higher costs and worse outcomes, (3) lower costs and worse outcomes or (4) lower costs
and better outcomes than TAU. The CEAC was produced using the net benefit approach, for which the
QALY difference is multiplied by the societal value (threshold) placed on a QALY and the incremental
service cost is subtracted. A positive incremental net benefit means that CBT is more cost-effective and the
proportion of positive values for each societal QALY value gives the probability that CBT is cost-effective
at that threshold. In this study, the cost-effectiveness of receiving CBT rather than TAU on its own was
examined. Models for analysing incremental cost-effectiveness were fitted using Stata® version 12.0
(StataCorp LP, College Station, TX, USA).
Qualitative data
We used purposive sampling and wrote to 20 participants in the trial who had received CBT at the end of
their follow-up period, inviting them to take part in qualitative interviews to explore their experiences of
the trial and their therapy. We planned to interview 12 therapists to explore their experience of delivering
therapy to this population. Semistructured, one-to-one interviews were conducted using a topic guide
either in the participants’ homes or within the department where the research was taking place. All
interviews were audio recorded for transcription at a later date. Data were analysed using thematic
content analysis. Findings from these data were used to generate recommendations on what may be
improved in the delivery of CBT to people with advanced cancer.
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Chapter 5 Results
Project set-up
Permissions
Table 5 summarises the process taken for research to take place.
Project set-up started in December 2011. Because of limited resources, some services were not able to
complete data for the number of people assessed for eligibility, namely oncology centres 7, 9 and 16
(see Table 5).
Furthermore, the time taken from the submission of documentation to the approval for research to start is
shown in Table 5. The time taken for submission and documentation varied between as little as 1 month
for oncology centre 16 and 9 months for oncology centres 1, 2, 3 and 6.
Oncology centres 4 and 14 encouraged early involvement to prepare the documentation for review and
discussion prior to submission to R&D, for approval for research to proceed. As this process would normally
be considered part of the submission and approval process, we have included it in Table 5 in order to
make a comparison with other centres. As the research nurse undertaking recruitment from oncology
centre 11 left her role, oncology centre 11 had to withdraw from the study.
Screening and recruitment
Where available, the number of people assessed for eligibility, screened and recruited from primary care and
hospice settings (Table 6) and from oncology clinics (Table 7) is shown. The proportion of those recruited
was lowest for GPs (2.6%) and greatest for the hospice (35.3%). There was considerable variability in the
percentage of people screened and recruited within a particular recruitment source (GP and oncology) and
caution needs to be exercised because of the small sample population in the GP sample. However, as shown
for the oncology service, the proportion of people recruited varied considerably between hospices. Oncology
centre 2 recruited > 50% of participants screened and oncology centre 1 recruited 2.4%, although it should
be noted that each site was made up of a different combination of clinics described in Chapter 3,
Recruitment methods and procedures. Also shown is the number of people recruited and screened per
month; these methods did not apply to primary care recruitment, as only a one-off sweep of records was
undertaken at one time point and, therefore, the last two columns of Table 6 are blank. The proportion of
participants randomised to each arm was similar from each site.
Table 8 shows the reasons that people were not screened and the reasons they were not referred to the
study, although data were limited. The commonest reasons were: in GP practices, people did not have a
diagnosis of advanced cancer; in oncology clinics, patients were not in the IAPT area; and, in hospices,
there was a slower turnover of patients so people had already been screened. In oncology clinics, staff
often indicated that people did not wish to be approached; however, informal feedback from researchers
suggested that there was some gatekeeping taking place.
We had limited available information on screening by tumour group (Table 9). Not all clinics were able to
provide these data, as staff indicated that they were too busy to consider anything but referral into the
study. As shown, the highest proportion of people recruited came from neurological clinics and the lowest
proportion came from chest clinics. Unfortunately, we were not able to collect data specifically from
prostate clinics.
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TABLE 5 Trial set-up and recruitment times
Trial site
Year
2011
2012 2013 2014 2015
Quarter
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Oncology centre 1 S R A
Oncology centre 2 S R A
Oncology centre 3 S R A
Marie Curie Hospice R A
Oncology centre 4 D S R A
Oncology centre 5 S R A
Oncology centre 6 S R A
Oncology centre 7 S R A
Oncology centre 8 S R A
Oncology centre 9 S R A
Oncology centre 10 S R A
Oncology centre 11 S R A Withdrew
Oncology centre 12 S R A
Oncology centre 13 S R A
Oncology centre 14 S R A
Oncology centre 15 R A
Oncology centre 16 S R A
A, site active; D, discussion prior to submission; Q1, first quarter (January–March); Q2, second quarter (April–June); Q3, third quarter (July–September); Q4, fourth quarter (October–December);
R, R&D approval for study granted; S, project submitted to site R&D for approval.
Note
Orange denotes discussion prior to submission; grey denotes project submitted to site for research and development (R&D) approval; red denotes R&D approval granted; green denotes site active.
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Recruitment rate
Figure 1 shows cumulative original, amended and actual recruitment by month and year from the start
of the project in August 2012. This figure is supplemented by the data in Table 5. No participants were
recruited until December 2012 because of the delay in permissions; this is represented by the relatively
flat recruitment line from August 2012 to February 2013, when recruitment was initially slow.
As permissions came through, recruitment accelerated to around 7.8 participants per month (93 participants
over 12 months for the period from June 2013 to the end of May 2014).
Our recruitment target and methods had to be revised to allow for delays in permissions that were beyond
our control. We overcame these hurdles by increasing the number of clinics within a locality from which
recruitment was taking place and enrolling other areas of the UK into the study. This required us to establish
whether or not IAPT services had the capacity to take on additional cases and whether or not IAPT services
from different regions could actually participate, especially as changes in the configuration of IAPT services
nationally were taking place. This made them cautious about being able to commit to the trial.
TABLE 6 Screening and recruitment in primary care and hospice
Practice
Number
assessed for
eligibility
Number
screened
Number
recruited
Percentage
of screened
patients
recruited
Number of
database
searches
Number
screened per
month of
recruitment
Number
recruited per
month of
recruitment
Primary care recruitment
Primary care
centre 1
415 16 0 0.0 1
Primary care
centre 2
81 7 0 0.0 1
Primary care
centre 3
26 20 0 0.0 1
Primary care
centre 4
220 13 1 7.7 1
Primary care
centre 5
155 10 2 20.0 2
Primary care
centre 6
69 105 0 0.0 1
Primary care
centre 7
26 26 1 3.8 1
Primary care
centre 8
266 20 0 0.0 1
Primary care
centre 9
123 9 0 0.0 1
Primary care
centre 10
1 1 1 100.0 1
Primary care
centre 11
2 1 0 0.0 1
Primary care
centre 12
20 4 1 25.0 1
Total 1404 232 6 2.6
Hospice recruitment
Marie Curie
Hospice
336 79 28 35.4 39 1.6 0.7
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It became evident that the same patients were being seen in both the oncology clinics and hospices.
Therefore, we chose to expand the project to centres with large numbers of oncology patients, such as
oncology centre 14. It is also notable that, in the final 6 months, the recruitment rate fell to 3.3 participants
per month (20 participants were recruited in the final 6 months). This is because the reservoir of patients
available became depleted.
A CONSORT flow diagram is provided in Figure 2. Of those assessed for eligibility, only 2.7% (230/8398)
were suitable for the trial. However, at least one outcome measure was available on 80.4% (185/230)
of participants.
Reasons for withdrawal from the study
Twenty-one (9.1%) of the 230 recruited participants died and 51 (22.2%) participants withdrew. Although
the ethics committee stipulated that patients did not need to give a reason for withdrawal from the study,
we aimed to collect this information when possible (these reasons are summarised in Table 10). The number
of participants who withdrew from the study during the first 6 weeks was twice as high in the CBT group as
in the TAU group.
Reason for missed follow-up
The CONSORT flow diagram (see Figure 2) provides participant flow. It is also of note that follow-up was
missed at different time points. The specific reasons why participants were not followed up at 6, 12, 18
and 24 weeks are given in Table 11.
TABLE 7 Screening and recruitment in oncology clinics
Oncology
centre
Number of patients
Percentage
of screened
patients
recruited
Months of
recruitment
Number of patients
Assessed for
eligibility Screened Recruited
Screened per
month of
recruitment
Recruited per
month of
recruitment
1 167 167 4 2.4 40 4.2 0.1
2 182 8 4 50.0 39 4.4 0.1
3 173 82 13 15.9 39 5.2 0.3
4 1501 477 26 5.5 32 38.3 0.8
5 235 68 16 23.5 32 4.5 0.5
6 263 81 11 13.6 29 3.0 0.4
7 N/A N/A 9 N/A 35 N/A 0.3
8 71 45 8 17.8 35 1.9 0.2
9 N/A N/A 3 N/A 34 N/A 0.1
10 535 319 15 4.7 30 17.8 0.5
11 541 13 10 76.9 29 0.2 0.3
12 976 353 39 11.0 31 21.0 1.3
13 414 196 26 13.3 31 10.8 0.8
14 1738 20 2 10.0 11 1.8 0.2
15 160 84 8 9.5 15 14.7 0.5
16 N/A N/A 2 N/A 6 N/A 0.3
Total 6956 1913 196 10.2
N/A, not applicable.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
Demographics
Demographic information concerning sex, marital status, ethnicity and employment status is illustrated in
Table 12, in which it can be seen that two-thirds of the sample population were female. The mean age of
participants was 60 years. Around three-quarters of the participants were white, with the remaining
population being of a variety of ethnicities. The 19 participants whose ethnicity was described as ‘other’
were white Jewish (one), white Irish (two), European (two), white other (one), Greek Cypriot (two), Turkish/
Cypriot (one), Mediterranean (one), British Bangladeshi (one), South American (one), North African (one),
white/black Caribbean (one), Iraqi (one), Filipino (one) and Armenian (one), with two unknown. Around
two-fifths of participants were retired and one-fifth of participants were unable to work because of illness
disability. The employment status of six participants was reported as ‘other’: two were on sick leave, two
were disabled, one was medically retired and in one the reason was unknown. There was a balance of
TABLE 8 Reasons for exclusion from trial and conversion rate
Reason for exclusion
Recruitment site, n
GP practices Hospital oncology clinics Hospices
Total register list 1404 6956 352
Reason for not screeninga
Aged < 18 years 10 5 122
IAPT area 0 2612 2
Diagnosis 979 665 24
Prognosis 44 197 0
Difficulty with English 43 156 3
Problems with alcohol 9 3 0
Screened already 0 112 172
Not screened: other reason 138 392 26
Not screened: no reason recorded 0 694 0
Missed 0 207 26
Approached for screening 232 1913 79
Reason for not referring
Declined 49 959 13
PHQ-2 score of < 3 points 8 501 23
MINI negative diagnosis 1 23 3
Screened out (measure unspecified) 0 34 0
High suicidality 0 3 2
Other reason 168 43 10
Not referred: no reason recorded 0 144 0
Referred for baseline 6 206b 28
Conversion rate (% approached for
screening referred for baseline)
2.6 10.8 35.4
a The sum for reasons is greater than the register list for GP practices and hospices because some patients recorded were
excluded on multiple reasons.
b The number referred from oncology is higher than the number recruited because not every patient that was referred
went on to enter the study.
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participants from different educational backgrounds. The two trial arms, (1) TAU plus CBT and (2) CBT
alone, were similar with respect to demographic factors.
Demographics of cancer
Two-thirds of patients had tumours of one of the five main groups (breast, colorectal, lung, prostate
and haematological), with the majority, around one-third, having a primary diagnosis of breast cancer.
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FIGURE 1 Cumulative original, amended and actual recruitment time.
TABLE 9 Screening and recruitment, by tumour group
Tumour group
Number of patients
Percentage of screened patients recruitedScreened Recruited
Breast 127 19 15.0
Colorectal/GI 369 27 7.3
Lung 247 17 6.9
Haematological 380 31 8.2
HPB 61 6 9.8
Neurological 83 14 16.9
Total 1267 114 9.0
Note
Tumour group of clinic was not recorded for all screened patients.
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Analysed for primary outcome
(n = 93)
   • Lost to 6-week follow-up, n = 29
      • Died, n = 2
      • Withdrew, n = 10
      • Missed follow-up, n = 17
   • Lost to 12-week follow-up, n = 46
      • Died, n = 3 (total, n = 5)
      • Withdrew, n = 8 (total, n = 18)
      • Missed follow-up, n = 23
   • Lost to 18-week follow-up, n = 52
      • Died, n = 4 (total, n = 9)
      • Withdrew, n = 7 (total, n = 25)
      • Missed follow-up, n = 18
   • Lost to 24-week follow-up, n = 50
      • Died, n = 0 (total, n = 9)
      • Withdrew, n = 3 (total, n = 28)
      • Missed follow-up, n = 13
Allocated to CBT
(n = 115)
Completed baseline assessment
(n = 115)
Analysed for primary outcome
(n = 92)
   • Lost to 6-week follow-up, n = 33
• Died, n = 3
• Withdrew, n = 5
• Missed follow-up, n = 25
   • Lost to 12-week follow-up, n = 36
      • Died, n = 4 (total, n = 7)
      • Withdrew, n = 8 (total, n = 13)
      • Missed follow-up, n = 15
      • No BDI-II, n = 1
   • Lost to 18-week follow-up, n = 44
      • Died, n = 2 (total, n = 9)
      • Withdrew, n = 2 (total, n = 15)
      • Missed follow-up, n = 20
   • Lost to 24-week follow-up, n = 50
      • Died, n = 3 (total, n = 12)
      • Withdrew, n = 8 (total, n = 23)
      • Missed follow-up, n = 15
Allocated to TAU
(n = 115)
Completed baseline assessment
(n = 115)
6-week follow-up
Baseline data collection then randomisation
12-week follow-up
18-week follow-up
24-week follow-up
Analysed for primary outcome
Excluded
(n = 8168)
Assessed for eligibility 
(n = 8398)
Completed 6-week follow-up
(n = 86)
Completed 12-week follow-up
(n = 69)
Completed 18-week follow-up
(n = 63)
Completed 24-week follow-up
(n = 65)
Completed 6-week follow-up
(n = 82)
Completed 12-week follow-up
(n = 79)
Completed 18-week follow-up
(n = 71)
Completed 24-week follow-up
(n = 65)
FIGURE 2 Participant flow and recruitment; a CONSORT flow diagram.
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Of the 41 ‘other’, 14 were neurological, four were oesophageal, three were bowel, two cervical, two liver,
two bone, two anal, two sarcoma, one nose, one throat, one ovarian, one testicular, one parotid gland, one
mesothelioma, one myelofibrosis and three patients had cancer of unknown primary diagnosis (Table 13).
The mean time since diagnosis of cancer was skewed by 44 participants with a haematological cancer,
among whom the mean time since diagnosis was 2970 days. The median length of time since the primary
diagnosis was just over 2 years (770 days).
TABLE 10 Reason for withdrawal from study
Reason for withdrawal
Number by group prior to each follow-up point
6 weeks 12 weeks 18 weeks 24 weeks
Total (%)CBT TAU CBT TAU CBT TAU CBT TAU
No reason given 4 2 2 1 1 1 11 (21.6)
Ill health 2 1 3 3 3 1 5 18 (35.3)
Too busy 1 1 1 3 (5.9)
Moved away 1 1 2 (3.9)
Unhappy with group allocation 2 1 1 4 (7.8)
Did not want to answer questions 2 1 3 (5.9)
Did not think study would help them 1 1 (2.0)
Felt that therapy did not suit them 2 1 3 (5.9)
Difficulties with IAPT service 1 2 3 (5.9)
Did not like therapist 1 1 (2.0)
No longer wanted therapy 1 1 (2.0)
Could not receive therapy as outside IAPT area 1 1 (2.0)
Total 10 5 8 8 7 2 3 8 51 (100.0)
TABLE 11 Reason for missed follow-up
Reason for missed follow-up
Number by group that missed each follow-up point
6 weeks 12 weeks 18 weeks 24 weeks
Total (%)CBT TAU CBT TAU CBT TAU CBT TAU
No reason recorded 6 9 6 3 3 7 2 2 38 (26.2)
Could not contact participant 4 5 4 5 6 3 5 6 38 (26.2)
Ill health 2 9 10 5 5 6 4 6 47 (32.2)
Ill health of family member 1 1 (0.7)
Too busy 1 1 1 2 5 (3.4)
Away at the time of follow-up 1 1 1 1 1 5 (3.4)
Did not want to attend or answer questions 1 1 1 1 1 5 (3.4)
Unable to answer questions 1 1 (0.7)
Issues with IAPT service 2 1 1 4 (2.7)
Did not like therapist 1 1 (0.7)
Total 16 25 23 15 18 20 13 15 145 (100.0)
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TABLE 12 Baseline patient demographic characteristics, by randomisation group
Demographic characteristics
Randomisation group
TotalTAU CBT
Age (years), mean (SD); min., max. 59.5 (12.4); 27, 93
(n= 115)
59.5 (10.3); 37, 81
(n= 115)
59.5 (11.4); 27, 93,
(n= 230)
Sex, n (%)
Male 37 (32.2) 41 (35.7) 78 (33.9)
Female 78 (67.8) 74 (64.3) 152 (66.1)
Total 115 (100.0) 115 (100.0) 230 (100.0)
Marital status, n (%)
Married 55 (48.2) 59 (51.3) 114 (49.8)
Partner – living with 9 (7.9) 9 (7.8) 18 (7.9)
Partner – not living with 1 (0.9) 2 (1.7) 3 (1.3)
Divorced/separated 18 (15.8) 13 (11.3) 31 (13.5)
Widowed 9 (7.9) 10 (8.7) 19 (8.3)
Single, never married 20 (17.5) 22 (19.1) 42 (18.3)
Other 2 (1.8) 0 (0.0) 2 (0.9)
Total 114 (100.0) 115 (100.0) 229 (100.0)
Ethnicity, n (%)
White 84 (73.0) 83 (72.2) 167 (72.6)
Black – British/African/Caribbean 17 (14.8) 14 (12.2) 31 (13.5)
Indian/Pakistani/Bangladeshi 6 (5.2) 7 (6.1) 13 (5.6)
Other 8 (7.0) 11 (9.6) 19 (8.3)
Total 115 (100.0) 115 (100.0) 230 (100.0)
Employment, n (%)
Employed 16 (14.3) 27 (23.7) 43 (19.0)
Self-employed 5 (4.5) 13 (11.4) 18 (8.0)
Unemployed – seeking work 2 (1.8) 1 (0.9) 3 (1.3)
Unemployed – not seeking work 10 (8.9) 13 (11.4) 23 (10.2)
Homemaker 2 (1.8) 0 (0.0) 2 (0.9)
Retired 49 (43.8) 38 (33.3) 87(38.5)
Unable to work due to illness/disability 24 (21.4) 20 (17.5) 44 (19.5)
Other 4 (3.6) 2 (1.8) 6 (2.7)
Total 112 (100.0) 114 (100.0) 226 (100.0)
Education, n (%)
Higher degree 15 (13.0) 13 (11.3) 28 (12.2)
Degree 27 (23.5) 31 (27.0) 58 (25.2)
A Level (or equivalent) 15 (13.0) 9 (7.8) 24 (10.4)
HNC (or equivalent) 8 (7.0) 4 (3.5) 12 (5.2)
NVQ (or equivalent) 13 (11.3) 13 (11.3) 26 (11.3)
GCSE (or equivalent) 16 (13.9) 24 (20.9) 40 (17.4)
continued
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TABLE 12 Baseline patient demographic characteristics, by randomisation group (continued )
Demographic characteristics
Randomisation group
TotalTAU CBT
No qualification 8 (7.0) 7 (6.1) 15 (6.5)
Other 13 (11.3) 14 (12.2) 27 (11.7)
Total 115 (100.0) 115 (100.0) 230 (100.0)
GCSE, General Certificate of Secondary Education; HNC, Higher National Certificate; max., maximum; min., minimum;
NVQ, National Vocational Qualification.
TABLE 13 Tumour sites and time since diagnosis, by randomisation group
Randomisation group
TotalTAU CBT
Time since primary diagnosis (days),
mean (SD); min., max.
1484 (1680); 16, 8548
(n = 99)
1386 (2235); 12, 17,644
(n= 104)
1433 (1975); 13, 17,644
(n= 203)
Primary tumour site, n (%)
Breast 36 (31.3) 36 (31.3) 72 (31.3)
Colon/rectal 17 (14.8) 12 (10.4) 29 (12.6)
Endometrial 1 (0.9) 0 (0.0) 1 (0.4)
Kidney 1 (0.9) 1 (0.9) 2 (0.9)
Leukaemia 3 (2.6) 2 (1.7) 5 (2.2)
Lung 10 (8.7) 17 (14.8) 27 (11.7)
Melanoma 1(0.9) 0 (0.0) 1 (0.4)
Lymphoma 9 (7.8) 8 (7.0) 17 (14.8)
Myeloma 8 (7.0) 13 (11.3) 21 (18.3)
Pancreatic 2 (1.7) 0 (0.0) 2 (0.9)
Prostate 5 (4.3) 7 (6.1) 12 (5.2)
Other 22 (19.1) 19 (16.5) 41 (17.8)
Total 115 (100.0) 115 (100.0) 230 (100.0)
Secondary tumour site, n (%)
None 25 (24.3) 30 (29.7) 55 (27.0)
Breast 8 (7.8) 7 (6.9) 15 (7.4)
Colon/rectal 2 (1.9) 4 (4.0) 6 (2.9)
Endometrial 1 (1.0) 0 (0.0) 1 (0.5)
Kidney 1 (1.0) 1 (1.0) 2 (1.0)
Leukaemia 1 (1.0) 0 (0.0) 1 (0.5)
Lung 10 (9.7) 5 (5.0) 15 (7.4)
Non-Hodgkin lymphoma 1 (1.0) 1 (1.0) 2 (1.0)
Prostate 2 (1.9) 2 (2.0) 4 (2.0)
Other 52 (50.5) 51 (50.5) 103 (50.5)
Total 103 (100.0) 101 (100.0) 204 (100.0)
max., maximum; min., minimum.
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Diagnosis of depression, previous psychiatric history and treatment
All participants included in the study satisfied a MINI diagnosis of depressive disorder. Three-fifths of
participants had a previous history of depression, with the mean number of previous episodes being just over
two. The duration of the current episode of depression was also skewed, with the median duration being
around 12 weeks. One-tenth of participants had previously received CBT, with less than one-third receiving
treatment for depression (Table 14).
Potential sources of bias
One-quarter of participants were receiving an antidepressant, three-quarters desired CBT and there was a
70% expectation of improvement from CBT that was equally distributed in participants allocated to either
TAU or TAU plus CBT (Table 15).
Antidepressant usage
Fifty-five (23.9%) of the 230 participants were taking an antidepressant, 26 out of 115 in the TAU group
and 29 out of 115 in the CBT group. There was no significant between-group difference as to whether or
not an antidepressant was prescribed. Although the names of the antidepressants were recorded, the dose
TABLE 14 History and treatment of depression, by randomisation group
Randomisation group
TotalTAU CBT
Number of previous episodes of depression (those with previous
depression), mean (SD); min., max.
2.2 (1.9); 1,
10 (n = 63)
2.6 (2.4); 1,
12 (n = 59)
2.4 (2.1); 1,
12 (n = 122)
Duration of current depression (weeks), mean (SD); min., max. 74.3 (242.7); 0,
2080 (n= 90)
86.6 (266.5); 0,
2080 (n= 84)
80.3 (253.8); 0,
2080 (n= 174)
Previous depression, n (%)
Yes 69 (60.0) 68 (59.1) 137 (59.6)
Total 115 (100.0) 115 (100.0) 230 (100.0)
Ever had CBT before, n (%)
Yes 12 (10.4) 12 (10.4) 24 (10.4)
Total 115 (100.0) 115 (100.0) 230 (100.0)
On current depression treatment, n (%)
Yes 33 (29.2) 33 (29.2) 66 (29.2)
Total 113 (100.0) 113 (100.0) 226 (100.0)
On antidepressant treatment, n (%)
Yes 27 (23.5) 28 (24.3) 55 (23.9)
Total 115 (100.0) 115 (100.0) 230 (100.0)
Treatment preference, n (%)
The CBT group 92 (80.0) 87 (75.7) 179 (77.8)
The group with no CBT 3 (2.6) 2 (1.7) 5 (2.2)
Do not have a preference 20 (17.4) 26 (22.6) 46 (20.0)
Total 115 (100.0) 115 (100.0) 230 (100.0)
max., maximum; min., minimum.
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was available in only 35 cases. The mean dose-equivalent of fluoxetine prescribed was 23.4 mg (SD 8.2 mg)
for the TAU group (n = 17) and 31.8 mg (SD 8.2 mg) for the CBT group (n = 18). There was no significant
difference in the mean dose by group allocation.
Other psychological therapies
The record of any psychological intervention reported by patients or recorded in their case notes during
the period of the trial is summarised in Table 15.
Expectations at baseline132
Prior to randomisation, participants were asked to predict the degree to which they thought that their
mood would or would not improve on a 7-point Likert scale ranging from –3 to 3.
Treatment preference
Patients’ preferences for treatment were collected on a 4-point Likert scale (0–3), as in Serfaty et al.66
Clinical outcomes
All participants met caseness for depressive disorder using the MINI. We present clinical outcomes (see
Tables 16–19) for the main outcome (BDI-II) and secondary outcomes (PHQ-9, EQ-5D, satisfaction with
care and ECOG-PS).
Main outcome
Data for the main outcome measure, the BDI-II, are shown in Table 16 and on the histograms of Figure 3.
Mean BDI-II score by time and group is also presented (Figure 4).
TABLE 15 Baseline patient demographic characteristics, by randomisation group
Randomisation group
TotalTAU CBT
CBT treatment expectation, mean (SD); min., max. 7.0 (1.9); 1,
10 (n= 111)
7.2 (1.8); 4,
10 (n= 113)
7.1 (1.9); 1,
10 (n= 224)
Treatment preference, n (%)
CBT group 92 (80.0) 87 (75.7) 179 (77.8)
TAU group 3 (2.6) 2 (1.7) 5 (2.2)
No preference 20 (17.4) 26 (22.6) 46 (20.0)
Previously received CBT, n (%) 12 (10.4) 12 (10.4) 24 (10.4)
Antidepressant use, n (%)
Baseline 26 (22.6) 29 (25.2) 55 (23.9)
12-week follow-up 20 (17.4) 22(19.1) 42 (18.3)
24-week follow-up 16 (13.9) 20 (17.4) 36 (15.7)
Other psychological therapy, n (%)
Baseline 5 (4.3) 3 (2.6) 8 (3.5)
12-week follow-up 6 (5.2) 1 (0.9) 7 (6.1)
24-week follow-up 5 (4.3) 3 (2.6) 8 (7.0)
max., maximum; min., minimum.
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At baseline, the data were normally distributed, as exemplified by the similar mean and median scores
(see Table 16). A BDI-II score of 20–28 points suggests the severity of depression to be moderate and a
score of 29–63 points suggests severe depression. A total of 194 out of the 230 participants had at least
moderate depression, 17 participants had mild mood disturbance (a BDI-II score of 14–19 points) and
19 participants had minimal depression (a BDI-II score of 0–13 points). BDI-II scores decreased for both
groups by around 5 points during the course of the study. There appears to be a slight skewing of the
data for CBT at 18 and 24 weeks. This is shown in Table 16 and Figure 3. The histograms show that there
appears to be a shift to the left by week 12 for the CBT group with respect to the BDI-II score with TAU
plus CBT (see Figure 3). The BDI-II scores for CBT and TAU, from baseline to 24 weeks, are also shown
(see Figure 4).
Statistical modelling was conducted in accordance with the methods described in the original analysis plan
(Table 17). There were no baseline differences for BDI-II, antidepressant use or clustering by therapist or IAPT
service. Nor, using this model, were there any differences in previous history of depression, baseline EQ-5D,
baseline duration of depression, or length between primary diagnosis and baseline visits. It is noteworthy
that the ICC for clustering by therapist was low. Indeed, the analyses of the primary outcome variable (BDI-II)
over all time points were identical, whether clustering by therapist or IAPT service, or whether no clustering
at all was included in the model. This is because, averaged over time points, there was no evidence that the
components of variance associated with therapist and IAPT service were other than zero.
TABLE 16 Beck Depression Inventory, version 2, total score: summary statistics, by randomisation group for each
follow-up
Time point and
randomisation group
Summary statistic
Min. Q1 Median Q3 Max. Mean SD n
Baseline
TAU 4 18 24 30 52 24.5 9.7 115
CBT 2 17 24 32 53 25.2 10.4 115
Total 2 18 24 31 53 24.9 10.0 230
6 weeks
TAU 0 15 21 30 50 23.1 10.8 82
CBT 1 16 23 30 57 23.6 10.8 86
Total 0 15 23 30 57 23.3 10.8 168
12 weeks
TAU 0 13 20 29 49 21.4 11.1 79
CBT 3 14 20 26 54 21.3 11.0 69
Total 0 14 20 27 54 21.3 11.0 148
18 weeks
TAU 0 12 20 27 54 21.2 12.5 71
CBT 5 12 17 28 56 20.6 11.9 63
Total 0 12 19 27 56 20.9 12.2 134
24 weeks
TAU 0 13 19 27 48 20.4 11.4 65
CBT 2 11 18 25 54 19.4 11.4 65
Total 0 12 19 27 54 19.9 11.4 130
max., maximum; min., minimum; Q1, first quartile; Q3, third quartile.
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FIGURE 3 Histograms of BDI-II score at baseline and at 6, 12, 18 and 24 weeks. (a) TAU, baseline; (b) TAU, 6 weeks;
(c) TAU, 12 weeks; (d) TAU, 18 weeks; (e) TAU, 24 weeks; (f) CBT, baseline; (g) CBT, 6 weeks; (h) CBT, 12 weeks;
(i) CBT, 18 weeks; and (j) CBT, 24 weeks.
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FIGURE 4 Mean BDI-II score, by time and randomisation group.
TABLE 17 Beck Depression Inventory, version 2, total statistical analysis
Model Treatment effect (intervention – TAU) 95% CI p-value
Model with baseline BDI-II, baseline antidepressant use, time and group: clustering by therapista
Number in model = 185
Estimates –0.836 –2.755 to 1.083 0.393
Model with baseline BDI-II, baseline antidepressant use, time and group: clustering by IAPT service
Number in model = 185
Estimates –0.836 –2.755 to 1.083 0.393
Model with baseline BDI-II, baseline antidepressant use, time and group: no clustering by therapist
Number in model = 185
Estimates –0.836 –2.755 to 1.083 0.393
Model with baseline BDI, baseline antidepressant use, time and group: clustering by therapist. Plus baseline previous history
of depression, baseline EQ-5D health score, baseline duration (weeks) of current depression and length (days) between
primary diagnosis and baseline visit
Number in model = 122
Estimates 0.105 –2.273 to 2.483 0.931
Model with baseline BDI-II, baseline antidepressant use and group: clustering by therapist. 6 weeks’ follow-up only
Number in model = 168
Estimates –0.136 –2.157 to 1.884 0.895
Model with baseline BDI, baseline antidepressant use and group: clustering by therapist. 12 weeks’ follow-up only
Number in model = 148
Estimates –1.504 –3.714 to 0.707 0.182
Model with baseline BDI, baseline antidepressant use and group: clustering by therapist. 18 weeks’ follow-up only
Number in model = 134
Estimates –0.964 –4.133 to 2.205 0.551
Model with baseline BDI, baseline antidepressant use and group: clustering by therapist. 24 weeks’ follow-up only
Number in model = 130
Estimates –1.875 –4.845 to 1.096 0.216
a The predetermined primary analysis for the trial.
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Although we did not find a significant benefit of CBT plus TAU versus TAU alone for the treatment of
depression, participants who were widowed, divorced or separated had significantly poorer outcomes on
the BDI-II without the addition of CBT to TAU (Table 18 and Figure 5). There was no clustering by therapist
or IAPT service.
As shown in Figure 5, those in the TAU group who were widowed, divorced or separated remained
unwell, whereas those who received CBT behaved similarly to the other participants, with some
improvement in BDI-II scores.
Contamination-adjusted intention-to-treat analysis
Table 19 presents the frequency and percentage of the total number of CBT sessions attended by the
24-week follow-up in the intervention group. A number of patients were entered as ‘not included in the
analysis’ because they did not have an 18- or a 24-week follow-up that was used to calculate the CAITT,
the rationale being that, even though CBT sessions may have been received, the outcome data used to
calculate the CAITT were missing for these individuals.
For the modelling, a total of 153 individuals were included in the model [those with relevant outcome data
(for the control and intervention group) and number of CBT sessions available (for the intervention group)].
The estimated ‘per-session’ effect on the BDI-II was –0.295 points (95% CI –0.760 to 0.170 points; p = 0.213).
Thus, on average, every session of CBT would be expected to decrease the total BDI-II score by 0.3 points
(compared with no sessions). However, this effect was not found to be statistically significant (p = 0.213).
TABLE 18 Beck Depression Inventory, version 2, total scores by time point, marital status and level of education
Model Treatment effect (intervention – TAU) 95% CI p-value
Model with baseline BDI, baseline antidepressant use, time and group: clustering by therapist. Plus group by time
interaction
Number in model = 185, p-value for interaction = 0.471
Estimates 0.127 –2.202 to 2.456 0.915
6 weeks
12 weeks –0.847 –3.281 to 1.586 0.495
18 weeks –1.365 –3.875 to 1.146 0.287
24 weeks –1.728 –4.262 to 0.806 0.181
Model with baseline BDI, baseline antidepressant use, time and group: clustering by therapist. Plus group by marital
status interaction
Number in model = 183, p-value for interaction = 0.002
Estimates 0.645 –1.791 to 3.081 0.604
Married/partner
Widowed/divorced/separated –7.211 –11.147 to –3.276 < 0.001
Single, never married 0.836 –3.372 to 5.044 0.697
Model with baseline BDI, baseline antidepressant use, time and group: clustering by therapist. Plus group by education
status interaction
Number in model = 170, p-value for interaction = 0.710
Estimates –0.463 –3.558 to 2.631 0.769
Below A Level
A Level and above –1.234 –3.862 to 1.395 0.358
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FIGURE 5 Mean BDI-II score by marital status and randomisation group with time.
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Secondary outcomes
Secondary outcomes for the PHQ-9, ECOG-PS and satisfaction with care are shown (see Tables 20–22).
Patient Health Questionnaire-9 scores and the changes observed were similar to the BDI-II. Data for the
PHQ-9 are shown in Table 20.
TABLE 19 Distribution of frequency of CBT sessions
CBT session (pre 24 weeks) Frequency, n % Number of sessions
0 15 13.0 0
1 4 3.5 4
2 4 3.5 8
3 5 4.4 15
4 4 3.5 16
5 3 2.6 15
6 1 0.9 6
7 5 4.4 35
8 3 2.6 24
9 13 11.3 27
10 4 3.5 40
11 5 4.4 55
12 6 5.2 72
Total in the CAITT analysis 43 62.6 317
Not included in analysis 37.4 226
TABLE 20 Patient Health Questionnaire-9 total score (points): summary statistics by randomisation group for each
follow-up
Time point and
randomisation group
Summary statistic
Min. Q1 Median Q3 Max. Mean SD n
Baseline
TAU 1 10 14 17 24 13.5 4.8 115
CBT 3 10 15 18 27 14.0 5.3 115
Total 1 10 14 17 27 13.8 5.1 230
12 weeks
TAU 0 8 11 15 26 11.4 5.8 79
CBT 0 6 9 15 26 10.3 5.7 68
Total 0 6 10 15 26 10.9 5.8 147
24 weeks
TAU 0 5 9 14 24 9.9 6.3 64
CBT 1 5 9 14 25 10.0 6.2 64
Total 0 5 9 14 25 9.9 6.2 128
max., maximum; min., minimum; Q1, first quartile; Q3, third quartile.
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Selection criteria stipulated that participants needed to have a PHQ-2 score of ≥ 3 points to enter into the
trial. It is of note that one participant in the TAU group had a score of only 1 point on the PHQ-9 at baseline.
This is because the baseline measures were repeated immediately prior to randomisation and scores may
change in the time from the week at screening for entry into the trial to when the baseline measures were
collected. Recovery in IAPT services is taken as < 10 points on the PHQ-9. The number of participants with
scores of < 10 points in the TAU group at baseline, 12 and 24 weeks was 20, 33 and 35, respectively, and
in the TAU plus CBT group at baseline, 12 and 24 weeks the number was 26, 37 and 33, respectively.
The PHQ-9 suggests that a score of 10–14 points indicates moderate depression and a score of 15–19 indicates
moderately severe depression. As shown in Table 20, the scores are not skewed and consistent with our target
population, namely people with a diagnosis of depression of moderate severity. At the end of treatment, both
groups had median depressive symptoms at the mild end of the severity range (range 5–9 points).
Eastern Cooperative Oncology Group Performance Status scores suggested that only one-fifth of participants
were fully active, with two-fifths being of restricted mobility (Table 21). Participants were equally balanced
TABLE 21 Eastern Cooperative Oncology Group Performance Status: frequencies and percentages, by
randomisation group for each follow-up
Time point
Randomisation group
TotalTAU CBT
n % n % n %
Baseline
Fully active 23 20.0 22 19.1 45 19.6
Restricted 45 39.1 52 45.2 97 42.2
Ambulatory 34 29.6 29 25.2 63 27.4
Limited 13 11.3 12 10.4 25 10.9
Disabled 0 0.0 0 0.0 0 0.0
Dead 0 0.0 0 0.0 0 0.0
Total 115 100.0 115 100.0 230 100.0
12 weeks
Fully active 12 15.6 9 13.2 21 14.5
Restricted 33 42.9 30 44.1 63 43.4
Ambulatory 24 31.2 23 33.8 47 32.4
Limited 7 9.1 5 7.4 12 8.3
Disabled 1 1.3 1 1.5 2 1.4
Dead 0 0.0 0 0.0 0 0.0
Total 77 100.0 68 100.0 145 100.0
24 weeks
Fully active 9 14.3 15 23.1 24 18.8
Restricted 25 39.7 25 38.5 50 39.1
Ambulatory 19 30.2 21 32.3 40 31.3
Limited 10 15.9 4 6.2 14 10.9
Disabled 0 0.0 0 0.0 0 0.0
Dead 0 0.0 0 0.0 0 0.0
Total 63 100.0 65 100.0 128 100.0
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between the groups with respect to disability and this appeared to remain constant with time. Although the
ECOG-PS questionnaire contains the category ‘dead’, these data were excluded in the analysis to maintain
consistency with the primary outcome measure, as it is not possible to collect mood ratings from deceased
participants. The CanTalk data suggest that participants’ physical functioning was towards the active end of
the scale, with the greatest proportion being fully active or restricted, a similar portion being classed as
ambulatory, fewer participants being limited and no participants being classed as disabled.
The mean satisfaction with care was 80% (40 out of a total score of 50 points) at baseline (prior to
randomisation) and did not change with time or by treatment group (Table 22). This finding is also
represented graphically (Figure 6).
TABLE 22 Satisfaction with care total score (points): summary statistics, by randomisation group for each follow-up
Time point and
randomisation group
Summary statistic
Min. Q1 Median Q3 Max. Mean SD n
Baseline
TAU 11 36 40 47 50 39.7 9.2 114
CBT 14 35 41 47 50 39.6 8.3 115
Total 11 35 40 47 50 39.6 8.7 229
12 weeks
TAU 16 38 42 46 50 40.8 7.3 79
CBT 4 33 43 48 50 39.5 10.1 68
Total 4 36 43 47 50 40.2 8.7 147
24 weeks
TAU 11 36 43 47 50 40.8 8.4 64
CBT 11 33 44 47 50 39.4 10.1 65
Total 11 35 43 47 50 40.1 9.3 129
max., maximum; min., minimum; Q1, first quartile; Q3, third quartile.
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FIGURE 6 Satisfaction with care total score, by randomisation group and time for each follow-up.
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Intervention
Training for the intervention
Training was delivered to 129 therapists and information regarding their experience of the training session
was collected from 22% of them (29/129) by asking them to rate the questions on a 4-point Likert scale
(Table 23).
Take-up and engagement with cognitive–behavioural therapy
A total of 543 (39.3%) sessions out of a potential total of 1380 sessions (12 × 115) were taken up, of
which 32 were by telephone (5.9%): seven participants took up one telephone session, three participants
took up two sessions, one participant took up three sessions, one participant took up four sessions and
one participant took up 12 sessions. The mean time from being referred to being seen by IAPT was
29.4 days (SD 26.7 days).
Among the total of 115 participants randomised to CBT, the mean number of sessions received was
4.7 (SD 4.9). It is notable that, of the 115 participants allocated to CBT, 41 (35.6%) did not take up any
sessions and 36 (31.3%) had at least eight sessions. The reason for sessions not being received was
predominantly participants withdrawing after randomisation (Table 24). The median time from being
referred to being seen by IAPT was 21 days [quartile range (QR) 13–37 days].
Not referred
Six participants were not referred to therapy: two moved out of the IAPT area, two were not referred to
the therapist by the IAPT administrator, one declined to be referred and one could not be contacted.
A total of 26 participants withdrew prior to commencing therapy: 12 had physical problems, five were
no longer depressed, four were too busy, two were unable to travel, one declined therapy, one received
therapy outside the study and one gave no reason. Five participants were discharged by IAPT services
prior to starting therapy: four were reported to be no longer depressed and one was receiving therapy
TABLE 23 Summary of feedback from therapists attending CanTalk training
Section
Feedback, mean score (SD)
Helped my
understanding (0–3) Helped my skills (0–3)
Helped my
confidence (0–3)
Psychological distress in cancer and the
application of CBT
2.82 (0.39) 2.69 (0.47) 2.62 (0.50)
Overview of CanTalk trial 2.80 (0.48) 2.62 (0.56) 2.67 (0.56)
Overview of CBT in CanTalk 2.93 (0.26) 2.85 (0.37) 2.88 (0.34)
First phase of therapy (sessions 1–4) 2.89 (0.31) 2.77 (0.51) 2.77 (0.51)
Demonstration video: hot cross bun 2.82 (0.66) 2.95 (0.22) 2.85 (0.37)
Small group exercise: formulation and
treatment planning
2.71 (0.56) 2.67 (0.58) 2.7 (0.57)
Middle phase of therapy (sessions 5–8) 2.93 (0.27) 2.73 (0.45) 2.80 (0.41)
Demonstration video: working with
patient with severe physical symptoms
2.91 (0.30) 2.91 (0.30) 2.80 (0.42)
Final phase of therapy (sessions 9–12) 2.89 (0.32) 2.73 (0.45) 2.76 (0.44)
Existential issues 2.85 (0.36) 2.81 (0.40) 2.64 (0.49)
Specific topics decided on the day 2.86 (0.38) 3.00 (0.00) 2.67 (0.52)
Note
Based on 29 completed feedback forms.
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elsewhere. A total of 21 participants withdrew after commencing therapy without giving a reason.
Thirteen participants were discharged by IAPT service after commencing therapy: six did not attend on two or
more occasions, three were too unwell to continue attending, three did not feel that CBT was beneficial and
one could not be contacted to continue therapy. A total of 36 participants completed 8–12 sessions of therapy.
Withdrawal and time to referral
Participants commented in the qualitative interviews that the delay between the time of assessment and
referral was an issue. Thus, although not included in the original analysis plan, we were interested to know
whether or not this may have had an impact on retention. As shown in Table 24, 47 participants withdrew
early (26 before commencing therapy and 21 soon after commencing therapy), whereas 36 participants
demonstrated engagement with therapy, having received 8–12 sessions. Data were available for 30 out of
47 (63.8%) participants who withdrew early and for 27 out of 36 (75%) who completed therapy. The median
time from referral to seeing a therapist for those who withdrew early was 26 days (QR 16.0–41.24 days) and,
for the 36 who were well engaged, was 16.0 days (QR 11.0–35.0 days).
Quality of cognitive–behavioural therapy and adherence to manual
Quality of cognitive–behavioural therapy using the Cognitive Therapy Scale – Revised
Of the 543 therapy sessions delivered, 55 tapes, namely 1 in 10, were rated. Of these, 21 (38%) were from
the initial phase of therapy (sessions 1–4), 19 (35%) were from the middle phase (sessions 5–8) and 15 (27%)
were from the final phase of therapy (sessions 9–12). The mean CTS-R score was 47.6 points (SD 13.8 points)
(the upper end of the ‘proficient’ range). Forty-seven (90%) out of 52 tapes scored ≥ 36 points on independent
ratings of the CTS-R. The mean CTS-R score by phase of therapy was 47.9 points (SD 10.6 points) for 21 early
sessions, 48.1 points (SD 18.8 points) for 19 middle sessions and 46.7 points (SD 10.9 points) for 15 late
sessions. These scores indicate strong adherence to the therapeutic model in CBT.
Elements delivered in therapy recorded in the Therapy Components Checklist
Subjective TCCs from therapists were returned for 293 out of 543 (54%) therapy sessions delivered. The
total number of the elements ticked by the therapist and the proportion of times a particular intervention
was used is shown in Table 25. Guided discovery, activity scheduling, discussion about specific cancer
topics, covering the impact of the physical illness, and beliefs and expectations about the illness were most
TABLE 24 Therapy status of participants randomised to CBT group
Therapy status n (%)
Not referred 6 (5.2)
Withdrew prior to commencing therapy 26 (22.6)
Deceased prior to commencing therapy 2 (1.7)
Discharged prior to commencing therapy 5 (4.3)
Withdrew after commencing therapy 21 (18.3)
Deceased after commencing therapy 4 (3.5)
Discharged after commencing therapy 13 (11.3)
Completed therapya 36 (31.3)
No information available 2 (1.7)
Total 115 (100.0)
a ‘Completed’ refers to patients who completed at least eight sessions of therapy and were deemed by the therapist to
have completed the course of therapy.
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TABLE 25 Self-rated components of therapy
Component
Frequency with which
the component was
used,a n
Percentage of
sessions in which the
component was used
General procedures
Total 178 60.8
Initial assessment 48 16.4
Describe Beck’s model and concept of CBT 47 16.0
Agree goals of therapy 57 19.5
Present a shared formulation 35 11.9
Goal-setting 55 18.8
Review of shared formulation 35 11.9
Review of success list 29 9.9
Relapse prevention/future planning 33 11.3
Behavioural techniques
Total 109 37.2
Relaxation training 21 7.2
Breathing space 9 3.1
Activity schedule 86 29.4
Pleasure experiences sheet 23 7.8
Cognitive techniques
Total 168 57.3
Refocusing techniques 25 8.5
Mindfulness 12 4.1
Four-step process for resilience and coping 18 6.1
Coping map 12 4.1
List of strengths and resources 47 16.0
Reattribution 30 10.2
Decatastrophising 30 10.2
Advantages/disadvantages 27 9.2
Success list 26 8.9
Thoughts diary 38 13.0
Personal rule (pros/cons) 26 8.9
Managing worry (worry tree handout) 17 5.8
Blueprint for coping 28 9.6
Cognitive–behavioural techniques
Total 169 57.7
Guided discovery 117 39.9
Pleasure prediction sheet 8 2.7
Pleasure experiences sheet 16 5.5
Negative triad/negative automatic thoughts 46 15.7
continued
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the most common interventions. It also needs to be noted that general procedures ranged from 9.9% to
19.5% of sessions. However, general procedures would depend very much on the stage of therapy.
Validity of therapists’ self-rating using the Therapy Components Checklist
We present the comparison of therapists’ self-reports of what their intervention was and the observer
rating for that particular therapy session (Table 26). The TCC has 46 potential responses. Given that we had
paired objective and subjective ratings in 39 TCC responses, a potential of 1794 data points were available.
The frequencies are as follows: both the therapist and observer agreed that the intervention took place in
66 data points; neither the therapist nor the independent rater believed that an intervention took place in
1431 data points; the therapist considered that an intervention took place but the independent rater did not
in 212 data points; and the therapist considered that the intervention was not delivered but the independent
rater felt that it was in 85 data points. Data with Kappa scores of ≥ 0.7 are considered significant.
The findings suggest that there was a strong relationship between therapist’s self-report and the
independent rater’s report for most of the components delivered or not delivered, with the majority of
PABAK scores being > 0.70. Notably low PABAK agreement scores were for the items ‘Guided discovery’
and ‘Impact of physical illness’ (both of which had a PABAK score of 0.03, indicating very little agreement).
We would like to point out that guided discovery, believed to be an essential component of CBT, was
TABLE 25 Self-rated components of therapy (continued )
Component
Frequency with which
the component was
used,a n
Percentage of
sessions in which the
component was used
Applying resilience 43 14.7
Thinking traps handout 36 12.3
Reality testing 30 10.2
Searching for alternatives 43 14.7
ABC form 16 5.5
Specific cancer topics
Total 205 70.0
Impact of physical illness 123 42.0
Beliefs and expectations about illness 104 35.5
Plans and hopes for care as disease advances 58 19.8
Relationship between emotional and physical symptoms 59 20.1
Concerns about current and future ability to cope 75 25.6
Concerns about loss of control 40 13.7
Concerns about accepting help 57 19.5
Concerns about dying (mode/afterwards/life expectancy) 40 13.7
Impact of disease and mood on behaviour 85 29.0
Impact of disease/death on loved ones 90 30.7
Discussion of ‘the meaning’ of the illness 30 10.2
Acceptance of unfinished business 8 2.7
ABC form, antecedents, behaviours, consequences form.
a Frequency with which the component was used out of 293 sessions for which the therapist-completed checklists
were available.
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TABLE 26 Therapist-rater agreement for components of therapy delivered
Intervention used
Agreement
PABAK
score
Ticked by
therapist
and observer
Not ticked
by therapist
or observer
Ticked by
therapist but
not observer
Ticked by
observer but
not therapist
General procedures
Initial assessment 0 36 3 0 0.85
Describe Beck’s model and concept
of CBT
5 31 3 0 0.85
Agree goals of therapy 3 29 5 2 0.64
Present a shared formulation 1 29 4 5 0.54
Goal-setting 1 28 9 1 0.49
Review of shared formulation 0 33 4 2 0.69
Review of success list 1 32 6 0 0.69
Relapse prevention/future planning 5 32 1 1 0.90
Behavioural techniques
Relaxation training 2 36 1 0 0.95
Breathing space 1 37 1 0 0.95
Activity schedule 4 23 9 3 0.38
Pleasure experiences sheet 0 37 2 0 0.90
Cognitive techniques
Refocusing techniques 1 35 2 1 0.85
Mindfulness 0 37 2 0 0.90
Four-step process for resilience and
coping
0 32 6 1 0.64
Coping map 0 34 2 3 0.74
List of strengths and resources 0 28 7 4 0.44
Reattribution 0 35 1 3 0.79
Decatastrophising 0 38 1 0 0.95
Advantages/disadvantages 1 35 3 0 0.85
Success list 1 32 3 3 0.69
Thoughts diary 1 29 6 3 0.54
Personal rule (pros/cons) 0 37 1 1 0.90
Managing worry (worry tree
handout)
1 34 2 2 0.79
Blueprint for coping 1 31 4 3 0.64
Cognitive–behavioural techniques
Guided discovery 9 11 5 14 0.03
Pleasure prediction sheet 0 39 0 0 1.00
Pleasure experiences sheet 0 37 1 1 0.90
Negative triad/negative automatic
thoughts
0 32 5 2 0.64
continued
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reported by therapists as being delivered in 39.9% of sessions. However, the observer’s report suggested
that therapists were indeed using more guided discovery than they reported. By contrast, therapists
reported more discussion about the patients’ physical illness than reported by the observer.
Qualitative findings
Health-care workers’ views about the CanTalk trial
An additional qualitative substudy was conducted, looking at the views of 14 health-care workers. This
study looked at health-care workers’ views of psychological [non-Clinical Trial of Investigative Medicinal
Product (CTIMP)] research in general and of the CanTalk trial more specifically. An initial analysis of the
data generated the following emerging themes.
TABLE 26 Therapist-rater agreement for components of therapy delivered (continued )
Intervention used
Agreement
PABAK
score
Ticked by
therapist
and observer
Not ticked
by therapist
or observer
Ticked by
therapist but
not observer
Ticked by
observer but
not therapist
Applying resilience 0 33 6 0 0.69
Thinking traps handout 4 26 3 6 0.54
Reality testing 3 29 2 5 0.64
Searching for alternatives 0 33 4 2 0.69
ABC form 1 35 2 1 0.85
Specific cancer topics
Impact of physical illness 2 18 15 4 0.03
Beliefs and expectations about
illness
5 21 10 3 0.33
Plans and hopes for care as disease
advances
2 27 10 0 0.49
Relationship between emotional/
physical symptoms
0 34 5 0 0.74
Concerns about current/future
ability to cope
0 27 12 0 0.38
Concerns about loss of control 1 32 5 1 0.69
Concerns about accepting help 1 31 6 1 0.64
Concerns about dying 3 29 4 3 0.64
Impact of disease and mood on
behaviour
2 22 14 1 0.23
Impact of disease/death on loved
ones
3 24 10 2 0.38
Discussion of ‘the meaning’ of the
illness
1 33 4 1 0.74
Acceptance of unfinished business 0 38 1 0 0.95
ABC form, antecedents, behaviours, consequences form.
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Recruitment issues
Themes include issues with (1) finding the time to conduct these trials, (2) money (with the perception that
CTIMPs provide better financial incentives), (3) the competing interests of CTIMP trials and (4) geographical
catchment areas, in that not all participants were eligible to participate in CanTalk owing to the limitations
of IAPT catchment areas.
The role of the clinician
Themes include (1) the influence of the clinician on their team’s involvement with the study, (2) the
influence of the clinician on patients in encouraging participation, (3) ‘gatekeeping’, in which some
clinicians may try to protect participants from research studies and (4) the importance of the clinicians’
initial agreement to involvement in the study.
The sensitive nature of the research
Themes include (1) psychological research ‘opening a can of worms’ with health-care workers who are
unsure how to help patients if they become distressed, (2) issues about how the study fits in or clashes
with existing psychological services and teams that operate within the hospital and (3) concerns regarding
people with significant psychological issues who may not be eligible to be referred to the trial.
The role of the trial team
Issues include (1) the study being ‘mis-sold’ to hospital research units, with the trial team presenting the
study as easier to recruit for than it turned out to be and (2) members of the trial team recruiting at clinics
being important for the success of the study, given the limited research resources of hospitals and the trial
team’s more detailed knowledge of the study.
Therapists’ views of treating patients with advanced cancer
Sixteen therapists were interviewed qualitatively using semistructured questionnaires and their repsonses
transcribed and coded onto a Microsoft Excel® 2010 (Microsoft Corporation, Redmond, WA, USA)
spreadsheet. Although such interviews were not required for the purpose of this report, a brief summary
is presented here.
Background information
The range of experience of therapists interviewed was 1–18 years (median 8 years). The 16 therapists had
treated 29 out of 33 assessed participants (four had dropped out or were withdrawn for health reasons).
A total of 193 sessions were delivered, 14 of which were by telephone contact.
Knowledge of cancer
Nine out of 16 therapists had treated a patient with cancer previously and five indicated that they had
direct experience of cancer with family or a friend. General themes suggested that therapists would have
liked more knowledge about cancer, but had gained this from talking to the patient and most did not feel
that it adversely affected the therapeutic process.
Experience of training
The overall experience of training on how to apply CBT skills to people with cancer was felt to be
excellent, although therapists would have liked to have had more information about the type of cancer
and how treatment may have affected the patient.
Concerns about treating advanced cancer patients
Therapists described feeling anxious about treating cancer patients and were concerned that applying CBT
to this patient group may appear to be trivialising their situation and feared not having sufficient expertise.
Therapists had mixed views about the degree of physical ill heath to expect, but were surprised how
receptive patients were to the CBT model and how they could work psychologically.
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Support and supervision
Therapists reported variability about the quality of support from their regular supervisors and thought that
it would be helpful for more supervisors to have attended the CanTalk training. Therapists would also have
liked more specialist support from the CanTalk supervisors.
Experience of working with patients
Therapists generally found it easy to co-ordinate meetings with patients, but recognised that their physical
problems posed a challenge. They tried to be more flexible in their delivery of care and felt that patients
were motivated and could challenge unhelpful beliefs in therapy. They found their experience of working
with this patient group more positive than expected. However, a number of therapists indicated that the
issues that came up in therapy were not always cancer related.
Therapy materials
Therapists generally liked the materials, but felt that it was not always easy to stick to the manual. They
found themselves having to tailor the treatment to the needs of the patient, requiring more flexibility than
they thought they were allowed.
Patients’ views of cognitive–behavioural therapy
Background of patients interviewed for qualitative element
Qualitative interviews were conducted with 10 patients who had received CBT. The mean number of
sessions received was 9.4. Of these patients, eight were female and three came from one IAPT service,
with the remaining seven coming from seven different IAPT services. Four were diagnosed with lung
cancer, four with breast cancer, one with colorectal cancer and one with Non-Hodgkin lymphoma.
The majority had some awareness that they were depressed.
Expectations and knowledge of cognitive–behavioural therapy
Most patients had no prior experience of CBT but had some limited knowledge about what the therapy
would involve. Most people wanted to participate in the study because they wanted to seek support for
depression or because they had an interest in psychological therapies and research. The patients who had
previously received psychodynamic therapy found CBT to be more clinically effective, with more time being
appropriately given to their diagnosis.
Structure and delivery of cognitive–behavioural therapy
The mean number of CBT sessions received by those interviewed was 9.4. There was a general view that
the location of the IAPT service was convenient and that the appointments were well organised and
flexible. Some patients were dependent on a taxi service to travel to the appointments (which was funded
for by the study). Transport problems could be a barrier to patients attending therapy at an IAPT service.
The average waiting time between referral and starting therapy varied largely between participants.
Some participants were very happy with the referral process, whereas others felt that it was problematic,
especially because of the delay between being referred and being seen.
Experience of cognitive–behavioural therapy
Patients’ experience of CBT was that it was helpful, especially as it was practical and non-threatening. They
also reported that CBT facilitated their ability to talk to family and friends about cancer and that it had a
positive impact on their social life and helped them to cope. Participants felt that they developed effective
cognitive skills to help them deal with negative or unhelpful thinking.
Although patients would recommend CBT to others, they wondered whether or not simple emotional
support may be what is needed. Most patients felt that it would have been helpful for therapists to know
more about their diagnosis and treatment, as they often had to inform them of this. All of the participants
spoke positively about their therapist and identified them as being professional, empathetic and genuinely
interested in them.
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Although the general view was that CBT was helpful and covered all the areas that participants felt was
necessary, they reported that the opportunity to just talk about their feelings was useful in itself. Participants
largely felt that CBT had a positive impact on their life, with only one participant commenting on a negative
impact of CBT, namely that they found completing homework tasks difficult. The majority of participants
who had completed therapy were aware of how to seek help in the future and how to make use of relapse
prevention techniques.
Other therapeutic options for advanced cancer patients
Although participants stated that CBT should be offered, it was generally felt that CBT is not apprpriate for
everyone and that therapy should be tailored to the needs of the patient. There was a sense that patients
should be given space to talk, but that this need not necessarily be through the medium of CBT, and that
other interventions, such as counselling, may be more suitable. The majority of participants said that they
would recommend CBT to other cancer patients. Participants thought that psychological therapy should be
offered to all patients with advanced cancer.
Improvements to therapy
Suggestions for improvement were varied. One participant felt that therapy would be better placed in the
hospital where the patient is receiving cancer treatment as this would be more convenient and would fit
around their existing hospital appointments. Two patients highlighted that it would have been useful to
have been given a manual/workbook to take away from therapy to enable them to reflect on the session
at home. One participant suggested that individual therapy for carers would be beneficial to help them
deal with some of the emotional difficulties that come with the caring role. Some patients felt that weekly
sessions were too time demanding and that bi-monthly appointments would have been more suitable.
Adverse events
The only adverse event (AE) stipulated in the protocol was an increase in suicidality or a death being under
investigation for possible suicide by a coroner. No AEs were recorded.
The study protocol did not require the routine reporting of deaths and instances of hospitalisation as
‘SAEs’, given their expectedness within this study population. Despite this, clinicians reported five events as
SAEs over the course of the study. These were two SAEs for patients in the CBT group (one death and one
hospitalisation) and three SAEs in the TAU group (two deaths and one hospitalisation). However, these
deaths were not unexpected and not SAEs as defined in the protocol. We did, of course, record deaths in
each arm over the course of the study. Of a total of 21 recorded deaths, nine were in the CBT arm and
12 were in the TAU arm.
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Chapter 6 Health economics results
A health and social care perspective was adopted in line with NICE’s recommendations.151 Service usecosts were calculated from resource data to calculate the total cost of resources used by each study
participant. QALYs were calculated from EQ-5D scores at baseline, 12 and 24 weeks’ follow-up. Costs
were compared for the groups using a bootstrap regression model to account for non-normality in the
distribution of cost data. A cost–utility analysis was undertaken using QALYs calculated from the EQ-5D
measure. Cost-effectiveness was assessed by estimating an ICER to show the extra cost incurred by CBT
to generate one extra QALY. To deal with uncertainty around the ICER, a CEP and CEACs were created.
Sample size
Full economic data were available for 230 participants at baseline, 148 participants at 12 weeks’ and
128 participants at 24 weeks’ follow-up.
Service use
As there was no expectation that hospital utilisation would be affected by the intervention, its inclusion
would have introduced more variability to the costs. Hence, the proportion of those who used different
community health services and the mean number of contracts that the participants made are presented
in Table 27.
At baseline, service use was, for the most part, similar between the two groups. Although more participants
in the TAU group than the CBT group (94% vs. 86%) accessed their GP and had slightly more appointments,
the difference was not significant. Similar non-significant differences were observed in the proportions of
participants reporting regular contact with a psychiatrist (TAU 71% vs. CBT 63%) and social services (TAU
57% vs. CBT 41%). Participants in the CBT group were more likely to report being in contact with a
specialist nurse (CBT 47% vs. TAU 35%).
At both 12- and 24-week follow-up stages, no significant differences in the service use between the two
groups were apparent. Use of GP services decreased slightly at 24-week follow-up for both groups.
Baseline access to community mental health services was similar in both the CBT plus TAU group (78%)
and the TAU alone group (71%). The frequency of contacts with mental health community services
(excluding IAPT) increased at the 12-week follow-up for both groups (89% for CBT and 90% for TAU) and
slightly decreased for CBT but increased for TAU at the 24-week follow-up (80% and 94%, respectively).
There were no between-group difference with time with respect to the BDI-II and PHQ-9.
The number of contacts with social care declined steadily in both groups throughout the follow-up period,
while the demand for palliative care services increased during that period.
The mean service costs for participants (not including the costs of the interventions) are presented in Table 28.
The figures were similar across the two randomisation groups. Compared with baseline, costs associated
with service use increased for both randomisation groups with follow-up. The differences in costs between
the two randomisation groups at both follow-ups were marginal.
Costing the intervention
In total, 1380 sessions were available for participants in the CBT arm; however, fewer than half (n = 543)
were taken up. A total of 65% of CBT arm participants attended at least one session and 31% attended
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TABLE 27 Number of participants using services and their volume of use
Service
Time point
Baseline 12-week follow-up 24-week follow-up
CBT (n= 115) TAU (n= 115) CBT (n= 68) TAU (n= 80) CBT (n= 64) TAU (n= 64)
n (%) Mean SD n (%) Mean SD n (%) Mean SD n (%) Mean SD n (%) Mean SD n (%) Mean SD
Number of contacts
GP 99 (86) 3.1 2.4 108 (94) 3.4 2.8 64 (94) 2.6 1.8 73 (91) 2.9 2.3 52 (81) 2.9 2.2 51 (80) 2.8 2.2
District nurse 36 (31) 2.2 1.7 31 (27) 2.2 2.5 34 (50) 1.3 0.6 28 (35) 1.5 0.6 24 (38) 1.8 1.3 26 (41) 1.4 0.6
Practice nurse 77 (67) 4.79 9.21 72 (63) 4.29 6.29 48 (71) 3.67 2.33 53 (66) 4.39 3.43 41 (64) 3.34 5.56 39 (61) 3.16 5.27
Specialist nurse 54 (47) 6 4.5 40 (35) 5.9 3.5 42 (62) 3.5 3.9 37 (46) 2.9 2.4 40 (63) 3.3 3 39 (61) 2.8 1.8
Occupational
therapist
43 (37) 4.8 3.2 42 (37) 6.7 12 55 (81) 3.6 5.5 51 (64) 3.5 3 42 (66) 2.6 1.3 43 (67) 2.4 1.5
Physiotherapist 37 (32) 11.8 18.1 40 (35) 10 12.8 43 (63) 6.8 8.6 40 (50) 6.8 9 39 (61) 5.6 6.2 37 (58) 9.9 14.7
Community
matron
16 (14) 2.3 1.3 17 (15) 4.6 4 16 (24) 2.8 2.9 15 (19) 2.9 2.5 14 (19) 3.4 3.8 13 (20) 4.6 5.3
Mental health
services
73 (63) 2.9 3 82 (71) 2.7 1.4 52 (76) 2.8 2.9 55 (69) 2.9 2.5 51 (80) 2.5 2.1 50 (78) 2.8 2.2
Social care 47 (41) 4.6 3.3 66 (57) 4.7 3.9 42 (62) 3.1 3.5 50 (63) 3.5 3.4 37 (58) 3.5 2.6 43 (67) 3.1 2.8
Palliative care 0 – – 0 – – 3 (4) 1 0 2 (3) 3 2.7 3 (5) 1.5 1.6 1 (2) 1 –
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at least eight sessions. The mean number of sessions attended in the CBT arm per participant was 4.8. It
was assumed that when a session was offered but a participant did not attend it still constituted the IAPT’s
therapist opportunity cost. The mean cost of CBT intervention was £948.75 (SD £427.00) per participant.
Quality-adjusted life-years
Line plots for EQ-5D VAS and histograms for EQ-5D index scores are presented in Figures 7 and 8,
respectively.
There were no differences in EQ-5D median scores at baseline, nor was there any advantage of CBT over
TAU at 12 weeks. At 24 weeks, there was a trend towards improvement with CBT; however, this was not
significant. A similar pattern was shown for the VAS on the EQ-5D. There was no statistically significant
TABLE 28 Cost of service use (£, 2014/15) prior to baseline and follow-up
Service
Time point, cost (£)
Baseline 12-week follow-up 24-week follow-up
CBT (n= 115) TAU (n= 115) CBT (n= 68) TAU (n= 80) CBT (n= 64) TAU (n= 64)
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
GP 81 118 92 108 53 63 63 101 64 100 76 90
District nurse 21 39 21 41 14 18 15 20 14 20 15 23
Practice nurse 16 20 17 28 30 58 38 77 21 30 23 34
Specialist nurse 72 151 40 83 33 83 22 39 28 60 24 40
Occupational
therapist
46 143 62 211 30 94 30 93 28 98 34 117
Physiotherapist 86 160 74 160 43 89 65 118 77 231 53 92
Community matron 26 98 65 180 35 153 22 60 17 38 17 29
Psychiatrist/mental
health services
90 162 82 114 61 133 72 125 51 90 60 104
Social care 64 129 43 84 29 63 37 65 22 51 26 122
Palliative care 0 0 0 0 45 78 30 68 38 74 27 62
Total costs 502 1020 496 1009 373 832 394 766 360 792 355 713
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FIGURE 7 Median EQ-5D VAS scores at baseline, 12 and 24 weeks, by time and randomisation group.
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improvement in QALYs at 24 weeks. Both these figures and the data on which they are based show that any
mean changes over time or mean differences between trial arms in either of these scores were minimal.
In the CBT group, the mean EQ-5D-5L values were 0.64 (SD 0.24) at 12-week follow-up and 0.68 (SD 0.22)
at 24-week follow-up. The figures for TAU were similar: 0.64 (SD 0.24) and 0.63 (SD 0.27), respectively.
Summary statistics are presented in Table 29 and the results of the statistical analysis in Table 30.
Table 29 shows the EQ-5D scores at baseline and at each follow-up period, and total QALYs over the
24-week follow-up. The data are presented as both median scores and lower and upper QRs (Q1 and Q3),
as well as mean, SD and the number of participants available.
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FIGURE 8 Mean EQ-5D values at baseline, 12 and 24 weeks, by randomisation group.
TABLE 29 EuroQol-5 Dimensions scores and QALY estimates: summary statistics by randomisation group for each
follow-up
Time point and
randomisation group
Summary statistic
Min. Q1 Median Q3 Max. Mean SD n
Baseline
TAU 0 0.43 0.673 0.77 1 0.612 0.23 115
CBT –0.22 0.53 0.696 0.79 0.95 0.625 0.23 115
12 weeks
TAU –0.19 0.55 0.68 0.81 1 0.64 0.24 80
CBT –0.17 0.5 0.71 0.82 1 0.64 0.24 68
24 weeks
TAU –0.12 0.56 0.69 0.81 1 0.63 0.27 64
CBT –0.12 0.58 0.73 0.83 1 0.68 0.22 64
QALYs
TAU –0.16 0.28 0.44 0.56 0.69 0.39 0.19 64
CBT –0.11 0.36 0.57 0.74 0.82 0.5 0.21 64
max., maximum; min., minimum; Q1, first quartile; Q3, third quartile.
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The maximum QALY accrual was 0.82. The mean QALY accrual was 0.504 for the CBT group and 0.386
for the TAU group. The difference adjusting for baseline was 0.118 in favour of CBT; this difference in
QALYS was not statistically significant (p = 0.12).
Cost–utility analysis
The cost–utility results are presented in Table 30, showing the incremental cost-effectiveness for each CBT
session compared with TAU for the period of the trial.
Analysis suggests that CBT has higher costs and produces more QALYs than TAU. To reduce the degree of
uncertainty around the estimates, bootstrapping is applied.
Cost-effectiveness
Figure 9 is a scatterplot of incremental costs and QALYs and shows the cost-effectiveness plane of
1000 bootstrap-replicated ICERs for CBT compared with TAU, based on health and social care costs and
QALYs over 24 weeks, adjusted for baseline costs and utility.
TABLE 30 Differences in incremental costs, effects and cost-effectiveness at 24 weeks
Cost of outcome category
Randomisation group
Incremental
difference (adjusted) p-valueCBT (n= 64) TAU (n= 64)
Health and social care cost (NHS/PSS), £ (mean) 4437 3755 682 (457) 0.08
QALY (EQ-5D) 0.504 0.386 0.118 (0.105) 0.12
BDI-II score (points) 19.4 20.4 1 (0.295) 0.21
PSS, Personal Social Services.
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FIGURE 9 Cost-effectiveness plane: CBT vs. TAU, ratio of incremental cost to QALY gained.
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The CEP indicates that there is a 15.5% chance that CBT is cheaper and produces more QALYs,
and a 74% chance that CBT is more expensive and produces more QALYs.
The CEAC indicating the probability that CBT is cost-effective compared with TAU, based on health and
social care costs and QALYs over 24 weeks, is shown in Figure 10.
Willingness to pay (WTP) for an improvement in QoL per participant per year is around £20,000–30,000.151
As illustrated by the CEAC (see Figure 10), at a WTP for an improvement in QALY of up to £20,000, the
probability that CBT is cost-effective compared with TAU is not > 51%. At a WTP for an improvement in
QALY of up to £30,000, the probability is at most 52.5% and it never rises above 56% at a WTP of up
to £100,000.
Furthermore, translating ICER results into monetary terms from the adjusted analysis, we can estimate that
an additional £47,985 would need to be invested to generate a unit increase in the participant’s QoL.
Cost-effectiveness of improving negative symptoms
In comparison with the TAU group, participants in the CBT group showed an improvement in QoL at
24 weeks; however, the difference was not deemed statistically significant at the 0.05 level.
Complier average intention-to-treat analysis has estimated that, on average, every CBT session would be
expected to decrease the total BDI-II score by 0.3 points compared with TAU. Although this effect was not
found to be statistically significant (p = 0.213), dividing the cost by the difference-in-change scores shows
that CBT had higher costs and better outcomes; however, the difference between the groups was marginal.
Taking account of the ICER, which is the cost incurred by CBT to produce an extra unit improvement on this
scale, Figure 9 indicates there was a 14.5% probability that CBT was dominant (i.e. less costly and more
effective) compared with TAU. The north-east quadrant, defining a scenario of CBT having higher costs and
better outcomes, has a 62% proportion of ICERs, whereas the south-west quadrant, indicating lower costs
and worse outcome, is represented by the lower proportion of bootstrapped ICERs.
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FIGURE 10 Cost-effectiveness acceptability curve.
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Chapter 7 Discussion
Main findings
In the CanTalk trial, we aimed to determine the clinical effectiveness and cost-effectiveness of CBT for the
treatment of depression in people with advanced cancer that was no longer amenable to cure.
The CanTalk trial was designed and reported in accordance with CONSORT guidelines and was powered
to detect a significant difference between TAU and TAU plus CBT, delivered by IAPT therapists in a RCT.
Our sample specifically included participants with tumours from as wide a range of tumour groups as
possible and in whom disease was advanced and cure no longer probable. Caseness for depression was
carefully assessed through a multistage screening and measurement procedure using standardised tools.
Results in the light of previous findings
Our main finding is that CBT (plus TAU) did not show any benefit over TAU in terms of either our primary
outcome or our other measures. Although CAITT analysis suggested that the estimated mean change in BDI-II
score per therapy session was –0.3 points for CBT compared with TAU, the wide CI (95% CI –0.760 to 0.170
points) was consistent with the main result, showing no significant benefit of CBT (p = 0.21). A subanalysis
has suggested that for a particular subgroup of participants, those who were widowed, divorced or separated,
there may be a benefit from CBT (mean change –7.21, 95% CI –11.15 to –3.28; p < 0.001).
Previous work reviewing the use of psychological interventions for depression in advanced cancer has raised
questions concerning research design, generalisability of the findings and, more specifically, uncertainty
about whether or not CBT, either group or individual, is effective in an advanced cancer population. Although
three published Cochrane reviews23–25 have suggested that psychosocial therapies are effective for advanced
cancer, the last two24,25 covered women with metastatic breast cancer only. The largest study30 that used CBT
for low mood in metastatic breast cancer had only 62 participants and suggested no effect of CBT at 3 and
6 months. A more recent study by Savard et al.63 suggested a benefit of CBT for treating depression in a
similar population, but numbers were limited to a small sample size of 45 patients. The small sample size calls
into question how much authority these results should hold.
In addition to the finding by Savard et al.63 that cognitive therapy (as opposed to CBT) was effective for
depression in metastatic breast cancer, the SMaRT (Smart Management Research Trials) Oncology-3 trial20
found that integrated collaborative care delivered in a secondary care setting for people with lung
cancer was substantially more efficacious than usual care. However, both of these studies20,63 delivered
interventions to specific populations of oncology outpatients.
It is generally agreed that CBT is an effective treatment for depression, so what might explain our findings
in people with advanced cancer? There are two broad possibilities. One is that limitations in the CanTalk
trial obscured a treatment effect. The other is that CBT, as delivered in accordance with the CanTalk
manual, is ineffective in this patient group. We will consider these possibilities in turn.
Reason for a treatment effect in widowed, divorced and separated individuals
The CanTalk trial demonstrated a significant effect of CBT for people who were widowed, divorced or
separated. Although we found a highly significant effect, the trial was not powered to detect a significant
difference by marital group and it is possible that this was a type I error.
The effect of demographic variables as moderators of response to CBT in adults has been previously
reported.152–154 Fournier et al.153 found that being married, unemployed and having more antecedent life
events were associated with a better response to CBT than to antidepressants.
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A study by Button et al.152 was consistent with our findings, suggesting that being widowed, divorced or
separated was associated with better responses to CBT. Although no explanation was offered by Button
et al.152 for this finding, we considered two main possibilities. The first is that this is a random finding.
However, our finding is a highly significant effect (p < 0.01) and is consistent with previous reports.
Second, people who are emotionally isolated or have suffered a bereavement or separation may benefit
from the non-specific component of CBT, by having a warm and friendly person to talk to, with positive
effects on their mood. We have not explored the outcome when broken down into separate categories for
the subgroup (widowed, divorced or separated) as this was not a part of our pre-analysis plan. It might
have also been useful to know whether or not the participants’ status was a recent event. Although there
appears to be some indication that CBT is helpful, it would be premature to specifically recommend CBT
to people who are widowed, divorced or separated until further research validates these findings.
Establishing whether improvement is associated with the specific effects of CBT or, rather, a non-specific
treatment effect such as having a warm, friendly person to talk to remains to be evaluated. There are
very few studies that examine the impact of non-specific interventions with CBT in depression. Although
older people with depressive disorder have reported feeling that just talking helped, this did not improve
their depression scores.66,67 However, preliminary findings from more recent feasibility work, comparing
acceptance and commitment therapy (a new-wave therapy derived from CBT that uses cognitive diffusion
and mindfulness methods rather than attempting problem-solving) with a talking control for people with
advanced cancer155 indicates that being given the space to simply talk and be heard is well received. It is
possible that additional psychosocial support, possibly in the form of CBT, should be considered in this
demographic group.
Subsidiary findings
Eastern Cooperative Oncology Group Performance Status
In a previous study156 that measured ECOG-PS in 1000 patients with advanced cancer, the proportions
of patients found to be fully active, restricted, ambulatory, limited and disabled were 3%, 16%, 26%,
42% and 12%, respectively, compared with 20%, 42%, 27%, 11% and 0%, respectively, in this study,
suggesting that our population was less disabled, despite having advanced cancer. This finding could be
explained by our recruitment of outpatient attenders rather than a mixed inpatient and outpatient sample,
as was the case in the other study.
Possible limitations of the study
Power
We recruited a total of 230 participants. Our original power analysis suggested that 240 participants
(accounting for attrition at follow-up) would provide 90% power to detect a 6-point difference at 12 weeks
and 80% power to detect a 6-point difference at 24 weeks (see Table 4). Retention in the trial exceeded
our original estimates so that, with 230 participants, we had sufficient numbers to detect a 3-point change
on the BDI-II at 90% power, suggesting that our trial was overpowered. Savard et al.63 reported a clinically
significant improvement with CBT in metastatic breast cancer patients but these findings should be treated
with caution as the sample size was small, with 21 in the CBT group and 16 in the ‘wait list’ group. One of
the strengths of our study is that it is sufficiently powered to produce robust findings and to answer the
question of the benefit of CBT delivered by an IAPT service for people with advanced cancer.
Attrition is common and unavoidable in studies of those with advanced, progressive disease. It is always a
serious consideration when considering the validity of the findings, as differential dropout in the two study
arms may reduce the internal validity of the findings. We conducted a sensitivity analysis, assuming that
all people in the CBT group who dropped out recovered and we still could not demonstrate any benefit
of CBT.
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Representativeness of the sample population
Screening data
The proportion of participants recruited as a proportion of those screened in the CanTalk trial varied
between 35.4% for hospice, 10.4% for oncology outpatients and 2.6% for GPs. Data for oncology
outpatients with good prognosis cancer19 showed that 500 out of 1428 (35%) were recruited, with
142 out of 490 (29.0%) patients with poor prognosis (lung) cancer being recruited.20 In the CanTalk trial,
participants were selected from all cancer types. These factors might have accounted for the difference in
recruitment rates. Furthermore, our recruitment methods relied, in part, on busy clinic staff, who varied in their
commitment to the research process. Qualitative interviews suggested that clinic staff did not have time to
engage with this study and often viewed drug trials as more worthy of research. Recruitment rates are also
likely to be better when research is led and conducted in one service, such as in the SMaRT oncology trials.18–20
This was not feasible in the CanTalk trial because of the UK-wide recruitment base required.
Demographics
The mean age of our sample population was 59.5 years, as participants were people with ‘advanced
cancer’, which is predominantly a disease of people in the second half of life. In the UK, over one-third of
new cancer diagnoses are in people aged ≥ 75 years.157 Breast, prostate, lung and bowel cancers together
accounted for over half (53%) of all new cancers in the UK in 2013.157 Among females the highest lifetime
risks are associated with breast, lung and bowel cancers and and among males the highest lifetime risk is
of prostate, lung and bowel cancers. These tumour groups made up 60.8% of our sample population.
The slightly higher rate is because we chose to recruit from the major tumour groups as a priority to
ensure that we recruited people with the most common cancers. However, the rates of depression are
lower in genitourinary cancers20 and, therefore, the lower rate of people with prostate tumours and
depression is consistent with findings.
Reliability of the diagnosis of depression
Typically, the CanTalk trial targeted people with a depressive episode (ICD-10 F32), a recurrent depressive
disorder (ICD-10 F33) or a mixed anxiety and depressive disorder (ICD-10 F41.2), as identified by the MINI.
However, it is not always easy to distinguish depressive disorder from an adjustment disorder with a
prolonged depressive reaction (ICD-10 F43.21).
Rayner et al.22 found that 69% (27/39) of patients in palliative care who were diagnosed with major
depressive disorder at baseline had remitted 4 weeks later. Our target population, after adjusting to a
recent major life event around their cancer diagnosis, could experience remission of their symptoms. This is
consistent with the observation that people allocated to TAU alone also improved. This is also a common
finding in RCTs because of regression to the mean.
The mean time from the initial diagnosis was almost 4 years in our study population. Therefore, it is
unlikely that a diagnosis of cancer per se was the trigger for distress; however, it is possible that people
were adjusting to the realisation that cure was no longer likely. Unfortunately, the entry definition for the
study was for ‘people with cancer not amenable to cure’ and this group is more heterogeneous in term of
adjustment disorders. For example, patients with lung cancer that is not amenable to cure, which is often
known from the time of diagnosis, may have had more time to adjust than people who entered into the
study with a recent 1 month reoccurrence of breast cancer. In hindsight, it may have been useful to ask
participants whether or not they had had recent upsetting information about their disease prognosis
or recurrence.
Reliability of the main outcome measure
The BDI-II was used as the main outcome measure. The BDI has been used in trials of psychotherapy for
patients with advanced cancer.63,120,121 However, in the light of our findings, we need to consider whether
or not the BDI/BDI-II is a valid scale for measuring change in depressive symptoms in advanced cancer. The
difficulty with assessing severity of depression in cancer is that there are a number of items on depression
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scales that complicate estimations of severity. For example, people may lose weight because of the cancer
itself or nausea associated with treatment, sleep may be increased or decreased because of the use of
opiates or decreased because of associated physical disease, such as pain.
Prior to setting up the study, we considered the different scales to be used for measuring depression in cancer
and also reflected that people with advanced cancer, our target population, are likely to be older than average.
Unfortunately, there is no ideal scale for measuring depression in cancer158 and a variety of scales
have been used.159,160 These include the BDI-II,118 Brief Symptom Inventory,161 Centre for Epidemiologic
Studies–Depression Scale,162 Geriatric Depression Scale,163 Hospital Anxiety and Depression Scale,164
PHQ-9,102 Profile of Mood States – Short Form,165 Zung Self-Rating Depression Scale166 and the Modified
Edinburgh Postnatal depression Scale.167
As we were evaluating the effects of CBT, we decided on the BDI-II for two main reasons. First, the BDI-II,
or its previous version (the BDI), has been used in previous studies to measure depressive symptoms in
advanced cancer. Second, the BDI-II contains a balance of cognitive and somato-affective elements. The
rationale behind CBT is that targeting cognitions associated with depression results in an improvement in
mood. Although other scales may ask some cognitive-related questions, such as suicidal thoughts and
hopelessness, they tend to be less weighted towards the measurement of cognitive elements. The BDI-II
includes thoughts about being punished, worthless, being a failure, self-dislike and self-criticism, all of
which, along with addressing existential issues, were a target of the CanTalk intervention. Nevertheless,
like all measures of depression, the BDI-II also includes somatic symptoms, for example cachexia, which, in
this population, are related to the underlying physical disease, rather than to depression per se. Even with
CBT, these elements may be less amenable to change, making it harder to detect a significant treatment
effect using the BDI-II.
Finally, a criticism associated with the BDI-II is that it takes quite a long time to complete, and this may
increase the number of missing items, which makes it unreliable. This was not the case in this study, as we
found that the number of missing items was low.
Screening using the PHQ-2 suggested significant depressive symptoms, and this was confirmed with the
MINI, giving a DSM-IV diagnosis of depression in all participants who entered the trial. Nevertheless, in
36 out of 230 (15.6%) cases, the BDI-II score was < 17 points, suggesting mild mood disturbance (score
11–16 points) or normal ups and downs (0–10 points). Even though our analysis adjusted for baseline
depression score, the inclusion of participants with low depression scores generally reduces the ability to
influence significant change. This observation was also consistent with qualitative feedback from some
therapists, who indicated that, by the time some patients were seen, they were no longer ‘depressed’.
Randomisation
In this randomised trial, various demographic and other factors that are known to predict depression
outcome were well balanced in both arms.
However, more people were employed in the CBT group. Unemployment is known to be associated with
poorer prognosis of depression. This imbalance would be expected to favour CBT, but we did not find this
to be the case. Although our population included a lower proportion of single, never married people
(17%) than in the total UK adult population (33%), this may be explained by the fact that the mean age
of our population was higher than the UK average, and the proportion of single and never married people
is generally lower among the older population. This age distribution may also explain why people with a
degree or higher degree in our population was lower than for the UK population as a whole.
Both groups were also balanced on our recorded potential sources of bias, such as antidepressant use,
use of other psychological therapies, predicted improvement and treatment preference. Therefore, these
factors are unlikely to account for our lack of apparent treatment effect.
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Dropout
There was considerable morbidity among our population, which accounts for the fact that almost one-third
of people were not able to provide complete data at any any particular time point. However, this finding
may be misleading because, as shown by Figure 2 for example, although 24-week follow-up data were
available for 130 out of 230 (56%) participants, people dip in and out of follow-up. Analysis was possible
because at least one post-baseline data point was available for 185 out of 230 (80.4%) participants.
Furthermore, missing data for people who died can, in this study, be regarded as missing completely at
random,168 with respect to whether or not they have received CBT (potential cases of suicide excluded;
none occurred).
The patterns of early and late dropout may be relevant, especially as they may not be completely random.
Dropout early on (within 6 weeks) may occur because people are unhappy about their group allocation,
whereas dropout late in the treatment may occur because people are unable to comply with the rigours
of having to attend therapy sessions. Over 75% of participants indicated a preference for CBT; however,
withdrawal in the early stages was greatest for the CBT group. It is unlikely that dropout from the CBT
group is explained by people receiving their preferred treatment. One explanation for the greater dropout
in those allocated to CBT is that their expectations were not met because they had to wait to be seen by
IAPT services. It is notable that people who engaged well with therapy were seen within a median of
16 days, whereas those who engaged poorly had to wait a median of 26 days. We are aware of the need
for caution when interpreting these data, especially as it could be argued that a delay for people to be
seen by IAPT services occurs because people are physically unwell. However, using ECOG-PS, which is a
measure of disability, we found no significant differences in physical function at baseline between those
who were seen quickly and those who were not. Furthermore, overall satisfaction with care was equally
high in both groups. Our belief that delays in being seen by IAPT services explained some of these findings
was supported by qualitative interviews, in which participants voiced dissatisfaction at ‘having to wait’ to
be seen. If waiting to get CBT elicits dissatisfaction, then reduction in waiting time must be considered.
This observation is further supported by our finding that attrition later in the study (weeks 12–24) was
balanced across the two arms.
Satisfaction with care was high and this did not differ between the TAU and TAU plus CBT group.
Satisfaction with care as measured in this study related to a general satisfaction. In hindsight, it may have
been more helpful to collect quantitative data specifically related to participants’ satisfaction with CBT.
Engagement with therapy is an important issue when considering whether or not a particular intervention
can be delivered in a NHS setting. A total of 22% (25/115) of participants withdrew before starting
therapy. Data from IAPT for 2014/15169 suggest that just under 70% of participants referred to IAPT
enter treatment. The CanTalk trial found that, although 65% (75/115) of participants attended at least
one therapy session, only 31.3% (36/115) completed at least eight therapy sessions. A major reason for
dropout was that participants had significant physical ill health. Our quantitative and qualitative data
suggested that a proportion of participants withdrew either because of health reasons or because of
the rigidity of IAPT practice, the policy of which tends to be to discharge people if they fail to attend on
two occasions. Although ethics stipulated that patients did not need to give a reason for not taking up
treatment, it was perceived by the study researchers that patients felt that attending therapy sessions for
some was burdensome.170 Although it is costly, attrition may be minimised by seeing people in their own
homes and by allowing great flexibility for those with chronic physical health problems. Unfortunately, we
were not able to offer treatment in a home setting because of restrictions on lone working within IAPT.
Although we did offer the opportunity for telephone CBT, few sessions (5.9%) were taken up. Moreover,
these telephone sessions were accounted for by one participant who received all 12 sessions over the
telephone as they were unable to attend face-to-face therapy. Although our protocol recommended that
at least three sessions were offered face to face, we decided to be flexible. Although the alternative option
of offering computerised CBT should be considered, the benefit of these packages is questionable170 and
we cannot make recommendations on these interventions based on the results of our study.
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A total of 36 out of 115 (31.3%) participants referred for therapy were recorded as having ‘completed’ it.
However, the proportion of those who engaged was slightly higher (32.7%), as only 110 out of the 115
would have been able to take up therapy, with five participants dying by 3 months’ follow-up. This figure
compares with recent IAPT data171 suggesting that 41% of people complete therapy. Of the 110 participants
who could have received all 12 therapy sessions, 41 participants had withdrawn or data were missing.
Although for a proportion of these patients the decision to terminate therapy was agreed between the
patient and the therapist, it would have been useful to have had data on why these termination decisions
were made.
Seventeen out of 115 (14.8%) patients in our population were discharged from IAPT, in keeping with the
IAPT policy of discharging people who fail to attend. Qualitative interviews suggested that therapists tried
to be more flexible with our patient population. If IAPT is to treat patients with LTCs, such as advanced
cancer, consideration must be given to physical problems and attendances. Furthermore, six people were
not referred for therapy; despite us sending an e-mail to IAPT and confirming receipt in a follow-up
telephone call, we were informed by IAPT that a referral had never been received. Patients were subsequently
re-referred for ethical reasons, but the delay in this process meant that they had reached the final follow-up
point in the trial. Such administrative errors may be minimised by closer tracking of participants. However,
changes in staffing, IT systems and administrative errors do occur and remain potential sources of error.
These errors could be minimised in future trials by asking patients allocated to CBT to be proactive in
contacting the trial team and IAPT if they have not heard from a therapist within 3 weeks of allocation.
The quality of the intervention
We are aware that research-active sites tend to deliver higher-quality care. This could be reflected in
improved outcomes from IAPT. However, as 25 IAPT services from across England were involved, we
would argue that these were representative of a range of IAPT services. Engaging IAPT centres that have
an interest in participating in the study is a prerequisite for the study and, if anything, would be likely to
bias the outcome in a positive way.
Although a meta-analysis on therapist adherence and competence suggests that these factors play little
role in determining symptom change,77 competence is routinely measured in IAPT, and adherence to
treatment protocol is considered essential in evaluating trials of CBT. Therefore, we have to consider the
possibility that CBT failed to effect an improvement in depressive symptoms because the quality of therapy
was poor and that therapists did not adhere to the treatment manual. However, the CTS-R suggests that
the quality of delivery of CBT was at the upper end of the proficient range.
Findings from the Cognitive Therapy Scale – Revised
We are aware that not all therapy tapes were uploaded and it is possible that therapists uploaded what
they felt were the best therapy sessions. This would introduce a bias. The major reason given was that
therapists did not have time to upload tapes or they could not access IT systems because of governance
issues. However, we would argue that an assessment of the quality of therapy is justifiable despite
the limitations.
It is widely assumed that therapist adherence and competence predicts outcome; however, there may be
little relationship between adherence and competence and symptom change.77 Nevertheless, the CTS-R
is routinely used as a measure of competence of the therapy delivered. Despite competent delivery of
therapy in this study, we failed to observe a change in BDI-II with CBT. We chose to rate tapes of therapy
by period (beginning, middle or end). With practice, the quality of therapy, evaluated by the CTS-R, may
be expected to improve. However, a greater number of early therapy sessions are likely to occur, as people
often do not complete all sessions, and this may be associated with a skewing of the CTS-R score by phase
of therapy. However, as there were no differences in therapy CTS-R scores by session, the data suggest
that it is unlikely that poor delivery of treatment accounts for the lack of improvement from therapy.
Lichstein et al.74 suggest that, for successful treatment, therapy needs to be delivered and also received
and enacted. Although we did exclude participants on the basis of cognitive impairment, it is possible that
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some participants had difficulty in understanding the therapeutic model. However, this suggestion is
negated by our finding that higher scores were not associated with educational status. Furthermore, there
is no evidence to suggest that educational attainment, age and history of depression moderates a
treatment response to CBT.152 It is possible that, although the therapy was competently delivered and the
patients understood this, they did not act on it. Although the independent ratings of therapy using the
CTS-R suggest that therapists did set homework, we did not have the resources to evaluate whether or not
patients completed the tasks set out.
Adherence to treatment using the Therapy Components Checklist
Fidelity to the treatment manual appeared to be good, with therapists reporting the use of a wide range
of elements, subsequently confirmed by an independent rater. Although we acknowledge that limited
resources did not make it possible for an independent rater to assess all sessions for adherence using the
TCC, it did provide a useful measure of adherence.
If anything, the therapists underestimated some of their skills, such as the use of guided discovery, which
was reported by the rater using the TCC. Our findings suggest that CBT was well adapted to treating an
advanced cancer population and that it can be used to deliver a challenge to unhelpful beliefs and explore
existential issues. For example, cognitive techniques were reported as being used in 58% of assessed
sessions and specific cancer topics were discussed in 70%. What is not clear is how many of these
techniques were received and then enacted on.74 Evaluating these processes was beyond the scope of
this work.
We acknowledge that the psychometric properties of the TCC remain to be evaluated. With greater
resources this could be done through a study measuring inter-rater reliability and whether or not particular
components, correlated with each other, could be dropped. Further research could then explore whether
or not particular delivered components are associated with improved outcomes.
Finally, although assessors were asked to confirm that participants had a sufficient understanding of English
to engage in CBT, it is possible that a small number of participants suffered from cognitive problems
associated with cerebral involvement of cancer or, indeed, the side effects of medication. This may have
impaired people’s capacity to retain the contents of therapy.
Number of therapy sessions
National Institute for Health and Care Excellence’s guidelines142 for the treatment of depression suggest
that a range in number of sessions may be required, with 16–20 individual CBT sessions over 3–4 months.
When planning the study, the consensus view was that fewer sessions would be needed as it was felt that
most patients with cancer would have reasonable pre-morbid adjustment and that one of the main hurdles
in their lives is adjusting to a life-threatening illness. In CanTalk, a mean of 4.7 sessions (SD 4.9 sessions)
were taken up, which is lower than a mean of 6.3 treatment appointments attended overall for IAPT in
2014/15.171 However, the number of people with physical health problems treated by IAPT, although
increasing, remains low.
Complier average intention-to-treat analysis found a change in BDI-II score with CBT of 0.3 points per
therapy session and the wide CI suggests no benefit of CBT. We chose to adhere to a consensus opinion
among clinicians, notably that a change of 6 points is considered clinically significant on the BDI-II. It is
possible that a 6-point difference would be achieved by simply delivering more sessions. Although speculative,
as a linear relationship between the number of CBT sessions and a reduction in the BDI-II score cannot be
assumed, one could envisage a 6-point change with around 20 CBT sessions. More cautiously, scaling up
the ‘per-session’ estimate by the average number of sessions experienced within the treatment group for
those who took up at least one session (this comes to 7.14 sessions) produces an estimate of –2.11 points
(95% CI –5.43 to 1.21 points); this is an estimate of the average benefit in the treatment group for
‘compliers’ (defined here as those who had at least one session of CBT), which can be compared with the
principal ITT analysis estimate (–0.84, 95% CI –2.76 to 1.08).
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Our original assumptions were that our sample population had better pre-morbid resilience than a
population with repeated depressive episodes. In hindsight, it may be that the severe physical consequences
of their disease necessitate considerably more sessions for clinically significant change. In reality, it is going
to be very difficult and there may not be enough time to engage people for 20 sessions. Furthermore,
even if this were possible, resources are not currently available in the NHS to deliver sufficient therapy for
treatment to be successful. It follows that CBT is not a pragmatic treatment for people with depression and
advanced cancer.
It is notable that, when the CanTalk project was set up, we stipulated that, when possible, IAPT should
fast track people into therapy, ideally within 2 weeks. Our study findings suggested that there was an
association between the time for the IAPT appointment to be received and the number of therapy sessions
completed; the faster an appointment with IAPT, the more sessions were taken up. People with more
physical problems may be less able to attend appointments and may also be less likely to engage in therapy.
However, attendance was not found to be related to physical health status judged by the ECOG-PS.
Furthermore, IAPT services send out appointments irrespective of an individual’s health status. It follows
that, in order to encourage people to take up therapy sessions, rapid referral into therapy is desirable.
Although we requested that participants be fast tracked into therapy within 2 weeks of referral by the
research team, in reality this was not possible because of service constraints. Nevertheless, the mean time
for participants to be seen was 29 days, which is better than routine IAPT referral, for which waiting times
for a course of treatment (for those finishing a course of treatment in March 2015) are quoted as being
< 6 weeks to enter treatment for 37,097 (78.0%) people and < 18 weeks for 45,589 (95.9%) people.
In contrast, the presence of a CBT practitioner within a palliative care service ensures rapid access to
treatment. We deliberately excluded areas that offer this service from recruitment to avoid contamination
from the TAU group.
We are confident that the CanTalk trial is one of the largest and methodologically most robust trials of
therapy in psycho-oncology. So, if the results are sound, the outstanding question is why CBT delivered
using the CanTalk manual was ineffective in the IAPT setting.
Possible reasons for ineffectiveness of cognitive–behavioural therapy
in CanTalk
Depression in advanced cancer is more treatment resistant
A previous study62 of CBT in palliative care found an effect for anxiety but not depression. The nature
of depression in advanced disease may be different (e.g. depression in advanced disease may have a
biological underpinning that makes it less amenable to treatment). Despite the lack of effect on depressive
symptoms, therapists reported useful work with other problems and goals that patients brought to
therapy. CBT, as a collaborative effort in problem solving, works with what the patient brings and it may
be that problems other than depression were shifted by the therapy. Unfortunately, CanTalk did not use
measures of personal problems or anxiety, so it is not possible to determine if CBT had an impact on areas
other than depression. For many people with advanced cancer, anxiety may be a more disabling symptom
than depression, but we do not know if our treatment improved anxiety. CBT in palliative care is less
disorder focused and much more problem focused. For instance, symptoms of fatigue or pain may be the
main ones addressed in therapy and, although these are related to depressive symptoms, they may change
without effecting changes in depression. This raises questions of whether or not a disorder-specific
approach and disorder-specific measures are the best outcome measures in advanced diseases.
The intervention was not sufficiently well designed
There was no difference in mean satisfaction with care between patients allocated to TAU and TAU plus
CBT. This is probably because questions referred broadly to their total care and CBT made up only a
small element. However, the mean score of around 40 on a scale ranging from 0 to 50 suggests that
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considerable improvement could not be made with the care delivered. Engagement with therapy may
provide an indication of whether or not the intervention was acceptable. Although 65% of people took
up the offer of therapy, it is notable that around one-third completed 8–12 sessions. Data from IAPT for
2014/15169 suggest that the rates of uptake were similar to IAPT. However, our population had many more
physical problems and, therefore, continued engagement as health deteriorates is likely to be challenging.
Although telephone CBT was offered to participants, the majority elected to be seen face to face. Qualitative
interviews with therapists and patients suggested that the treatment could be delivered and that it was well
received. Generally the therapists and the patients liked the materials used and we were pleased that they
adhered to the protocol by showing flexibility in which elements were tackled and when.
The CanTalk manual was constructed on the basis of considerable clinical experience in working with
cancer patients and is geared towards addressing the cancer-related issues faced by patients with
advanced disease. The entry criteria for the study did not differentiate between depression resulting from
the disease and pre-existing depression or even depression subsequent to the disease but not related to
cancer. Some therapists reported that the problems with which patients presented were not cancer
related. Thus, the manual may have restricted them in their delivery of therapy.
An alternative explanation is that the therapists did not focus enough on cancer-related issues. It is
interesting that the TCC reveals a discrepancy between the observer and therapist ratings in the areas
of impact of illness, impact of disease and mood on behaviour, beliefs and expectations about illness,
concerns about current and future ability to cope, and impact of disease and death on loved ones.
Therapists were more likely than raters to have believed that they covered these issues in a session.
Although the problem-solving focus of CBT can help patients with early-stage cancer to develop effective
coping strategies and evaluate unrealistic hopeless and helpless beliefs, in advanced disease there is less
scope for problem solving. It may be that ‘third wave’ therapies, such as acceptance and commitment
therapy, which are based more on acceptance, could be more relevant. However, this is not the clinical
experience expressed by clinicians working in palliative care, in which problem-solving approaches to
fatigue, pain and avoidance of activity for example seem to work very effectively.
We need to consider whether or not a cognitive–behavioural approach is not the treatment of choice in
this target population. More recent work has been conducted by Walker et al.20 in the SMaRT Oncology-3
trial, in which 142 people with lung cancer (poor prognosis) were randomised to integrated collaborative
care, which uses elements of CBT or usual care. This found that the active arm was substantially more
efficacious than usual care alone, although data were available for 113 (80%) and 97 people at (68%) at
12 and 24 weeks, respectively. It may be that the use of CBT in combination with this integrated collaborative
care approach is more suitable for advanced cancer patients. However, this remains to be evaluated for
cancer patients with different tumour types.
Engagement with the intervention
A low uptake of therapy may explain failure to find a treatment effect. However, the CanTalk trial was a
trial of the clinical effectiveness, not efficacy, of CBT. The uptake of therapy for people referred to IAPT is
around 70%. In the CanTalk trial, of 99 people referred to therapy, 66 (67%) took up at least one therapy
session, which is similar to IAPT. Although we offered people the opportunity to tell us their reasons for
withdrawal, it is not ethical to pressurise people into providing a response. In qualitative interviews with
participants and therapists, there was a suggestion that CBT was well received. Physical problems meant
that people were not always able to attend therapy in a local IAPT centre or GP premises. In addition,
there may be stigma associated with attending a centre that is known to address mental health problems.
Despite this, only a small proportion of participants took up the option of telephone CBT. A strategy to
boost engagement could be to offer patients the opportunity to receive therapy in their homes or at the
oncology centre, but it is unclear whether or not this would be taken up. Delivering integrated care through
palliative care teams may facilitate engagement with psychological interventions and is recommended by the
Improving Outcomes in Supportive and Palliative Care for Adults with Cancer guidance.72
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Psychological interventions are less effective than previously thought
Cuijpers et al.172 suggest that the effectiveness of CBT for depression generally may have been
overestimated, possibly owing to publication bias, small sample size and a lack of suitable control groups.
Although the therapeutic outcomes from various psychological interventions are broadly similar173 and
the effectiveness of an intervention may be enhanced by improving retention with treatment, the findings
from CanTalk trial suggest a lack of treatment effect in patients with advanced cancer.
Procedural issues
It is notable that there was wide variation between centres for permission to start recruitment, despite all
the relevant documentation being provided. We allocated a maximum of 6 months for the set-up of the
project. Some centres and clinics were outstanding in quickly approving research and recruiting patients.
At others, there were hurdles that impeded us in recruiting participants promptly. We would suggest that
if some centres are able to set up permissions for research within 1 month, a duration of no more than
2 months should be expected in others, with possible financial incentives awarded to those who reach this
target and with these decreasing gradually to zero if a centre does not recruit within 6 months.
Differences in recruitment rates may depend on referral source (e.g. lung clinics were high recruiters);
however, these variations cannot be explained by recruitment source alone. Indeed, it came to our
attention that some services would be rewarded if they became research active and recruited at least two
participants within the first month. After this was achieved, recruitment was minimal, suggesting a degree
of gaming in the system.
Recruitment issues
Recruitment in the CanTalk trial suggested that GP practices yielded low recruitment rates, and, once
a GP database was screened, rescreening within the next year was unlikely to yield additional numbers.
Although our original proposal aimed to recruit participants through the General Practice Research
Framework, this was abolished at the start of the study because of a change in government funding
priorities. This may have been fortunate, as recruitment from GP practices yielded few patients. Screening
directly in secondary care was a more efficient way to identify and recruit patients with advanced cancer.
Qualitative interviews with health-care workers who helped to recruit for the CanTalk trial suggested that
there were difficulties with finding the time to recruit for the study. These included competing interests
with recruiting for CTIMPs, which were perceived as providing better incentives. Providing boosted
incentives for psychological studies may be a way of redressing this imbalance.
Furthermore, addressing the difficulty of conducting empirical research in a palliative care setting, regular
research briefing and education sessions held with local palliative care teams can help to emphasise the
value of research and address individual concerns.174
In oncology outpatient departments and hospices, there were reservoir effects, so that, over time, the
numbers of eligible participants waned, as all those eligible had been approached. There is a greater turnover
of patients when the prognosis is poor. This will be reflected in the service type (e.g. hospice) and the tumour
type (e.g. pancreatic cancer). Researchers need to pay close attention to monthly recruitment figures and if
there is a consistent reduction in people identified during a 3-month period, alternative strategies need to be
employed. Extended recruitment within the same clinics can be used for people whose survival time is likely to
be relatively short (4–12 months). However, for those who have a relatively longer survival (e.g. haematology),
for example at least 12 months, this strategy is problematic because of the low turnover of cases.
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Finally, there is a possibility that recruitment tails off because of fatigue in clinic staff. However, in this
case, one would expect recruitment to fall off equally in people with good or poor prognosis.
Health economics
Service use
General practitioner services
Two main reasons people access their GP is for help with physical or psychological problems. The reason
for the decrease in GP consultations we witnessed in the trial is that people were less distressed or were
less physically unwell. Our data suggest that our population was less distressed with time, in both groups.
The explanation that people were less physically unwell seems unlikely. Data from the ECOG-PS suggested
poorer function with time. It is possible that, when people become more ill, they are less likely to consult
their GP but, rather, access secondary care services.
Specialist nurse
Part of the CBT intervention was to empower participants so that they were more likely to ask for help.
This may explain why increased contact with the specialist nurse was observed.
Mental health services
Participants in both groups had more frequent contact with mental health community services than at
baseline. One possible explanation is that CBT increased the demand by participants for psychological help.
At 24 weeks, we can speculate that 94% of participants not allocated to CBT had contact with community
mental health partially because they lacked the required level of psychological support.
Social care
Although participants in both arms had a decrease in demand for social care, use of palliative care services
increased for both arms, suggesting that participants were becoming more physically unwell.
Costs
The increase in costs throughout both follow-ups for both groups may be partially explained by more
frequent inpatient admissions and general uptake of secondary care.
When planning services, one needs to take into account the full costs of an intervention, including the
IAPT therapist’s time allocated to a participant who may not, for example, attend a therapy session, as was
the case in this trial.
Quality-adjusted life-year
Although there was some QALY accrual for the CBT group compared with control, the difference was not
statistically significant. Because of the nature of the population, it is unlikely that there would be a significant
improvement in QALYs. It is more likely that psychological treatment would slow the expected deterioration in
QoL associated with poor psychological well-being. This suggests that there is no significant benefit of CBT to
patients’ QoL for people with depression and advanced cancer.
Cost-effectiveness acceptability curve
The CEAC is used in the health economic analysis to indicate the probability that an intervention is
cost-effective versus a control. The CEAC indicates that at a WTP for an improvement in a participant’s
QoL of up to £20,000, the probability that CBT is cost-effective compared with TAU is not greater than 51%.
This probability never rises above 56% at a WTP for an improvement in QALY of up to £100,000. Therefore,
this makes the intervention equivocal at the NICE threshold.
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Translating the ICER to monetary terms indicates that significantly more needs to be spent to generate a
unit increase in a participant’s QoL, as shown in Chapter 6. This is higher than the normally accepted WTP
for QALYs when they relate to the adoption of health technologies within the NHS. Furthermore, there is
uncertainty around the result as the 95% CI surrounding this ratio is not definable. The small QALY gain
and the considerable uncertainty surrounding this estimate are consistent with the overall effectiveness
results of the trial in relation to BDI-II outcome.
We have also considered the cost-effectiveness of improving negative symptoms. As reported in Chapter 6,
in addition to the statistically insignificant effectiveness result for nearly all comparisons and analyses
performed, it can be concluded that CBT is not cost-effective compared with TAU in this population.
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Chapter 8 Conclusions and implications
for practice
Summary of key findings
l This is the largest study to evaluate individual CBT, delivered through IAPT, for people with advanced
cancer not amenable to cure who had depressive disorder. Findings suggest that for people with a
range of cancers, CBT is not clinically effective for treating depression.
l The health economic analysis suggests that more financial resources are needed to generate a unit
increase in participants’ QoL than the normally accepted WTP for a QALY within the NHS. CBT for
depression in this population is, therefore, not sufficiently cost-effective to be recommended under the
current NICE guidelines.151
l CBT appeared to be effective for a subgroup of patients who were widowed, divorced or separated.
l The demographics of our population were typical of those treated in a NHS service and represented a
range of cancers including the common cancers (breast, lung, colorectal and prostate).
l Attrition occurred in around one-third of participants, with withdrawal in 22% and death in 9%.
Ill health was the main reason for withdrawal.
The intervention and supervision
l It was possible for CBT therapists to be trained to deliver CBT to an advanced cancer population.
l IAPT therapists may have been reluctant to explore some of the physical health, deterioration and
death issues with patients.
l A variety of CBT methods were used, with predominantly cognitive and cognitive–behavioural methods,
as well as discussion of specific cancer topics, being undertaken.
l The number of sessions taken up was consistent with other studies.
l Independent ratings of therapy, judged by the CTS-R as proficient, suggested that high-quality therapy
was delivered.
l Qualitative interviews suggested that therapy was well received.
l Although this was a pragmatic study, qualitative interviews suggested that therapists would have
preferred more specialist supervision than currently exists in IAPT services.
l Therapists’ self-report appeared to be an accurate reflection of what was delivered.
l No AEs were recorded.
Structure of services
l The lowest proportion of people recruited was from GP databases (2.6%), with the numbers of people
available for screening being small; the greatest proportion was from oncology clinics (10.2%).
l IAPT discharged 11% of participants because they did not satisfy requirements of IAPT for therapy.
l There was considerable replication of documentation required for the research to be approved by local
trusts, which held up the trial in some centres. The time taken from submission to approval for the
research to proceed varied from 2 to 9 months.
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Implications for practice
Clinical
The intervention
People with advanced cancer and depression who received an appointment quickly for CBT were more
likely to remain in treatment than people who experienced a delay. We know that people with physical
health problems are more likely to drop out from therapy. As IAPT is aiming to treat people with long-term
health conditions, retention may be facilitated by fast-tracking patients into therapy within 2 weeks, so as
to minimise attrition.
Although CBT has been shown to be effective for people with a cancer diagnosis, we found that it was
not effective for the treatment of depression in advanced cancer. The delivery of CBT in the CanTalk trial
was typical of CBT routinely delivered within an IAPT service. We do not recommend routinely offering
CBT delivered through IAPT, which is a relatively costly therapy, to people with advanced cancer.
As there is a significant DSM-IV prevalence of depression in people with advanced cancer, we would
support NICE’s guidelines142 to consider people’s psychological needs. However, only those with advanced
cancer who are attending oncology outpatients and/or GP practices, who are widowed, divorced or
separated and have significant depression should be considered for referral to IAPT for CBT. The optimum
clinical management of people who are not from this demographic group should be left to the discretion
of the managing team.
Supervision
Even though it is possible to train IAPT therapists to apply their existing CBT skills to specific conditions,
therapists desired more specialist support and supervision in order to deliver the treatment. IAPT services
should consider identifying specialists able to support CBT therapists so that they can tap into additional
knowledge about the condition being targeted.
Therapists also had their own concerns about existential issues and dying. The training prior to their seeing
patients was helpful in addressing some of these issues and we would consider this essential to providing
pastoral care for therapists.
The TCC provided a simple, useful guide to help therapists identify the elements of therapy that they did
or did not deliver. Should IAPT choose to measure adherence to treatment protocols, this approach could
be considered within an IAPT setting.
Research implications
Governance
The CanTalk team experienced considerable difficulty with the complexity of research governance. The
replication of submissions and long delay for responses were major hurdles to the project and accounted for
delayed recruitment. We support the NHS Health Services Research Authority aims for a more streamlined
approval system.
Recruitment issues
To ensure that participating health-care trusts screen or recruit for the trial, it will be important to agree
with the trust early on (ideally during site set-up) what time slots the trust can allocate to screening for the
study or which clinics it will be able to screen, and to monitor screening logs to ensure that these clinics
are screened on an ongoing basis. This can ensure that commitments to the study are maintained, as
competing demands on staff time may mean that trials perceived as providing better incentives such as
CTIMP trials take priority and inadvertently ‘push out’ time spent screening for the study.
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As described Chapter 7, Recruitment issues, there is a depletion in the numbers of patients available in
clinics in which the turnover of patients is slow. We recommend expanding or changing the source of
recruitment to similar oncology groups in different centres.
The recruitment setting
The number of patients with advanced cancer on GP lists was small. Although this group could be recruited
from GP practices, the yield was low. Significant numbers of GP practices would need to be engaged to
recruit sufficient patients for a study such as CanTalk. We would recommend that screening directly in
secondary care is a more cost-effective way to identify and recruit patients with advanced cancer.
Target population
Potentially, further research could involve identifying people with advanced cancer who are widowed,
divorced or separated, screen them for depression and randomise them to a RCT of CBT, delivered
through IAPT or a talking control, in order to determine whether or not change is likely to have been
effected by non-specific factors in therapy.
Although there is a policy of promoting the use of CBT, delivered through IAPT, for the treatment of
chronic health conditions, including cancer, we found that treating our physically ill population with CBT,
delivered through IAPT, was not effective. People with chronic health conditions have many of the same
characteristics as our population. Even though clinicians, therapists and patients may advocate the use of
CBT for chronic conditions, further research to generate a robust evidence base is required to determine
whether or not CBT delivered through IAPT is effective.
The intervention
It is unclear whether or not the setting where therapy was delivered contributed to a lack of treatment
effect. Further work could involve evaluating CBT delivered by cognitive therapists embedded in an
oncology rather than an IAPT setting. However, given the lack of even a trend towards benefit, we do
not think the use of a pure CBT approach warrants further research.
The Walker et al.20 approach using integrated collaborative care in an oncology service setting appeared
to be effective and was a sufficiently powered trial for people with lung cancer. Further research should
involve testing a collaborative care approach in people with a range of cancers delivered in a secondary
care setting.
Final recommendations
Summary of service implications
l CBT delivered through IAPT is neither clinically effective nor cost-effective for people with depression
and advanced cancer.
l People who are widowed, divorced or separated and who have advanced cancer may benefit from
screening and referral to IAPT for CBT.
l Clinical supervision may benefit from involving people with additional expertise for specialist client
groups, possibly through a centralised supervision system.
l Therapist’s self-report sheets may be helpful in guiding the components of therapy delivered.
Research recommendations
l Recruitment should be considered over a wide recruitment base from oncology and hospices, but this
should be no longer than 6–12 months to avoid reservoir effects.
l Further studies should consider researching the use of an integrative care model, such as that described
in the SMaRT oncology trials,18–20 for all people with advanced cancer.
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l The mechanism of change in the treatment of people who are widowed, divorced or separated
and who have advanced cancer and depression needs to be evaluated to see whether specific or
non-specific effects bring about a change with CBT.
l We support the NHS Health Research Authority aims of making it easier for research studies to be set
up and the elimination of duplicate application. We would recommend a target for approvals to be
processed within 2 months.
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Appendix 1 Serious adverse events protocol
Serious adverse event (adapted from the Joint Project Guideline notes on
Pharmacovigilance)175
Any AE or adverse reaction that:
l results in death
l is life-threatening
l requires hospitalisation or prolongation of existing hospitalisation
l results in persistent or significant disability or incapacity
l consists of a congenital anomaly or birth defect.
Serious adverse events
Suicide intent, self-harm and overdose are highly unlikely but are associated with major depression and,
therefore, would be expected SAEs. We do not expect treatment to cause these events. Therefore, if any
of the following SAEs are reported or observed then the SAE procedure should be implemented as soon
as participant safety has been assured.
1. Suicide ideation or intention
Suicide ideation is characterised by thoughts of suicide without clear intention or plan to attempt suicide.
Suicide intention is characterised by intentions or plans to attempt suicide. If a participant reports
possible suicide ideation or intention they will be assessed for suicide risk using the MINI Section C:
Suicidality at screening or the BDI-II during follow-ups.
a. Low to moderate risk:
i. At home – they will be encouraged to contact the GP if their mood continues to deteriorate. They
will be asked for consent to call their GP on their behalf and a family member. If they refuse contact
with a GP or family, but are still at high risk to themselves or others, proceed to call GP.
ii. In a health-care setting – ask the patient to speak with their GP/oncologist or see the psychological
support services available.
b. High risk (i.e. the participant reports immediate suicide intent):
i. At home – they will be asked to contact their GP immediately, either themselves or by someone on
their behalf. Check if a relative can be contacted. Remain with them until a family member or the
GP arrives. Follow up with the research site to inform them of event (see lone worker policy). When
the participant refuses help and risk is deemed immediately life-threatening then the police should
be notified.
ii. In a health-care setting – they will be encouraged to contact their GP immediately. Remain with
them until a family member or the GP arrives. If in the patient’s home, inform research site of event
(see lone worker policy). When the participant refuses help and risk is deemed immediately life-
threatening then the police may also be notified.
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2. Self-harm
a. If participants exhibit any signs of self-harm, they will be encouraged to contact their GP that day.
In the event that they refuse to seek help and their safety is a concern, their GP will be notified.
b. When the participant refuses help and risk is deemed immediately life-threatening then the police
should also be notified.
3. Overdose
a. If the participant reports or exhibits signs of excessive drug consumption/intention to overdose they will
be encouraged to contact their GP that day.
b. In the event that they refuse to seek help and their safety is a concern, their GP will be notified.
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Appendix 2 Topic guide: clinicians’ experiences
During this interview I am going to ask you a number of questions to help to explore your experiencesof referring patients to psychological research studies in general and then more specifically to the
CanTalk trial. You have read the information sheet for the study. Are there any questions you have? So
you know that CanTalk is a research trial recruiting patients with incurable cancer and low mood, then
randomising these patients into either care as usual or 12 sessions of cognitive–behavioural therapy plus
care as usual. I am going to ask you a number of questions about your experiences of helping to recruit to
CanTalk and this conversation will be audio recorded. We may also use quotes from the interview in
publications however these will be anonymised.
My first question will focus on you and your role in the oncology clinic . . .
1. Describe your role in the oncology clinics.
l Can you describe your current role in this clinic to me?
l How did you come to be in this role?
l How do you feel about your role?
My next question will look at your research participation to date . . .
2. Research participation.
l Have you been involved in any type of research in your role and can you tell me about it?
¢ What type of methodology
¢ Duration of trial
¢ CTIMP or non-CTIMP
¢ Personal research or study (PhD, dissertation, etc.)
I would like to ask you a little bit now on your views on trials that are not of medicinal products or drug
trials . . .
3. Views on non-drug trials.
l How often do you participate in this type of research? [e.g. psychological research, complex
interventions and non-CTIMPS (non-drug trials)]
l To what extent do you feel these trials are part of your remit?
I would like to ask you more specific questions now about your views on the CanTalk trial itself . . .
4. Specific to CanTalk.
l What do you know about CanTalk study?
l (Preamble: as you are aware the CanTalk trial was conducted by researchers from UCL.) What are your
views about the research being carried out by the university and not embedded in the clinic team?
l What are your views on CanTalk’s comparison of active treatment with usual care (e.g.
randomised trials)?
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Now I will ask you questions about your participation in the CanTalk trial . . .
5. Participation in CanTalk.
l How do you think one’s feelings about research influence their involvement?
l How do both your patients’ reactions to research and experiences of participation affect your
involvement in the research?
l What factors do you think may influence recruitment? (Prompts – anything that might increase
recruitment? Factors influencing poor recruitment?)
I would like to ask you now to tell me about any patient feedback you have had about CanTalk . . .
6. Feedback about CanTalk.
l Have any of your patients mentioned the trial? (prompt positive or negative responses)
l How do you feel the trial affected your patients?
Lastly, I would like to ask you about your opinions on psychological research studies like this in the
future . . .
7. Future for psychosocial studies.
l Would you participate in this type of research in the future?
¢ Why do you say this?
¢ (Depending on response, if negative) What might make you invest more in these types of trials?
(More CPD points, professional development or topic you are passionate about)
Overall what did you think about the CanTalk study and do you have any suggestions for improvements to
CanTalk and studies like these in the future?
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Appendix 3 Topic guide: therapists’ experience
Prompts
1. Describe your role/involvement in the CanTalk study. – How long have you been a therapist? – Have you
seen any other patients with chronic health conditions aside from the CanTalk study? – Is your role as part
of the study ongoing or have you finished seeing patients? – How many patients have/did you see as part
of the study? – Where did you see patients (e.g. office or at home)?
2. What did you know about the patient’s diagnosis prior to their first appointment? – What was your
level of knowledge in cancer? Did you understand the patient’s condition (e.g. less well-known cancers
such as myeloma)?
l Would it have been useful to know more? If so, what do you suggest would have been the best way of
providing therapists with more information? (Online training facilities, workshops, information booklets?)
3. How did you feel about working with patients with advanced cancer? – What were your prior
expectations?
l How did working with these patients match or not match your expectations?
l What do you think about the training required to work with these patients?
l What other training would have been beneficial (prior to seeing patients)?
4. What was your experience of working with patients from the CanTalk study? – What problems or
issues, if any, did you encounter working with this patient group (e.g. personally – emotional issues)?
How do you think these may have impacted therapy sessions? – Issues with patient (e.g. not being able to
attend therapy, etc.)? How do you think this may have impacted therapy sessions? – How well supported
and supervised did you feel?
l Issues in the setting/structure: can you tell me how easy/difficult it was to coordinate your appointments
among all your other appointments? How much space and time did you have to conduct therapy
sessions?
5. Were there any components of CBT that you thought were most helpful/useful for this patient group?
Were there any components of CBT that you found challenging to deliver to this particular patient group?
– If they suggest some helpful/useful ones – does this differ from patients without chronic health conditions?
l If they suggest challenging ones – how did you tackle these challenges?
6. What do you think about CBT for this patient group?
l In what ways do you think patients should be supported psychologically? If not, why not?
l What do you think if future IAPT services were required to treat cancer patients for psychological issues
as part of normal services? If you were able to make any changes beforehand what changes or
improvements would you suggest?
7. Other – please feel free to share with us any other comments you have in relation to this topic. Is there
anything else that you would like to add that we have not discussed?
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Appendix 4 Topic guide: patients’ experience of
cognitive–behavioural therapy
Prompts
1. Describe the therapy you had?
Face-to-face/telephone therapy?
How many sessions did you have?
How did it end? Do you know how to get support in the future?
Where was it held?
How long did you wait to start therapy?
Were the appointments flexible?
2. What did you know about cognitive–behavioural therapy before you started the
CanTalk study?
Had you or someone you knew had it before?
What was your expectation of the therapy?
Why did you want to try this type of therapy?
3. What aspects of the cognitive–behavioural therapy did you find helpful and why?
Did it meet your needs?
Was there anything you learnt that you think is especially helpful for cancer patients?
Was there anything that was not discussed that you think should have been?
4. What did you think of your therapist?
Were they knowledgeable about your cancer diagnosis and treatment?
5. What impact has having cognitive–behavioural therapy had for your life?
Improvement on physical symptoms?
Coping with treatment/medication?
Social activities/work?
Relationships with family and friends?
Thinking/planning for the future?
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6. What do you think about cognitive–behavioural therapy as a treatment for cancer
patients with low mood?
Would you recommend it to other cancer patients?
Do you think it is the best way of supporting patients psychologically?
How do you think the therapy could be improved?
How do you think the service could be improved?
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